

# Optogenetics for light control of biological systems

Optogenetics uses natural and engineered photoreceptors genetically introduced into cells to control their activity using light. The most widely used optogenetic tools are channelrhodopsins (ChRs) from microalgae. These tools are being adapted to an increasing number of species.

## Experimentation

Optogenetic experiments rely on a genetically encoded actuator that responds to light of the appropriate wavelength and intensity and a light delivery system that allows temporally precise activation of the cells of interest. A number of optogenetic actuators are available. Light-activated ion channels such as ChRs are most commonly used in optogenetics, although light-driven pumps and enzymes can also be used. Optogenetic tools are introduced into cells using transgenic or viral delivery methods. Their localization and expression is controlled with the choice of promoter. Light targeting approaches have generally been developed for applications in neuroscience and cardiovascular science but are also beginning to be applied to other systems. Optical fibres implanted into the skull are used to introduce light into large brain regions. Single or multiple cells can be independently controlled in time and space using multiphoton excitation and light shaping.

• It is advisable to consider tissue heating and minimize irradiance to avoid heat-induced changes in neuronal activity and behaviour.

## Results

The impact of optogenetic manipulation on targeted cells is measured using electrophysiological and optical recordings, immediate early gene labelling and non-invasive imaging modalities. Electrophysiological recordings can be done in vivo or in vitro and are the most direct way to characterize light-mediated effects. Fluorescent activity reporters can be integrated into the system but require minimization of the crosstalk between the recording and manipulation modalities. When combined with patterned illumination, optogenetic experiments can be used to determine how neural circuits drive behavioural processes.

## Applications


Most applications in optogenetics have involved brain research. Recent applications are extending to other organs with excitable cells, as well as to microorganisms and plants.

1 To optimize the systems, further efforts are required, including the development of effective optogenetic tools and treatment strategies and improving gene delivery efficiency.

2 Multiple clinical trials using ChRs for treating retinal degenerative diseases have been initiated. Partial vision restoration in a blind patient with retinitis pigmentosa has been reported.

3 In cardiovascular research, optogenetics has been used for pacing or suppression of wave propagation during arrhythmias. Optogenetics can increase battery life of cardiac devices by delivering lower-energy light pulses.

4 Improving optogenetics for translational cardiovascular research requires improving genetic targeting, safer viral vectors, longer wavelength opsins and miniaturized light delivery sources.



5 The light required for plant growth will activate optogenetic tools when the entire visible spectrum is used. Therefore, combining a blue light-regulated transcriptional repressor with a red light-triggered switch is recommended.

6 Rhodopsin-based optogenetics in plants are not as developed as in animals, but they have been used to study pollen tube development and to mimic guard cell anion channel activity to close stomata.

## Reproducibility and data deposition

Reproducibility of actuators relies on codon use optimization; ChRs and other actuators are used in a diverse range of organisms and tissues. Gene delivery using viral vectors is affected by variations in the quality and purity of the vector as well as the viral titre. The spectral profile should be reported, including the light source, all filters and the optical components used in optogenetic experiments. Data type and format can be very diverse and so reporting standards and data sharing should follow guidelines for each subfield of optogenetics. Specifics of the instruments used, data acquisition and analysis software need to be reported.

## Limitations and optimizations

Tissue heating and photodamage need to be carefully evaluated in optogenetics. It is important to design experiments that minimize photon exposure and light absorption by, for example, using short illumination cycles and opsins with red-shifted absorption peaks. Multiphoton optogenetics uses pulsed lasers with high peak energies. Any risks can be mitigated by ensuring illumination with low power and that the targets are sufficiently separated compared with the thermal diffusion length.

## Outlook

The optogenetics toolbox is expected to grow, with optimization of existing tools in terms of kinetics, ion or substrate selectivity, and widening of the spectral range from UV to near-infrared. Additional actuators remain to be discovered. Optogenetics has translational potential, with promising protocols for existing and new therapies being developed. Using optogenetics in any system of excitable cells will drive basic knowledge in a number of fields in the life sciences.



# Optogenetics for light control of biological systems

Valentina Emiliani<sup>1</sup>, Emilia Entcheva<sup>2</sup>, Rainer Hedrich<sup>3</sup>, Peter Hegemann<sup>4</sup>✉, Kai R. Konrad<sup>3</sup>, Christian Lüscher<sup>5,6</sup>, Mathias Mahn<sup>7</sup>, Zhuo-Hua Pan<sup>8</sup>, Ruth R. Sims<sup>1</sup>, Johannes Vierock<sup>4,9</sup> and Ofer Yizhar<sup>10</sup>

**Abstract** | Optogenetic techniques have been developed to allow control over the activity of selected cells within a highly heterogeneous tissue, using a combination of genetic engineering and light. Optogenetics employs natural and engineered photoreceptors, mostly of microbial origin, to be genetically introduced into the cells of interest. As a result, cells that are naturally light-insensitive can be made photosensitive and addressable by illumination and precisely controllable in time and space. The selectivity of expression and subcellular targeting in the host is enabled by applying control elements such as promoters, enhancers and specific targeting sequences to the employed photoreceptor-encoding DNA. This powerful approach allows precise characterization and manipulation of cellular functions and has motivated the development of advanced optical methods for patterned photostimulation. Optogenetics has revolutionized neuroscience during the past 15 years and is primed to have a similar impact in other fields, including cardiology, cell biology and plant sciences. In this Primer, we describe the principles of optogenetics, review the most commonly used optogenetic tools, illumination approaches and scientific applications and discuss the possibilities and limitations associated with optogenetic manipulations across a wide variety of optical techniques, cells, circuits and organisms.

## Microelectrode

An electrode with a micrometre-sized tip used to record single-neuron activity.

## Optrode

An electrode coupled to an optical fibre used to record and manipulate neural activity in cells expressing an optogenetic actuator.

## Optogenetic actuators

Light-sensitive proteins that transiently modify cellular properties during illumination.

Light-dependent processes are abundant in nature, occurring in diverse organisms from bacteria and algae to plants and animals, and are used for energy capture and storage, to regulate developmental processes and to mediate orientation<sup>1–3</sup>. Although the photoreceptors involved in light-sensing have been studied for decades, the use of such proteins for actuation of naturally light-insensitive cells began only in 2002 with the expression of the *Drosophila* rhodopsin and its associated signalling proteins in neurons<sup>4</sup>. The discovery of channelrhodopsin (ChR), identified in the same year in the green alga *Chlamydomonas*, in conjunction with the almost universal cellular availability of the chromophore all-*trans* retinal (vitamin A) in most cells and organisms, accelerated the progress of this new technology. Almost in parallel with the initial application of channelrhodopsin 2 (ChR2) in isolated neurons in 2005 (REF.<sup>5</sup>) and brain slices in 2006 (REF.<sup>6</sup>), ChRs were rapidly adapted for use in living model organisms, including chicken embryos<sup>7</sup> and *Caenorhabditis elegans* in 2005 (REF.<sup>8</sup>), *Drosophila* in 2006 (REF.<sup>9</sup>), freely moving mice in 2007 (REF.<sup>10</sup>), zebrafish in 2008 (REF.<sup>11</sup>) and even non-human primates in 2009 (REF.<sup>12</sup>). The first experiments that pointed towards potential therapeutic applications were performed in 2006, pioneered by the expression of ChR in inner retinal

cells to restore vision in blind mice<sup>13</sup>. Optogenetics is based on sensory photoreceptor sequences from microalgae, fungi or bacteria. The combination of photoreceptor-encoding DNA with control elements such as promoters and targeting sequences, typically derived from genes expressed selectively in the target tissue, allows the protein specificity not only in the choice of target cell population but also in the subcellular compartments to be manipulated. The DNA constructs are incorporated into target cell populations, tissues or living organisms using vectors such as plasmids, viral vectors or bacteria using established transformation technologies (FIG. 1).

The robust function and revolutionary utility of ChR2 in neuroscience resulted in the description and application of many photoreceptor subtypes, engineered or retrieved from genomic or cDNA databases, progress in protein expression and targeting, microelectrode and optrode technology and, finally, the combination of optogenetic actuators with optical fluorescent reporter systems and high-resolution subcellular imaging, accelerating the interdisciplinary growth of optogenetic technology with unprecedented pace. The need to control neuronal activity with increased spatial resolution has, in turn, motivated the development of advanced optical

✉e-mail: Hegemann@rz.hu-berlin.de  
<https://doi.org/10.1038/s43586-022-00136-4>

## Author addresses

<sup>1</sup>Wavefront Engineering Microscopy Group, Photonics Department, Institut de la Vision, Sorbonne Université, INSERM, CNRS, Paris, France.

<sup>2</sup>Department of Biomedical Engineering, George Washington University, Washington, DC, USA.

<sup>3</sup>Julius-von-Sachs Institute for Biosciences, Molecular Plant Physiology and Biophysics, University of Wuerzburg, Wuerzburg, Germany.

<sup>4</sup>Institute for Biology, Experimental Biophysics, Humboldt-Universitaet zu Berlin, Berlin, Germany.

<sup>5</sup>Department of Basic Neurosciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

<sup>6</sup>Clinic of Neurology, Department of Clinical Neurosciences, Geneva University Hospital, Geneva, Switzerland.

<sup>7</sup>Department of Neurobiology, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.

<sup>8</sup>Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, MI, USA.

<sup>9</sup>Neuroscience Research Center, Charité – Universitaetsmedizin Berlin, Berlin, Germany.

<sup>10</sup>Departments of Brain Sciences and Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel.

methods for patterned photostimulation. Digital mirror devices or liquid crystal spatial light modulators coupled to single-photon or two-photon excitation have enabled single and multi-target excitation in vitro and in vivo with single-spike precision and cellular resolution in head-restrained and freely moving animals<sup>14</sup>. Optogenetics has developed as a basic science methodology for dissecting biological functions; whereas it was initially adopted by neuroscientists to study brain function and dysfunction, optogenetics has expanded into new research fields such as cardiology, microbiology, immunology, parasitology and plant science. These developments are culminating in highly anticipated clinical applications, as envisioned in the early days of optogenetics, including multiple clinical trials currently in progress for selected human disorders. A crude timeline of key breakthroughs in optogenetic technology is displayed in FIG. 2.

With the growth of optogenetic technology came an abundance of tools with diverse functional properties. This Primer is focused predominantly on rhodopsin-based optogenetic tools, which are the most widely used within the growing optogenetic toolbox. Although the differences between tools can be subtle, their spectral sensitivity, kinetic properties and ion selectivity can have a major influence on the outcome of an optogenetic experiment. Understanding these features and careful design are therefore crucial for the success and interpretability of optogenetic experiments. As the technology matures and gains popularity across multiple fields of biology, this Primer aims to provide experimentalists with the most relevant knowledge needed to design, perform and interpret optogenetic experiments.

## Experimentation

Optogenetic experiments are based on the combination of several fundamental components: a genetically encoded actuator that, after reconstitution with an organic molecule serving as a chromophore, responds to light and can be used to influence the function of the tool-expressing cell or tissue in a light-dependent manner; a light source providing light at the appropriate

wavelength and intensity; and a light delivery system, which allows for illumination of targeted cells for temporally precise activation of the optogenetic actuator. Together, these components allow the experimenter to modulate the biological system and interrogate its function.


## Selecting the correct actuator

When designing an optogenetic experiment, the first considerations should be the cellular parameter to be modulated and the available optogenetic actuators for such an endeavour. An enormous number of light-switchable tools have been developed for controlling ion fluxes and membrane voltage, G-protein signalling, regulation of second messengers such as Ca<sup>2+</sup>, cAMP, cGMP, IP3 and receptor tyrosine kinases (RTKs), organelle repositioning, transcription and translation (FIG. 2). Most actuators rely on photoreceptors or light-sensing modules of natural origin, although photoswitchable synthetic organic compounds have also been employed<sup>15</sup>. The use of photoswitchable synthetic organic compounds is also known as chemo-optogenetics or photopharmacology, and the interested reader might consult related reviews<sup>15,16</sup>. Many light-modulated actuators have been described that do not rely on opsin proteins. Whereas this Primer is focused on the opsin-based toolbox, the reader might find more information about non-opsin-based optogenetic tools in several excellent recent reviews<sup>17,18</sup>.

**Light-activated ion channels.** Until recently, the most widely applied optogenetic photoreceptor was ChR2 from the alga *Chlamydomonas reinhardtii* (known as CrChR2 or simply C2) and its variant ChR2-H134R<sup>8,19</sup>. Presently, almost 900 ChR sequences have been identified, including many with properties superior to those of the original prototypes<sup>20</sup> (FIG. 2). ChRs may be subdivided into cation or anion-conducting channels, termed CCRs and ACRs, respectively. CCRs typically conduct multiple types of cations with high preference for protons. Na<sup>+</sup> selectivity varies widely among different CCRs<sup>21</sup> and divalent cations are only poorly conducted under most physiological host conditions. Whereas there are no Ca<sup>2+</sup>-selective CCRs available to date, continuous metagenomic screening recently revealed a new class of potassium-selective channels (KCRs)<sup>22</sup>. ACRs are selective for numerous anions, similar to most human anion channels<sup>23</sup>.

In host cells, Na<sup>+</sup> and H<sup>+</sup>-conducting CCRs can be used as depolarizing actuators, whereas the action of ACRs depends on the chloride reversal potential in the targeted cells or subcellular compartment (BOX 1). ACRs may clamp the voltage to near the resting potential and inhibit action potential firing by shunting inhibition (BOX 1). However, in cardiac cells, immature neurons and presynaptic terminals, chloride gradients are less pronounced and ACRs may depolarize the cell membrane<sup>24,25</sup>. In plants, the chloride gradient is always directed outward, and ACR activation will generally lead to membrane depolarization. Thus far, KCRs have been applied under highly controlled in vitro conditions, but — once established for in vivo experiments — hold





**Fig. 1 | Principles of optogenetics.** DNA encoding a sensory photoreceptor derived from a microorganism, plant or animal (orange) is cloned under regulation of control elements that allow targeting of specific host cells (blue), packed into a vector such as a viral vector or bacteria and injected into the tissue, organ or organism of interest. Targeted cell (orange) now expresses light-sensitive protein and can be controlled with light in various ways, depending on the specific photoreceptor expressed.

major promise for optogenetic inhibition in all variants of cells and host model systems.

Our current molecular understanding of ChRs mostly relies on CrChR2, which has been extensively studied and modified with respect to kinetics, ion selectivity, inactivation and absorption wavelength<sup>26,27</sup>, revealing principles that have been successfully transferred to other CCRs (see Supplementary Fig. 1). Recently discovered ChRs such as ChRmine and KCRs belonging to a new family of cation-conducting ChRs hold great promise, but understanding of their molecular mechanism is only beginning to emerge<sup>28,29</sup>. The maximal colour sensitivity of known ChRs so far spans from 445 nm for TsChR to 610 nm for the ChrimsonSA mutant and Ruby-ACR<sup>30–32</sup> (FIG. 2). Such distinct colour sensitivity may allow the combination of different ChRs within the same experiment for activation and inhibition of the same or different cells. However, all rhodopsins absorb blue or UVA light to a certain extent due to transition to higher excited state levels. This has to be taken into consideration when combining multiple rhodopsins in single or multiple cell populations (see Supplementary Fig. 2). For bidirectional voltage modulation, for example, the more potent actuator should be selected to absorb at

the shorter wavelength (FIG. 2), thereby allowing for lower light powers used in the blue range, which will, in turn, minimize the undesired activation of the red-shifted actuator. Another consideration is the reversal potential of the conducted ion. In nature, as well as in neuronal experiments, ACRs operate closer to the reversal potential than Na<sup>+</sup> or H<sup>+</sup>-conducting depolarizing CCRs. Although it is possible to co-express two opsins using two separate viral vectors, this approach inevitably leads to incomplete co-expression. To overcome this drawback, several constructs have been engineered that allow tandem expression of two opsins from the same vector. The most prominent examples are eNPAC, which co-expresses eNpHR3.0 and ChR2(H134R) initially linked by a 2A self-cleaving peptide<sup>33</sup>, and BiPOLES<sup>34</sup>, which combines the red-shifted CCR Chrimson with the blue-shifted GtACR2 in a single targeting-optimized fusion construct. Owing to the stoichiometric membrane expression, equal photocurrents near the cellular resting potential and comparable light sensitivities of both channel modules, BiPOLES outperforms previous bi-cistronic combinations of ChR2 with different ion pumps<sup>35,36</sup> and guarantees subcellular co-localization and selective red-light excitation for multicolour

#### Bidirectional voltage modulation

Changing the voltage in the depolarizing (excitatory) or hyperpolarizing (inhibitory) direction.




(for example, GtACR1, GtACR2 (REF.<sup>217</sup>) and HcKCR1 (REF.<sup>221</sup>), inward directed proton pumps (for example, NsXer<sup>258</sup>) and outward-directed proton, sodium and chloride pumps (for example, Arch3.0 (REF.<sup>169</sup>), eKR2 (REF.<sup>259</sup>), eNpHR3.0 (REF.<sup>260</sup>), all plotted according to their peak excitation wavelength and temporal kinetics. **d** | Soluble enzyme bPAC<sup>38</sup> and rhodopsin–guanylyl cyclase CaRhCGC<sup>67</sup> produce cAMP and cGMP following illumination, whereas non-bleaching opsins mOPN4 (REF.<sup>51</sup>), eOPN3 (REF.<sup>57</sup>), PPO<sup>56</sup> and JellyOP<sup>50</sup> activate different G-protein pathways. **e** | Genetically encoded sensors with diverse excitation spectra (x axis) can be used to monitor changes in Ca<sup>2+</sup> voltage and pH, such as GCaMP and R-CaMP<sup>156</sup> and FRGeco<sup>261</sup> for Ca<sup>2+</sup> (REF.<sup>262</sup>), ASAP3 (REF.<sup>263</sup>), VoltroN<sup>264</sup>, VARNAM<sup>265</sup>, Quasar<sup>203</sup> and Archon<sup>266</sup> for voltage, and pHluorin<sup>267</sup> and pHmScarlet for pH. In experiments combining sensors and actuators, both need to be chosen carefully to minimize optical crosstalk. ec, extracellular; GPCR, G-protein-coupled receptor; ic, intracellular; optoGPCR, hybrid between structurally related opsin and GPCR; RTK, receptor tyrosine kinase.

# Box 1 | Compartment-specific functions of microbial rhodopsins

Anion-conducting channels (ACRs) (such as GtACR2, iC++ and iChoc) can be used to control chloride conductance in a light-dependent manner. However, the effect on neuronal excitability depends on the chloride reversal potential, which can differ between subcellular compartments, as well as on the membrane potential. The figure (left) shows a neuron coloured according to the typical chloride reversal potential. In the somatic compartment (top inset), shunting inhibition occurs if the reversal potential of a channel is close to the resting membrane potential of the cell. In this case, channel activation does not lead to a substantial current but, rather, to a conductance that will oppose any change of the membrane potential from the channel reversal potential, referred to as shunting conductance. The input resistance of the neuron is reduced, causing a smaller amplitude of subsequent excitatory potentials. If the channel reversal potential lies between the resting potential and the action potential threshold, however, the effects of shunting inhibition are more complex. In this case, ACR activation will lead to a depolarization, but excitatory potential amplitudes will still be reduced. Consequently, ACR activation will still lead to a reduced spike rate. Upon channel closing, the input resistance then increases while the membrane potential is still depolarized, leading to a transiently increased excitability. Furthermore, if ACRs are activated over extended periods of excitatory drive,  $\text{Cl}^-$  can accumulate in the cell, and the depolarizing phase of shunting inhibition will become more accentuated, leading to activity-dependent effects of shunting inhibition. At the presynaptic terminal (bottom), ACR activation leads to depolarization, and potentially even action potential initiation, especially at light onset when the pool of activatable voltage-gated sodium channels is large. ACR-based optogenetic manipulations should thus take the unique features of compartment-specific physiology into account.

Compartment-specific chloride current



applications. A combination of optogenetics and chemogenetics has been exemplified by direct fusion of slow cycling step function rhodopsins (SFOs) with a luciferase that produces light upon peripheral injection of its small-molecule substrate. These luminopsins allow direct light stimulation by optical fibres, while at the same time providing chemogenetic access in awake and anaesthetized animals *in vivo*<sup>37,38</sup>.

**Light-driven pumps.** The first application of optogenetics for neuronal silencing was achieved with the chloride pump halorhodopsin<sup>39</sup>. However, since the discovery of ACRs, the interest in optogenetic silencing of animal cells by light-driven pumps has decreased in animal cells because pumps require higher expression levels and higher light intensities for sufficient ion turnover (see Supplementary Fig. 3). By contrast, in plants — which

naturally hyperpolarize their membranes and drive secondary transporters via  $\text{H}^+$  pumps — light-driven  $\text{H}^+$  pumps are valuable tools. The advantage of light-driven pumps is their high ion specificity and robust electric response that depends less on the ionic composition of the surrounding buffers and the membrane voltage. Light-driven chloride pumps such as NpHR<sup>40</sup> or Jaws<sup>41</sup> allow reliable — although often weak — neuronal inhibition in synaptic terminals, where the action of ACRs is difficult to predict owing to variable and elevated intracellular chloride concentrations<sup>42</sup>. Pumps may be successfully used in small compartments such as neuronal vesicles, lysosomes<sup>43</sup>, mitochondria or thylakoids, where the action of ion channels is poorly defined owing to the lack of free ions<sup>44</sup>. In the plasma membrane, the use of light-driven ion pumps requires caution because both proton and chloride pumps can drive non-physiological ion concentrations in neurons and trigger off-target effects, including a transient increase of the chloride reversal potential, leading to excitatory actions of the inhibitory neurotransmitter GABA and alkalization of presynaptic terminals, leading to increased spontaneous neurotransmission<sup>42,45</sup>.

## Optogenetic control of biochemical signalling pathways.

Animal rhodopsins are G-protein-coupled receptors (GPCRs) and animal vision is the most studied G-protein signalling pathway. A pioneering study demonstrated that bovine rhodopsin expression may be used to activate G-protein signalling in *Xenopus* oocytes but without describing the signalling mechanism<sup>46</sup>. However, the off response of rod-rhodopsins remained uncontrollable in the absence of rhodopsin kinase and arrestin, and responses severely declined upon repetitive stimulation. The responses of  $\text{G}_{\text{i/o}}$  activating cone rhodopsins<sup>47–49</sup> or  $\text{G}_{\text{s}}$ -specific box jellyfish opsins<sup>50</sup> declined faster, but were still not tightly controllable. The solution was approached by revitalizing melanopsin OPN4, which can be switched on and off with blue and yellow light, albeit incompletely owing to substantial overlapping spectra of the dark state and signalling state<sup>51–53</sup>, and only the UV-sensitive Lamprey parapinopsin (PPO) with its green-absorbing signalling state offered efficient on and off switching with a dual-colour light source<sup>54–57</sup>.

GPCR signalling depends on many properties of the receptors, including substrate binding kinetics, G-protein specificity and timing of activation and receptor inactivation, which in total cannot be fully mimicked by rhodopsins. One way to more selectively mimic the activity of a specific GPCR is to engineer hybrids between structurally related opsins and GPCRs (optoGPCRs)<sup>58,59</sup>. OptoGPCRs open new, and possibly more specific, routes for the analysis of intracellular signalling pathways compared with unmodified rhodopsins, whereas the dynamics of G-protein coupling and pathway recruitment still has to be approached by testing various expression levels and light regimes. However, these optoGPCRs cannot be simply transferred to another cell type because G-protein promiscuity might activate unwanted pathways<sup>51,60</sup>. With optoGPCRs, the application of G-protein activation has enormously broadened the optogenetic actuator toolbox. These tools

will be well suited for temporally defined modulation of non-excitabile cells, potentially including glial cells in the brain and other non-neuronal cell types<sup>61</sup>.

RTKs are another large family of cell surface receptors that sense growth factors and hormones to regulate various cellular behaviours by target phosphorylation. Engineered light-sensitive epidermal growth factor receptor (EGFR1) and the fibroblast growth factor receptor 1 (FGFR1) have shown robust light activation of both RTKs and cellular signalling in human cancer and endothelial cells, and faithful mimicking of complex mitogenic and morphogenic cell behaviour<sup>35</sup>. The cobalamin-binding domain (CBD) and tropomyosin receptor kinase B (TRKB) have been fused to RTKs to yield light-sensitive receptors<sup>36,37</sup>. Fusions with TRKB have high specificity for the target proteins, although their application range is narrow and the constructs need to be optimized for every new application. Moreover, one drawback is that cobalamin-based light sensors or phytochrome-based light sensors generally require addition or cellular synthesis of the cofactor molecules, making their potential for in vivo applications more complex than the application of the retinal-based photoreceptors.

**Second messengers.** Photoactivated cyclases (PACs) have been employed for direct control of the second messengers cAMP and cGMP. The soluble bPAC from *Beggiatoa* spp. is a tandem of BLUF-type light sensors (blue light sensors using FAD (flavin adenine dinucleotide)) (FIG. 2) with carboxy-terminal adenylyl cyclases. These optogenetic actuators show millisecond-range on-kinetics upon photostimulation and second-range off-kinetics in the dark (bPAC  $\tau_{\text{off}} = 12$  s)<sup>38</sup>. Co-expression of bPAC with the small prokaryotic potassium channel SthK (PAC-K silencer) in two-component optogenetic approaches has been exploited for long-lasting neuronal hyperpolarization in cardiomyocytes (CM) as well as in fly, mouse and zebrafish neurons, providing high operational light sensitivity but low time resolution<sup>38,62–64</sup>. However, colour modification is only possible within a small range around 470 nm and occasional residual dark activity has been observed<sup>65</sup>. New spectral windows were opened by introducing rhodopsin guanylyl cyclases (RGCs), which are cyclases with amino-terminally linked rhodopsins. These rhodopsin cyclases (RhCs) are characterized by low dark activity, effective light absorption ( $\epsilon > 32,000 \text{ M}^{-1} \text{ cm}^{-1}$ ) and the promise of flexible colour tuning<sup>66–68</sup>. RhCs show millisecond-range off-kinetics, are naturally GTP selective and are convertible into ATP cyclases by genetic engineering. Some members of the fungal Chytridiomycota may use heterodimeric RhGCs, with one blue or green sensitive rhodopsin catalyst, and a second near-infrared sensitive modulator (NeoR,  $\lambda_{\text{max}} = 660\text{--}700 \text{ nm}$ ). These NeoRs might allow to extend the usable spectral range into the superior infrared spectral window<sup>69</sup>.

**Protein abundance.** Control over the concentration of selected proteins within a cell has been a long-standing goal and has stimulated the interest of protein engineers for decades. The most obvious point of intervention

is the regulation of transcription. Previously explored concepts were based on the connection of DNA-binding proteins to a photoreceptor such as Phytochrome, FKF1 or VIVID (light–oxygen–voltage (LOV) proteins), or CRY. Upon illumination, these photoreceptors bind to their signalling partner proteins PIF3, GIGANTEA/Tulips or CIB, respectively, with bound components of the transcription machinery as VP16 or VP64. In light, the transcription component is attracted to the promoter region of interest by the photoreceptor and signal–protein interaction, leading to the assembly of the transcription complex and initiation of transcription. However, the chosen GAL4 DNA-binding domains have to be incorporated into the model organism (reviewed elsewhere<sup>70,71</sup>). To address any promoter of interest, programmable DNA-binding proteins such as zinc finger DNA-binding proteins<sup>72</sup>, TALEs<sup>73</sup> and deactivated Cas9 have been functionalized as the second generation of transcription regulators<sup>74,75</sup>. The main caveat for Cas9 application is the prolonged occupancy of Cas9 at its DNA-binding site, especially in situations where the DNA is not cleaved, which disturbs gene expression prior to the intended start of the experiment<sup>76</sup>. Inserting a LOV domain into an anti-CRISPR protein such as AcrIIA4 or AcrIIC3 (CASANOVAs) overcomes this problem and makes Cas9 binding better controllable. This approach works reliably in HEK cells, but has not been rigorously tested for non-embryonic cells such as neurons<sup>77</sup>.

### Targeting strategies

Optogenetics was first applied in neuroscience, driven by the complexity of neural circuits and the demand for improved selectivity in perturbational approaches for studying neural circuits. Genetic techniques, viral vector technology and optical methods have grown rapidly around the developing optogenetic toolbox. As a result, the tools and enabling technologies for optogenetic experimentation in neuroscience, as well as the fundamental understanding of the caveats and constraints of their application, are more advanced in neuroscience than in other fields. In the following section, we review some of the major targeting approaches for expression of optogenetic tools in neural circuits.

One of the major benefits of the optogenetic paradigm is its selectivity to defined cells and circuits. In neuroscience applications, genetic targeting of optogenetic tools has advanced considerably, and has profited greatly from developments in viral vector technologies. As optogenetic tools are genetically encoded and mostly single-component actuators (requiring the introduction of only one gene to the target cell population), multiple delivery methods can be used to introduce them into the cells of interest. Targeting strategies are either based on promoter specificity directly or through a combination of a conditional transgene expression cassette that can be switched on or off using a recombinase.

**Transgenic expression of optogenetic tools.** Transgenic expression is the simplest approach to implement as it requires only the maintenance of an opsin-expressing animal strain<sup>78</sup> (FIG. 3a) or the crossing of two strains of animals. The latter involves a driver line — engineered to



express a recombinase or transcription regulator such as Cre and Flpo (in rodents) or a Gal4 driver (in zebrafish) in a particular cell population — and an animal strain expressing a conditional opsin gene under the control of the relevant driver (FIG. 3b). The F1 progeny of such a cross will express the opsin gene in all cells in which the driver protein is expressed and will therefore be amenable to optogenetic manipulation simply by illuminating the targeted brain region. The approach is simple to implement, but one should consider potential caveats, including the presence of axons from neurons in other brain regions, which might be activated along with the cell bodies in the illuminated region. In mice, expression of Chr2 or eNpHR3.0 from the ROSA26 locus<sup>79</sup> can be quite weak and not universally sufficient to drive activity in every neuron subtype. Expression of opsin genes from the TIGER locus<sup>80</sup> showed stronger opsin expression and might, therefore, be useful for some target neuron populations. However, this approach requires generation and/or breeding of a dedicated animal strain for every targeted neuron population, and thus lacks the versatility and cost-efficiency of viral vector-based approaches. Another potential confound is unintentional targeting in some driver lines (see for instance REF.<sup>81</sup>), making the verification of driver lines advisable<sup>82</sup>.

**Viral vector targeting.** Lentiviral or adeno-associated virus (AAV) vectors can be engineered to encode optogenetic actuators and delivered either directly to the brain parenchyma or through systemic injection to target either specific brain regions or brain-wide populations, respectively. Targeting of genetically identified neuronal populations is achieved either by using the tissue tropism of the virus serotype and a cell type-specific promoter or enhancer (FIG. 3c), or by injecting the viral vector into a transgenic recombinase-expressing animal strain (FIG. 3d). Promoter-based viral vector targeting is attractive as it does not require the maintenance of a specific animal strain for every target neuron population and can also be applied in non-genetic models. However, the limited viral payload size — particularly of AAVs — prohibits the use of most native promoters. The list of minimal promoter or enhancer sequences that have been validated to specifically express in defined neuron populations is quite restricted. However, this field is rapidly expanding<sup>83,84</sup> and is further diversified by synthetic approaches<sup>85</sup>.

**Circuit-based viral vector targeting.** The most commonly used retrograde viral tracer is AAVretro<sup>86</sup>, which can be taken up by presynaptic terminals and travel in retrograde to express at the soma of long-range projecting neurons (FIG. 3e). The herpes simplex virus 1 (HSV1) and canine adenovirus 2 (CAV2) both have retrograde targeting abilities, but these are less readily available and have been shown to impair the health of targeted neurons, particularly over longer expression times of weeks to months<sup>87</sup>.

**Systemic delivery of AAV-PHP capsids.** Targeting sparse brain-wide populations is beneficial for some experimental configurations. For example, structural

imaging of dendritic spines in the cortex or excitation of a randomly selected sparse ensemble in a given brain region. For this purpose, AAV-PHP vectors have been engineered to cross the blood–brain barrier with high efficiency (FIG. 3f). The AAV-PHP serotypes allow targeting of diverse central and peripheral nervous system neurons<sup>88,89</sup>. The same capsids can be used with Cre-dependent AAV expression plasmids to allow sparse brain-wide expression in a genetically defined neuronal subtype. However, the efficiency of AAV-PHP serotypes in crossing of the blood–brain barrier can vary in different mouse strains<sup>90</sup>.


**Electroporation.** Concentrated DNA can also be injected into the cerebral ventricles followed by in utero electroporation<sup>91–93</sup>, enabling the study of neural cell fate determination and migration or cortical layer-specific expression.

### Compartment-specific functions

The effective current resulting from light-gated channel conductance can vary dramatically owing to local ion concentration gradient differences. For neuroscience applications, this is particularly crucial for use of ACRs. At the somatic and dendritic compartments, this is an advantage, as they can be used for shunting inhibition. In contrast, ACRs can exert excitatory effects in axons and presynaptic terminals, in which the intracellular chloride concentration is higher (BOX 1). Ion pumping rhodopsins, on the other hand, translocate the ion over the membrane in a predetermined direction, which can be an advantage owing to the increased control of ion flux. However, the pumping-induced hyperpolarization and elevation in ion concentration can also have side effects, such as the alkalization of presynaptic boutons<sup>94</sup> or an artificial increase in intracellular chloride<sup>45</sup>. Similarly, the effects of G-protein-coupled animal rhodopsins on neuronal activity strongly depend on the given second messenger cascade in the local compartment. For instance, in the soma and dendrite,  $G_{i/o}$  signalling can activate G-protein-coupled inward rectifying potassium channels, whereas in the presynaptic compartment the  $G_{i/o}$  pathway mainly acts through inhibition of voltage-gated calcium channels and cAMP signalling<sup>57</sup>.

### Optimizing expression and targeting

Beyond single-channel conductance, one of the main factors determining maximal photocurrent is the number of functional opsin molecules in the membrane, which in turn depends on the expression level, protein-folding efficacy, retinal binding affinity, membrane trafficking and protein turnover rate. The expression level of a transgene can be controlled via promoter strength and transgene copy number. The opsin-folding efficacy and protein stability were shown to depend on the availability of the chromophore retinal<sup>95</sup>. Although retinal availability does not seem to be a limiting factor in mammalian tissues, it needs to be routinely supplemented in the food of invertebrate model systems and some cultured cell lines. In plants, the absence of retinal can be compensated for by its synthesis via



expression of a bacterial  $\beta$ -dioxygenase that facilitates rhodopsin expression. A common issue with unmodified opsin expression cassettes is aggregation of the synthesized protein in the endoplasmic reticulum. To overcome this limitation, trafficking motifs involved in transport of membrane proteins along the secretory pathway to the cell surface were utilized to improve

plasma membrane targeting (see Supplementary Fig. 4). The most widely used trafficking motifs utilized were first described for the potassium channel  $K_{ir}2.1$  — these motifs enhance endoplasmic reticulum export as well as Golgi to plasma membrane trafficking<sup>96</sup>, resulting in higher plasma membrane localization and increased photocurrents in animal<sup>97</sup> as well as plant<sup>98</sup> cells.

◀ Fig. 3 | **Cell type-specific targeting of optogenetic tools.** **a** | Transgenic mice constitutively expressing an opsin gene from their genome allow simple experiments that only require addition of light delivery apparatus. Promoter 'A' activity (indicated by A) will lead to transgene expression (green). **b** | Transgenic animal expressing a recombinase such as Cre under control of a cell type-specific promoter is crossed with a second line carrying a conditional expression cassette encoding the desired opsin. Dual transgenic offspring will then show organism-wide expression of the opsin in all cells that underwent promoter activation at any stage of development (green). Cre expression (indicated by A) is unnecessary once the conditional expression cassette was activated. **c** | Where a short minimal promoter sequence is available, targeted viral vector injections can be used to restrict expression spatially as well as by the gene expression profile. A viral vector containing the specific minimal promoter sequence upstream of the opsin gene will lead to expression in specific cells expressing the promoter (indicated by A), only in the region targeted with the injection (blue box). **d** | Approaches in parts **a** and **b** can be combined to achieve both spatial and gene expression specificity in cases where short specific promoters are not available, or where promoter activity is not specific during development. **e** | Projection neurons can be addressed by injection of an axon terminal-transducing, retrograde travelling viral vector encoding for the opsin or a recombinase into the target region. Recombinase-encoding viral vector is injected in a projection target (area B, red box) and travels retrogradely. A second viral injection of conditional expression cassette encoding the desired opsin into an upstream region (area A, blue box) will then lead to opsin expression only in neurons within area A that project to area B. **f** | Adeno-associated virus (AAV) capsids engineered for improved blood–brain barrier penetration allow brain-wide (mostly sparse) expression of an opsin through intravenous injection of the viral vector. IV, intravenous.

Further optimization of functional expression can be achieved by adjusting the linkers between the opsin and the often co-expressed fluorophore, mutating potential ubiquitination sites and screening random mutations in the opsin coding sequence<sup>99</sup>. Beyond improved photocurrents, targeting an opsin to a selected subcellular compartment can be used to investigate the function of the chosen compartment, such as the mitochondria, synaptic vesicles, lysosomes or endoplasmic reticulum (see Supplementary Fig. 4), or to use the differential effects of ion channels discussed above. Somatic restriction has been successful in increasing the specificity of single-cell stimulation by reducing inadvertent modulation of nearby neurites<sup>77,100–104</sup>, as well as in reducing ACR-mediated axonal excitation<sup>24</sup>. Somatic restriction has the added effect of accelerating the effective photocurrent off-kinetics, owing to the elimination of photocurrents arising from distal neurites in the illuminated tissue volume, as these are low-pass filtered while travelling along the neurite to the somatic compartment.

Although targeting microbial rhodopsins to presynaptic vesicles is feasible<sup>43</sup>, enrichment of rhodopsin abundance in the axonal plasma membrane has not been achieved. Cytosolic proteins can be enriched in the axon by mRNA shuttling motifs. However, local rhodopsin translation in the axon has not been successfully applied, potentially owing to a lack of transmembrane protein synthesis in the vertebrate axon<sup>105</sup>.


### Light delivery techniques

Although the vast majority of advanced light targeting approaches have been developed with the specific applications of neuronal and cardiac optogenetics in mind, these methods are generalizable and are beginning to be applied to other systems<sup>106</sup>. Optogenetics is readily applicable to light-accessible preparations such as cultured cells, tissue slices, transparent organisms, such

as zebrafish larvae, or the cortical surface of the mammalian brain, allowing for extensive flexibility in light delivery. For whole circuit or brain region optogenetics, light needs to reach the target with sufficient irradiance to induce opsin activation. Ideally, light should be guided into the target structure with minimum damage to the tissue. In behaving animals, stimulation should also be conducted with minimal disruption to the measured behaviour, limiting implantable weight and tether stiffness. Whole circuit/region optogenetic stimulation is typically carried out using a multimode optical fibre, guiding the light from the source to the target (FIG. 4a). Optical fibres targeting a deep brain region can be permanently implanted by attaching a fibre-optic implant to the skull using dental cement. The dimensions of the fibre and its optical properties strongly influence the spatial profile of light reaching the brain. Most commonly, flat-cleaved optical fibres are used. However, the high radiant flux density necessary at the fibre tip to achieve sufficient irradiance within the targeted volume can lead to heat-induced changes in neuronal activity and behaviour<sup>107,108</sup>. It is therefore advisable to consider tissue heating when planning the experiment and to use opsin-free light-stimulated controls. One approach to minimizing the irradiance required in optogenetic experiments is to maximize the operational light sensitivity of the opsin used (see Supplementary Fig. 3). Another factor is wavelength, as absorption is higher for shorter wavelengths and therefore the peak temperature increase is lower for longer wavelengths at the same radiant flux density. Increased optical fibre diameter also reduces the peak light power density. However, wider fibres also cause more tissue damage and have a higher chance of illuminating blood vessels, which strongly absorb visible light and thus increase potential heating-related artefacts. This trade-off can be, at least partially, mitigated by the use of tapered optical fibres (FIG. 4b), which can be used to flexibly illuminate a large brain volume<sup>109</sup>.

In these conventional optogenetic experiments, visible light is mostly delivered non-specifically to large tissue regions and genetic targeting strategies are used to express the optogenetic actuator in specific cell types. This approach has enabled tissue function to be mapped with unprecedented anatomical and cell type specificity. However, wide-field illumination synchronously activates or silences entire populations of all opsin-expressing cells, which does not replicate the physiological case: adjacent cells belonging to genetically defined classes have been observed to exhibit divergent activity patterns. To investigate complex population activity patterns, whole-region optogenetics is insufficient. Digital mirror devices coupled to single-photon excitation have enabled single-target and multi-target excitation in head-restrained and freely moving animals and found in situ applications in control of excitation waves underlying cardiac arrhythmias<sup>110–113</sup>. However, the use of visible light has limited these approaches to superficial brain layers or low scattering samples. Recent developments in opsin engineering, optical microscopy and multiphoton laser source development have given rise to circuit optogenetics<sup>114</sup>, which allows modulation of neuronal activity deep in scattering tissue with single-spike precision and






**Fig. 4 | Optical approaches for optogenetic stimulation. a–c** | Single-photon wide-field illumination (blue) of all genetically targeted opsin-expressing neurons using excitation through optical fibres: illumination using a flat-cleaved optical fibre causes high peak light power density at the fibre–tissue interface (part **a**); a tapered fibre increases the optical fibre–tissue interface resulting in a reduced peak light power density (part **b**); and single-photon multi-target patterned illumination by spatially shaping the intensity of the excitation beam by means of a digital micromirror device, placed in a plane conjugated to the sample plane (part **c**). Light distribution at the digital mirror device plane and at the sample plane only differ by a spatial scaling factor corresponding to the magnification of the optical system. Axial resolution is proportional to the square of the lateral spot dimensions. **d,e** | Two-photon multi-target illumination by holographic light shaping:

a spatial light modulator placed at a plane conjugated with the objective back aperture generates a 3D distribution of holographic spots, which are scanned with a spiral trajectory to cover the cell surface — axial extension of the generated spot is optimized to illuminate upper and lower cell membranes (part **d**); and a spatial light modulator is used to generate multiple extended spots with a size large enough to cover the whole cell soma — temporal focusing is used to maintain micrometre axial resolution independently of lateral spot size (part **e**). **f** | Timeline indicating critical optical developments that have enabled new optogenetic experiments throughout the past 15 years. Single-photon and two-photon milestones coloured blue and red, respectively. Holographic light shaping for neuronal activation was developed simultaneously for single-photon and two-photon activation, indicated by red–blue gradient for the milestone in part **f**. ChR2, channelrhodopsin 2.

# Box 2 | Single-photon versus two-photon excitation, mechanism and focal volume

In single-photon excitation, the absorption of a photon by a chromophore induces a molecular transition from the ground state ( $S_0$ ) to the excited electronic state ( $S_1$ ), whereas in two-photon excitation the same transition can be induced by the quasi-simultaneous absorption of two photons. As two-photon cross-sections are typically much smaller than those for single-photon absorption, significantly higher photon fluxes are generally required to generate similar excitation rates, requiring more complex and expensive components such as ultra-fast lasers. There are two main implications of two-photon absorption in microscopy. First, as the probability of excitation is a quadratic function of the instantaneous photon density, targets at the focal plane are much more likely excited than out of focus targets, whereas in single-photon excitation all targets throughout the light path can be excited. Second, the use of photons of lower energy, and therefore of longer wavelengths (deep red and infrared), can penetrate more deeply ( $\sim 700\ \mu\text{m}$ ) into scattering tissue.




single-cell resolution (FIG. 4c–e). Specifically, combining variants with enhanced kinetics<sup>30,77,115,116</sup>, higher conductance<sup>117–119</sup> or shifted absorption peaks<sup>30,119,120</sup> with optimized targeting and expression strategies<sup>77,101–103</sup> enables neuronal control with single-cell, single-spike precision at millisecond temporal resolution and the generation of action potential trains with high (50–100 Hz) spiking rates<sup>116,121</sup>. In parallel, advanced optical techniques based on two-photon excitation (BOX 2) have been developed to precisely guide light through tissue. The small single-channel conductance of commonly used optogenetic actuators such as ChR2 (40–90 fS)<sup>122</sup>, and the limited number of channels or pumps recruited within a conventional two-photon focal volume, mean that it is generally necessary to use spiral scanning or parallel light shaping using computer-generated holography or the generalized phase contrast method (see Supplementary Fig. 5) combined with temporal focusing<sup>14</sup> (see Supplementary Fig. 6) to increase the portion of excited membrane<sup>123,124</sup> and to sufficiently depolarize a neuron to firing threshold or, effectively, silence it. Holographic light multiplexing with spiral scanning<sup>125</sup> or ad hoc spatio-temporal shaping approaches (see Supplementary Fig. 7) have been used to generate patterned illumination at multiple axially distinct planes<sup>117,126,127</sup>. Multiplexing divides the available laser power between targets and, thus, requires powerful lasers. Owing to the higher peak photon density, amplified low repetition rate (200 kHz–10 MHz) fibre lasers enable higher rates of two-photon absorption than titanium:sapphire oscillators (at the same average power), and can therefore be used to reduce the necessary power to generate physiological signals<sup>128</sup>. Additionally, these sources deliver tens of watts of power, facilitating the simultaneous photostimulation of hundreds of cells throughout cubic millimetre volumes. The combination of these technologies has recently led to the first demonstrations of multi-target neural circuit manipulation<sup>77,118,129</sup>.

The ability to control neuronal activity with single-cell precision and millisecond temporal resolution allows to functionally probe neuronal networks beyond the resolution of synchronous modulation of entire networks or genetically defined network components. For instance, using temporally precise single-cell excitation in the visual cortex and olfactory bulb, the minimal number of co-activated cortical neurons necessary for visual perception<sup>130</sup> and the dependence of olfactory perceptual detection on both the number of activated neurons and their relative spiking latency were characterized<sup>131</sup>. The requirement of high numerical aperture objectives has limited two-photon optogenetics to circuits in superficial ( $\leq 500\ \mu\text{m}$ ) cortical areas of mouse brain, transparent zebrafish larvae<sup>132</sup> or in vitro applications. Micro-endoscopes are small optical probes that can be inserted into living tissues, and represent a promising solution to extend optical brain manipulation to deeper brain structures both in combination with holographic spiral scanning<sup>133</sup> or using multi-temporally focused light-shaping approaches<sup>134</sup>. Three-photon optogenetics, which relies on longer wavelengths and exhibits a cubic dependence of excitation efficiency on excitation power, could potentially be used to stimulate neuronal circuits in deeper brain regions (600  $\mu\text{m}$ –1 mm) with single-cell resolution. However, to date, three-photon photostimulation has only been demonstrated in vitro<sup>135</sup>.

## Results

### Output analysis

When designing optogenetic experiments, care should be taken to verify the impact of the optogenetic manipulation on the targeted cells. This can be achieved in numerous ways, including electrophysiological recordings in vitro or in vivo, optical recordings with genetically encoded sensors, immediate early gene labelling and non-invasive imaging modalities. Below we outline the major techniques used in such experiments, and the



**Fig. 5 | Expected results in optogenetic experiments.** **a** | Expression of optogenetic actuators such as channelrhodopsin 2 (ChR2) or NpHR in neurons leads to emergence of light-driven photocurrents, which can be recorded using the whole-cell patch clamp technique (left). Cells expressing chloride-conducting NpHR will show an outward current (top right, voltage clamp recording with cell resting at  $-70$  mV) whereas cells expressing cation-conducting ChR2 will show an inward photocurrent (bottom right, voltage clamp recording with cell resting at  $-70$  mV). **b** | Whole-cell current-clamp recordings in a neuron expressing excitatory ChR2, showing action potentials evoked by brief light pulses (blue bars).

**c** | Hyperpolarization and silencing of spontaneously occurring action potentials in a neuron expressing eNpHR3.0. **d** | Extracellular recordings, coupled with local light delivery, used to reveal activity of neurons in vivo, using the awake behaving optrode configuration<sup>268</sup>. **e** | Raster plot showing action potentials (black dots) occurring rapidly after a 5-ms blue light pulse delivered into the target brain region. **f** | Raster plot showing activity of neurons expressing inhibitory anion-conducting GtACR2, showing increased inhibition of action potential firing with increasing light intensity. Part **f** is reprinted from REF.<sup>24</sup>, CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>).

considerations that should be taken into account when designing and performing such experiments.

**Electrophysiological recordings.** To interpret the results of optogenetic manipulations, it is often necessary to determine the extent of optogenetic tool expression and its physiological effects on the targeted neurons. In the case of light-gated ion channels or pumps, recording the electrophysiological changes induced by the optogenetic manipulation is the most direct way to characterize light-mediated effects (FIG. 5a–c). As these effects can vary greatly between cell types, brain regions and even viral serotypes<sup>136</sup>, it is crucial to validate the optogenetic effector in every new experimental system before proceeding to behavioural or other functional read-outs. To describe effects on the level of spike rates and timing, whole-cell recordings are often not necessary. Instead,

extracellular recordings are often used (FIG. 5d–f), given their higher throughput and minimal crosstalk with light delivery (see REF.<sup>137</sup> for discussion of light-induced electrical artefacts). However, higher frequency spiking activity does not necessarily indicate increased synaptic transmission from the stimulated neurons<sup>136</sup>. Synaptic depression and depletion of neurotransmitter release can lead to erroneous interpretation and should be taken into account when performing optogenetic excitation experiments, particularly with neuromodulatory and neuropeptide-releasing neuronal populations.

**Optical recordings.** Fluorescent reporters are another common method for monitoring the effects of optogenetic manipulations. These techniques enable recording from the same cells over several recording sessions and the concurrent recording of high numbers of cells.



**Immediate early genes**

Genes that are rapidly induced by elevated neural activity such as *Fos*.

However, given that optogenetics itself relies on light delivery, fluorescent reporters can be efficiently integrated only if a spectral or light power separation can be achieved to minimize the crosstalk between the recording and manipulation modalities (see Supplementary Fig. 2). Additionally, when combining red-shifted  $\text{Ca}^{2+}$  indicators with optogenetic actuators, extra care must be taken, as these can show blue light-activated photo-switching behaviour that can resemble  $\text{Ca}^{2+}$  activity in amplitude and kinetics<sup>138</sup>.

Whereas genetically encoded calcium sensors continue to be the state of the art in terms of optical activity read-out, voltage indicators are gradually reaching a level of maturity that could allow for wider adoption by the field<sup>139</sup>. Novel fluorescent sensors for neurotransmitters, neuromodulators and other small molecules are continuously developed<sup>140–142</sup>. Another approach to read out gross neuronal firing rate changes is to characterize the expression of immediate early genes, for instance via immunohistochemistry on the protein level<sup>143</sup> or on the mRNA level using quantitative PCR, in situ hybridization or single-cell RNA sequencing<sup>144</sup>. Immediate early gene expression can be used to determine the relationship between the modulation of specific neuronal populations and global brain activity<sup>145</sup>. However, the temporal precision of this approach is limited to the average neuronal activity over minutes to hours and, unless combined with targeted recombination approaches<sup>146</sup>, only a single manipulation can be characterized per animal.

Although ChR variants with peak single-photon excitation wavelengths spanning the visible region of the electromagnetic spectrum have been engineered<sup>26</sup>, performing crosstalk-free, multicolour two-photon experiments is not trivial. Ideally, spectrally orthogonal ChRs and activity reporters would be chosen, but, unfortunately, the two-photon action spectra of commonly used opsins are extremely broad<sup>26</sup> (see Supplementary Fig. 8). As previously introduced, opsins with red-shifted action spectra exhibit persistent activation in the blue range, which coincides with wavelengths used for two-photon imaging of commonly used activity reporters (920–980 nm). One approach to reduce crosstalk is to use opsins with fast kinetics. Although this approach does not eliminate sub-threshold network perturbation, the (relatively) fast repolarization of neurons expressing ChRs with fast off-kinetics means they are unlikely to fire action potentials owing to excitation by the imaging laser during scanning. Successful employment of this method requires careful titration of imaging parameters, including the imaging power, frame rate and field of view. This is an interim approach until high-efficiency blue-shifted opsins, red-shifted activity indicators and amplified lasers in the appropriate spectral range become more widely available.

**Alternative recording modalities.** Electrophysiological and optical recording modalities both suffer from potential interactions with the light required to excite optogenetic actuators. The haemodynamic response is an alternative physiological response to neural activity that can be exploited to report the impact of optogenetic


modulation. For superficial brain areas such as the cortex, the haemodynamic response can be measured via intrinsic imaging<sup>147,148</sup>, whereas functional MRI<sup>149</sup> can be utilized to record brain-wide haemodynamics. Although the non-invasive nature and the ability to measure the haemodynamic response throughout the entire brain are major advantages, the main drawbacks are that the temporal resolution of this approach is fundamentally limited by the specificity and kinetics of the haemodynamic response itself and the limited spatial resolution of neurovascular coupling<sup>150</sup>. Heating should also be taken into account here as it can directly impact the haemodynamic response<sup>151</sup>. Functional ultrasound imaging is a rapidly developing technology that could be used to perform brain-wide detection of neural activity triggered by localized optogenetic stimulation. Although this method still relies on changes in neurovascular blood volume changes, it can be performed at a fraction of the cost of functional MRI recordings and is rapidly advancing to allow better spatio-temporal resolution and portability<sup>152</sup>.

**Linking neural to behavioural read-outs**

The exquisite spatial and temporal control of genetically defined cells with optogenetics are attractive features for experiments aiming at establishing causal links between neural activity and behaviour. The growing understanding of neuronal coding has also led to nuanced insight of the limits of interpretability of such experiments. However, when appropriately designed and controlled, optogenetic experiments can provide important information on how neural circuits drive behaviour.

Choosing the locus of intervention may be instructed by previous literature, lesion experiments and behavioural pharmacology. For example, we know that silencing the motor cortex with compounds such as muscimol or baclofen causes motor impairment whereas optogenetic stimulation elicits muscle contraction<sup>153</sup>. Although gain-of-function experiments may be a starting point, cell type-specific optogenetic inhibition of genetically defined neurons in the motor cortex would provide a more accurate picture, better dissociating the physiological motor response from an artificial perturbation<sup>154</sup>. Another way to determine the brain region and cell types of interest is the use of activity markers such as the immediate early genes *Fos* or *Arc*. Finally, technological advances in wide-field optical monitoring of intracellular calcium may allow to visualize the activity of large cortical areas<sup>150,155</sup> and selectively silence defined cortical regions transcranially<sup>156</sup>. Alternatively, high-density electrical recordings<sup>157,158</sup> can elucidate the activity of many neurons in deeper structures. This allows the experimenter to identify circuits with activity patterns that may be relevant to the behaviour to be studied.

Next, observational experiments should be implemented to characterize the functional properties of the cell population to be modulated (FIG. 6). This may be achieved using electrophysiology *in vivo* — for example, by tetrode recordings of photo-tagged neurons<sup>159</sup> or genetically encoded calcium sensor imaging<sup>160</sup>. The choice of the optogenetic intervention should ideally be instructed by these observational investigations



**Fig. 6 | Establishing links of causality with optogenetics.** Experimental road map based on identifying the neural correlate of behavioural sensitization to cocaine<sup>269</sup>. **a** | When injected, cocaine elicits a locomotor response quantified in a cyclotron. Response is enhanced upon second injection of same dose. **b** | Fos is an immediate early gene highlighting the neurons particularly active, which provided the entry point to identifying the medial prefrontal cortex to nucleus accumbens projection as the behavioural relevant circuit. **c** | Slice electrophysiology enables observation of selective potentiation of glutamate transmission onto

dopamine type 1 receptor medium spiny neurons (D1R MSNs)<sup>270</sup>. **d** | Depotential protocol (long-term depression (LTD) at 12 Hz) validated in slices restores standard transmission. **e** | In vivo validation involves opto-tagging, where spontaneously occurring spikes (grey, dashed trace) are compared with optogenetically evoked spikes (blue trace). Waveform and latency are important parameters. **f** | LTD protocol is eventually applied in vivo to reverse sensitization. ChR2, channelrhodopsin 2; EPSC, excitatory postsynaptic current. Part **d** adapted with permission from REF.<sup>269</sup>, AAAS.

and match the dynamic range of the activity observed. Additional selectivity can be achieved by aiming at axon terminals rather than cell bodies. Effectors aiming at hyperpolarizing terminals or creating shunting inhibition may not always be efficient or, at times, even perturb para-membranous ion concentrations such that the effect is difficult to predict<sup>42</sup>. With the advent of  $G_{i/o}$ -coupled effectors<sup>56,57</sup>, presynaptic inhibition is more straightforward, but it remains good practice to validate the efficacy of inhibition, as well as its spatial selectivity, particularly with the highly light-sensitive effectors. It is particularly important to take into account the firing frequency of the cells under investigation as presynaptic inhibition is potentially less efficacious at higher firing rates.

There are two distinct approaches for optogenetic manipulations, one with an acute effect and the other

with long-lasting effects. Acute manipulations require behavioural observations in real time. Ideally, a small set of optogenetic trials should be randomly interleaved with control trials. This assesses the acute effects on optogenetic trials along with longer-lasting changes to the subsequent control trials. Such laser on-off protocols can be used to control for adaptive behavioural changes throughout a given session. However, often the particular structure of the behavioural paradigm does not allow for hundreds of trials. The timing of the optogenetic stimulation or inhibition should therefore occur in a behaviourally defined window, and be only as long as is strictly necessary.

Long-term observation is appropriate when optogenetic interventions exploit synaptic plasticity mechanisms. For example, synaptic potentiation typically is achieved by high stimulation frequency, whereas

depression requires sustained low-frequency stimulation. Optogenetic synaptic plasticity protocols are particularly suited to study learned and adaptive behaviour. The goal of long-term observation experiments is to induce synaptic plasticity at identified synapses and observe the effect on behaviour at a later time point when optogenetic stimulation is no longer active. For example, low-frequency optogenetic stimulation can restore baseline transmission in cortico-accumbal synapses that have been potentiated by cocaine exposure<sup>161</sup>. Similarly, daily optogenetic stimulation of orbitofrontal to dorsal striatum axons for 10 min triggered long-term changes in synaptic strength and inhibited compulsion<sup>162</sup>.

## Applications

The vast majority of applications of optogenetics have involved neuroscience and brain research. Many of the general principles and approaches of optogenetics can be extended to other organs, particularly to those with excitable cells — such as skeletal muscle, heart, retina and gut — as well as to microorganisms and plants. These newer applications often present unique challenges and opportunities. Below, we illustrate some of these aspects with three select examples from visual, cardiac and plant applications.

### Vision restoration

Retinal degenerative diseases, such as retinitis pigmentosa and age-related macular degeneration, result in the loss of rod and cone photoreceptor cells, leading to partial or complete blindness<sup>163,164</sup>. Rendering inner retinal neurons responsive to light is one of the most obvious medical applications for optogenetics (FIG. 7A). The first proof-of-concept study involved the ubiquitous expression of ChR2 in retinal ganglion cells in retinal degenerated mice<sup>13</sup>. The approach since then has been reported by numerous studies using different optogenetic tools, retinal cell targeting strategies and animal models (see Supplementary Table 1).

Multiple clinical trials using ChRs for treating retinitis pigmentosa-related blindness have been initiated since 2015, with encouraging results (see Supplementary Table 2). Recently, the first published case study reported the partial restoration of vision (in the form of perceiving, locating and counting objects) in a blind patient with retinitis pigmentosa<sup>165</sup>. Positive preliminary results have also been reported in other clinical trials (see Supplementary Table 2). However, further efforts will be required to improve the outcome of optogenetic vision restoration, including the development of effective optogenetic tools and treatment strategies, and the improvement of gene delivery efficiency.


**Optogenetic tools.** ChRs have been the more commonly used optogenetic tools for vision restoration in animal models and the ones used so far in clinical trials. Two main issues should be considered when choosing an optogenetic tool for vision restoration. The first is the tool's expression efficiency and long-term safety in mammalian neurons; problems with the expression of an optogenetic tool are difficult to correct and, usually, result in cell toxicity in the long term. The second issue is the

low operational light sensitivity of ChR-expressing retinal neurons, in general, caused by the small unitary conductance and substantial inactivation. The requirement of high light intensity to activate the ChR-expressing retinal neurons constrains this application and also raises concerns regarding tissue photochemical damage, especially for short-wavelength sensitive ChRs. One solution to mitigate the potential photochemical damage is to use red-shifted ChRs, such as Chrimson, as the threshold of light intensity causing tissue photochemical damage is shifted to higher light intensities for longer wavelengths<sup>166–168</sup>. Another solution is to improve the light sensitivity of a ChR-expressing cell by slowing its closing kinetics or off-rate with molecular engineering<sup>169</sup> (see Supplementary Figs 1 and 2) combined with genome mining for more potent ChRs<sup>30</sup>. This strategy has been recently used to further optimize the more effective ChR variant CoChR. Functional vision is restored with improved CoChR mutants under ambient light conditions in a blind mouse model<sup>170</sup>. A third solution is to use GPCRs, including animal opsins (for example, rhodopsin and cone opsins)<sup>171–173</sup> or engineering of optoGPCR chimeras<sup>174</sup>, taking advantage of their high light sensitivity due to intracellular signal amplification. Further studies will need to evaluate the most effective optogenetic tools or develop better ones for this application.

**Gene delivery.** AAV vectors are the current choice for transgene delivery in the retina both in animal studies and in clinical trials<sup>175</sup>. Intravitreal injection is a preferred route of viral vector administration owing to its safe operation and ability to achieve widespread delivery to the retina. However, in non-human primates and in humans, virus transduction was mainly conferred to a narrow region surrounding the fovea or parafoveal region<sup>176,177</sup>, owing to the barrier of a thick limiting membrane in the retinal surface of primates<sup>22</sup>, which is one of the major factors limiting the outcome of AAV-mediated optogenetic therapy. Further development of more efficient gene delivery vehicles or techniques is required.

**Retinal cell targeting.** Most animal studies and clinical trials have employed ubiquitous promoters to express depolarizing ChRs in retinal ganglion cells. However, unlike the normal visual processing features in the retina including the segregation of ON and OFF signal pathways and the presence of antagonistic centre-surround receptive fields (FIG. 7Aa), this treatment strategy converts all retinal ganglion cells into ON cells (FIG. 7Ab). Although useful vision could still be generated as demonstrated in animal studies and reported from clinical trials, it is commonly believed that restoration of vision to mimic the intrinsic visual processing features in the retina would result in a better outcome. To this end, one strategy is to target an optogenetic tool to distal retinal neurons. Targeting a depolarizing ChR to ON bipolar cells using the mGluR6 promoter has been the most commonly employed strategy (FIG. 7Ac). Owing to the unique rod pathway in the mammalian retina, this could lead to ON and OFF responses at the level of retinal ganglion cells<sup>178–181</sup>, and possibly centre-surround receptive fields.





Targeting surviving cone photoreceptors with a hyperpolarizing optogenetic tool, such as eNpHR, has also been reported<sup>182</sup>. As a limitation for this strategy, the distal retinal neurons are more susceptible to severe retinal deterioration or remodelling than retinal ganglion cells after the death of photoreceptors<sup>183</sup>. Multiple treatment strategies will need to be developed for treating patients with different retinal degenerative conditions.

#### Cardiac research

The key benefits for clinical translation are sought in more versatile optogenetic pacing or suppression of wave propagation during arrhythmias, compared with currently used cardiac devices such as pacemakers and cardioverter/defibrillators<sup>184–191</sup> (FIG. 7B). Strategies for rhythm control enabled by optogenetic actuators aim to lower the energy needed to power cardiac

◀ Fig. 7 | **Optogenetic application for vision restoration, cardiac research and plant modification.** **A** | Strategies for optogenetic restoration of vision following photoreceptor degeneration. Visual processing pathways in normal retina, illustrating the rod/cone, ON/OFF pathways and antagonistic centre-surround receptive fields of retinal ganglion cells (ON cells, including rod bipolar cells and All amacrine cells (All), shown in grey tones; OFF cells shown in black; ON and OFF regions receptive field of retinal ganglion cells indicated + and -, respectively) (part **Aa**). Ubiquitous expression of a depolarizing optogenetic tool (green) in all retinal ganglion cells to convert them into ON cells (part **Ab**). Targeting a depolarizing optogenetic tool in ON bipolar cells to produce ON and OFF response in retinal ganglion cells and, possibly, the centre-surround receptive fields (part **Ac**). **B** | Optogenetics in cardiac research. Cell-specific targeting used for sympathetic (red) and parasympathetic (blue) nervous control of the heart using tyrosine hydroxylase (TH) and choline acetyltransferase (ChAT) promoters; cardiomyocytes (CM) from upper or lower chambers of the heart (atria (A) or ventricles (V)) can be selectively light-sensitized; and specific targeting of the fast conduction system (CS), cardiac fibroblasts (FB), vascular cells (VC) or macrophages (M) is also of interest (part **Ba**). Rhythm control can include optical pacemaking by short pulses (top trace), heart rate modulation by low-level constant (middle trace) or pulsed light by activating sympathetic nervous system (increase) or parasympathetic nervous system (decrease), and arrhythmias can be terminated to restore normal rhythm through a single long pulse (bottom trace), series of pulses and/or spatially patterned light (part **Bb**). Cardiotoxicity testing, a required component in drug development, enabled by high-throughput screening (HTS) optogenetic platforms, which can integrate patient-derived induced pluripotent stem cell-derived CM (iPSC-CM) for personalized therapy (part **Bc**). **C** | Optogenetic approaches in plants. Carbon dioxide entering through stomata with loss of water and oxygen (part **Ca**); and (**Cb-Cg**) expression of rhodopsins to control plant cell behaviour (scale bars: 15  $\mu$ m): absorbance spectra of anion channelrhodopsins GtACR1 (black) in relation to endogenous relevant plant photoreceptors (part **Cb**); optical fibre illumination of a leaf from an *Arabidopsis* plant mounted in a microscope set-up (part **Cc**) for simultaneous optical stimulation and electric recordings of guard cells embedded in the leaf epidermis (part **Cd**); representative membrane voltage recording from wild-type tobacco (red) and tobacco with stable GtACR1-expressing guard cell (black) in response to a 525 nm light pulse (10s) of 0.57 mW mm<sup>-2</sup> in presence of background red light (630 nm, 0.018 mW mm<sup>-2</sup>) to elicit stomatal opening (part **Ce**); and closure of stomatal aperture only induced in GtACR1-expressing cells in presence of green light (green bar in part **Cf**; green light spot in part **Cg**). BC, bipolar cells; GC, guanylate cyclase; RBC, rod bipolar cells. Part **A** adapted with permission from REF.<sup>245</sup>, Annual Reviews. Part **Cc**, image courtesy of S. Scherzer and A. Reyer. Parts **Cd**, **Cf** and **Cg** adapted with permission from REF.<sup>215</sup>, AAAS.

devices and extend battery life by delivering longer lower-energy light pulses — electrical pulse duration is limited owing to electrochemical toxicity via Faraday effects. Optogenetic actuators also eliminate discomfort and pain during classic cardioversion/defibrillation for better quality of life by using cell-specific genetic targeting to engage the fast conduction system<sup>188,192</sup> or to specifically target myocytes and avoid unintended contractions of thoracic skeletal muscle, diaphragm and vocal cords such as pain-inducing electrical defibrillation<sup>193</sup>. Computational modelling of the action of optogenetic tools in the heart helps explore strategies for control of arrhythmias, both with excitatory/depolarizing opsins and with inhibitory/hyperpolarizing opsins<sup>112,187,188,194,195</sup>. Longer-term in vivo clinical applications face the challenges of genetic modification of the hard to access cardiac muscle, potential immune responses and realizing embedded miniaturized light control devices that are reliable and safe<sup>191</sup>. Light penetration in the haemoglobin-rich heart muscle requires operation in the near-infrared and opsins excitable within that range, along with stabilization techniques to counter mechanical contractions. The atria are thinner (human atria are <5 mm) and present an easier target, along with more accessible autonomic nerves, such as the vagus nerve<sup>196</sup>.

#### Optical clamp

A technique using light and real-time feedback to keep membrane electrical parameters, such as voltage or action potential shape, at a set desired value.

AAV9 is the most efficient AAV serotype for targeting the ventricular myocytes in vivo when using a ubiquitous or a specific promoter, such as Myh6 (REF.<sup>197</sup>). The heart atria can be targeted optogenetically using the NPPA promoter and local viral gene delivery<sup>190</sup>. Cre-lox transgenic mouse models with suitable promoters have been used to transform the fast conduction system cells (Cx40)<sup>192</sup>, sympathetic neurons (tyrosine hydroxylase (TH))<sup>198</sup> and parasympathetic neurons (choline acetyltransferase (ChAT))<sup>196,199</sup> (FIG. 7Ba). To translate the approaches from rodents to larger animals, more work is needed in finding minimally invasive ways of transgene delivery to the heart and in minimizing immune responses. Previous clinical trials on gene therapy for cardiac disorders found that a large portion of the patients had antibodies against the viral vectors used, thus reducing the efficacy of the therapy<sup>200</sup>. Most of the published studies have used Chr2-H134R as an excitatory opsin. In general, more efficient and fast inhibitory opsins are desirable for arrhythmia control applications. There may also be a niche for step function-like depolarizing opsins that have fast recovery from inactivation as clamping tools in arrhythmia management. Bidirectional closed-loop control could make an all-optical approach named optical clamp at the whole organ level a reality. However, this will require spectral compatibility to accommodate not only for an excitatory and an inhibitory opsin but also for the optical read-out of a voltage indicator.

Overall, clinical applications of optogenetics in the heart face many challenges compared with the more accessible, immune-privileged applications to the eye that have seen translational advances. Considering the potential impact for control of arrhythmias, efforts should continue to improve the genetic targeting by more specific promoters, safer viral vectors, longer-wavelength opsins for better penetration and miniaturized distributed light sources. Basic science experiments with optogenetic tools provide invaluable insights for improvement of current cardiac devices and may yield new strategies for arrhythmia control<sup>111,113,191,201,202</sup>. These new strategies take advantage of the ability to produce complex space-time control patterns by light (unlike discrete signals from electrode arrays) to steer waves of excitation towards non-arrhythmic behaviour at very low energy. Optogenetics-empowered high-throughput systems can more immediately improve cardiotoxicity testing and drug development. All-optical cardiac electrophysiology, which combines optogenetic actuators and optical/optogenetic sensors<sup>203–205</sup>, offers immediate adoption and translation (FIG. 7Bc). Cardiotoxicity testing is crucial in the development of any new pharmaceutical, and high-throughput optogenetic methods with patient-derived cells represent impactful technology for personalized medicine<sup>206,207</sup>. Optogenetic techniques using hyperpolarizing opsins such as ArchT have been used to dynamically alter the action potential characteristics of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) towards a more mature phenotype to better predict drug responses<sup>208</sup>. The maturity of tissue-engineered constructs of such patient-derived iPSC-CMs can be improved through

chronic optogenetic pacing<sup>207</sup> towards new regenerative solutions for the heart (see Supplementary Fig. 9).

### Plants

A large set of photoreceptors that control phototropism, diurnal rhythms and photomorphogenesis play fundamental roles in plant growth and development. Blue light-absorbing phototropins and cryptochromes or red/far-red light-absorbing phytochromes are found in almost all plant tissues (FIG. 7Ca). Therefore, when using optogenetics tools in plants, the light regime used needs to be considered. The light required for plant growth will activate optogenetic tools when light of the entire visible spectrum is used; this can be avoided by combining a blue light-regulated transcriptional repressor with a red light-triggered switch<sup>209</sup>, allowing plants to grow in ambient white light. The use of flavoprotein-based optogenetic tools in plants has been described in detail recently<sup>210,211</sup>. Based on the LOV domain, a synthetic light-gated K<sup>+</sup> channel with considerable dark activity, called BLINK1, was recently expressed in *Arabidopsis* guard cells for control of stomatal behaviour<sup>212</sup>. The mechanism of BLINK1 light activation that clamps the membrane potential to  $E_K$  and facilitates stomatal opening and closing in the same way remains to be clarified. A rather simple but valuable technique to avoid non-specific activation of rhodopsin-based optogenetic tools is to grow plants exclusively in red light<sup>98,213</sup>. Both chlorophyll *a* and chlorophyll *b* absorb red light (FIG. 7Cb), and tobacco plants exclusively grown in red light are hardly distinguishable from those grown in white light<sup>98</sup>. Green light is the least absorbed wavelength by endogenous plant photoreceptors; therefore, green light allows for optogenetic manipulation with only minimal crosstalk<sup>98</sup> (FIG. 7Cb), especially with GtACR1.

Rhodopsin-based plant optogenetic approaches are still in their infancy compared with their long-standing use in animals. The combination of ubiquitous rhodopsin expression with global or local light-emitting diodes (LEDs) or laser light applications have been used in plants<sup>98,213–215</sup>. However, cell type-specific expression with global green light exposure certainly bears great potential, when combined with red light growth conditions. Use of the LeLAT52 pollen-specific promoter<sup>216</sup> allows plants to be grown in white light under greenhouse conditions for optogenetics-inspired research on pollen tubes<sup>98</sup>. For local rhodopsin stimulation at the single-cell level, optical fibres or laser light pulses have been successfully applied<sup>98,215</sup>. The fluorescence recovery after photobleaching module of conventional laser scanning microscopes allows local optogenetic stimulation of plant cells when using rhodopsins, such as GtACR1, with activation kinetics in the lower millisecond range<sup>98</sup>.

To perform plant optogenetics with rhodopsins, retinal can be added externally<sup>213</sup> (see Supplementary Fig. 10a–c) or plants can be empowered to produce retinal by expressing a  $\beta$ -dioxygenase from a marine bacterium targeted to the chloroplasts to synthesize retinal from carotenoids efficiently<sup>98</sup> (see Supplementary Fig. 10d–f). In contrast to animal cells, the plant cell

extracellular medium is low in ions and mostly moderately acidic, which may result in different electrical responses in plant and animal cells using the same rhodopsin (see Supplementary Figure 11). Activation of ACRs in the soma of neurons leads to membrane hyperpolarization<sup>217</sup>, whereas depolarization occurs in plant cells<sup>98</sup> due to the outward-directed anion gradient. When expressed in leaves or pollen tubes, activation of GtACR1 by green light (530 nm) resulted in membrane depolarization by about 60–100 mV within milliseconds<sup>98</sup>. Local GtACR1 activation on one side of the dome of apically growing pollen tubes has been used to demonstrate the involvement of an anion efflux in polar growth<sup>98</sup> (see Supplementary Fig. 10e,f), supporting earlier studies on the role of anion transport in polar growth<sup>218,219</sup>. In guard cells, native anion channel activity can be mimicked when GtACR1 is triggered by a series of light pulses (FIG. 7Cc–Ce), demonstrating that anion channel-driven depolarization is sufficient to close stomata<sup>215</sup>. Although plants do not have neuronal-like networks, voltage changes in the form of depolarization waves are transmitted between leaves or even between different organs<sup>220–222</sup>. The role of these long-range electrical signals can now be investigated with the help of GtACR1. Through GtACR1-induced anion efflux, depolarizations of any shape and intensity can be optogenetically generated to mimic the voltage changes observed in plants such as variation potentials, system potentials or action potentials<sup>223–225</sup>.

A wide range of processes in plants are induced by changes in cytoplasmic Ca<sup>2+</sup> and H<sup>+</sup> levels<sup>226,227</sup>. For both ions, there is a strong inward gradient, in contrast to animal cells where there are minimal differences in intracellular and extracellular pH (see Supplementary Fig. 11). The slow cycling ChR2 variant XXL with high proton conductance<sup>228</sup> is excellent to impose light-induced pH changes, and has already been used to feed the P-type plasma membrane H<sup>+</sup> pump with substrate and study its voltage dependence<sup>213</sup> (see Supplementary Fig. 10b,c). The resting potential of plants is negative with respect to  $E_K$  (–120 to –180 mV) due to the voltage-dependent activity of P-type plasma membrane H<sup>+</sup> pumps. The latter hyperpolarize the membrane and acidify the cell wall space<sup>229</sup>. This voltage deflection is used by the plant to open hyperpolarization active Shaker-type K<sup>+</sup> channels<sup>230</sup> and electrophoretically move K<sup>+</sup> ions into the cell<sup>231</sup>. The combined driving proton motive force of the electrical gradient and that of the H<sup>+</sup> is used by solute transporters using protons as co-substrate. The plant optogenetics toolbox therefore needs to be complemented by light-driven H<sup>+</sup> pumps such as Arch3. Of great potential for the study of Ca<sup>2+</sup> signalling is the ChR2 variant XXM, with increased Ca<sup>2+</sup> conductivity and medium open-state lifetime<sup>232</sup>. Combined with electrophysiology and Ca<sup>2+</sup> imaging, the molecular mechanisms for long-distance Ca<sup>2+</sup> signalling could be resolved. Ca<sup>2+</sup> signatures can represent either single events or rhythmically recurring signals. Whether and how different Ca<sup>2+</sup> signatures control specific processes in plants is still largely unexplored. In the future, Ca<sup>2+</sup>-permeable ChRs could be used to elicit defined Ca<sup>2+</sup> signatures.

## Reproducibility and data deposition

### *Reproducibility of optogenetic tools*

Reproducibility in optogenetics experiments depends on the consistency of the tools used, the organism/cell type, genetic transformation procedures and light delivery. Adherence to minimum reporting standards for all relevant parameters of an experiment can help increase reproducibility.

Optogenetic actuators are used in a diverse range of organisms, tissues and cell types. Because of differences in codon usage between the original host and the organisms in which the tools are applied, it is common to codon-optimize the coding sequence to facilitate translation in these heterologous systems. New codon-optimized sequences should be tested for expression, membrane targeting and function before applying these novel constructs in optogenetic experiments. The sequences of codon-optimized constructs should be appropriately reported in publications to allow reproduction of findings in other laboratories. However, even with codon optimization or adding trafficking motifs, the intracellular aggregation of many optogenetic actuators can still pose a problem for their applicability, particularly for translational applications. A thorough evaluation in targeted organism/cell type is needed because the intracellular aggregation not only reduces expression efficacy but also affects cell health or causes cell death.

Viral vectors are a popular gene delivery system for optogenetic tools. The quality of viral vectors, purity and viral titre can profoundly affect the transduction efficiency and experiment outcome. The quality of viral vectors produced by different laboratories, centralized viral vector cores and companies can vary widely. Variation can even occur from batch to batch produced at the same facility. Therefore, even when produced by centralized viral vector cores, service centres and major laboratories, viral vector preparations can vary in quality and efficiency. To minimize the variation, standardized purification and titration methods should be used. Each batch needs to be verified before scaling up experiments in order to obtain reproducible results.

### *Reproducibility of opsin expression*

Evaluation of the viral titre is needed to optimize viral vector spread and expression level, and to minimize overexpression-mediated off-target effects. Many opsin viral vectors were designed to co-express a fluorophore. Standard histological methods can be used to visualize the strength and spatial extent of viral vector expression. Characterizing viral expression for every experimental animal can increase interpretability by correlating the variability in behavioural effect to the variability in expression area and, for instance, optical fibre placement. Even when an experiment is planned based on published work, the experimental design should be validated in each new experiment owing to the potential variability of viral vector batches, optical hardware and mouse strain. When presenting results obtained using viral vectors, the source of the viral vector, its purification and titration methods, and the duration of expression should be reported.

Viral vector expression can impact cell health or change the electrophysiological properties of the targeted neurons. It is therefore necessary to include a control group injected with a titre-matched virus that expresses a control transgene. Researchers often use a virus encoding the same fluorophore that is co-expressed with the opsin. This control group can be used to evaluate direct effects of the virus injection surgery and potential phototoxic or heating effects due to the light delivery paradigm. Strong opsin expression has been reported to affect cell physiology<sup>233</sup>. It is therefore advisable to include an opsin-expressing group where no light is applied. Where the experiment allows for multiple repeats of the same manipulation, light and no light conditions can be tested in the same group, which presents a within-animal control.

Transgenic animals for optogenetics research should be genotyped continuously to confirm suitability for the experiments. For in vivo optogenetics with viral delivery, even when using the same tools in the same organism type, variations in responses may be due to variations in the immune response of the subjects (animals or humans) to the viral capsid, or the cargo (opsin and/or fluorescent reporter). To obtain reproducible data with viral delivery, testing for neutralizing antibodies can be implemented<sup>234</sup>. Appropriate control groups, immunohistochemistry and histology should be done routinely in animal experiments to demonstrate consistency of the optogenetic transformation.

### *Reproducibility of light delivery*

Activation of optogenetic tools depends on the photon irradiance or photon exposure in case of short flashes and the spectral profile of the delivered light. The spectral profile should be reported by listing the light source, all filters and optical components used in the experiments. Insufficient irradiance may lead to failure to engage the optogenetic tools and, therefore, failure to reproduce the phenotypic changes; excessive irradiance may lead to adverse thermal effects and photoreceptor bleaching that also affect reproducibility. For single-photon excitation, the spatial pattern of the delivered light is variable and highly depends on the positioning of the light source and the tissue properties. Although total power is trivial to report, the normalized values of irradiance are influenced by the uncertainties of area estimation and the non-uniform spatial profile of light delivery. At a minimum, effort should be made to measure and report irradiance at the tissue point of entry. Whenever possible, light-tissue interactions can be simulated<sup>235</sup> to yield relevant estimates of irradiance at points of interest.

Under optimal conditions, two-photon optogenetics is capable of stimulating individual neurons within a circuit with single-spike and single-cell resolution. Irrespective of the light sculpting method used (spiral scanning or parallel illumination), one must keep in mind that the effective spatio-temporal resolution of optogenetic stimulation depends on several factors, including the functional expression level of the opsin, the targeting specificity and the photon density required for sufficient actuation. Once a reliable and reproducible



experimental preparation has been established, and the average incident powers required identified, the physiological resolution should be measured experimentally rather than drawing any conclusions about the confinement of actuation based on the optical resolution of the light targeting method.

#### Data and metadata sharing

The data type and format from optogenetics experiments can be extremely diverse. Outputs may include spectra, ion channel recordings, functional recordings of responses by different measurement technologies, images of altered responses and behavioural analysis, among others. For each subfield where optogenetics is deployed, minimum standards of reporting and guidance of data sharing will help determine best practices. In general, specifics of the instruments used, the acquisition and the analysis software need to be included. GitHub, figshare and other general repositories for data and analysis tools can be used to increase reproducibility.

#### Limitations and optimizations

##### Tissue heating and photodamage

**Single-photon optogenetics.** Optogenetic experiments based on illumination with visible light excitation (450–630 nm) typically use optical fibres coupled to lasers or high-power LEDs for large (approximately cubic millimetre) field illumination, relatively long (0.5–60 s) exposure times and excitation powers in the order of milliwatts (0.5–20 mW). Under these conditions, the main cause for concern with respect to photodamage is heating due to light absorption. This has been investigated both theoretically, using Monte Carlo with finite-difference time-domain simulations<sup>107</sup> or the finite element method<sup>236</sup>, and experimentally using thermocouples<sup>107,236</sup>, infrared cameras<sup>237</sup> or electrophysiological recordings<sup>238</sup>. Depending on the precise stimulation protocol used, these experimental and theoretical studies report a wavelength and power density-dependent temperature increase between 0.3 and 6 K throughout the volume of illuminated tissue<sup>107,237</sup>. Temperature variations in the order of only 2 K can affect ion channel kinetics and conductance<sup>239</sup>, synaptic transmission<sup>240</sup> and neuronal firing rate<sup>107</sup>, and lead to a bias in turning behaviour across various brain regions<sup>238</sup>. Importantly, changes in temperature can induce physiological changes in the absence of detectable changes in behaviour<sup>241</sup>. It is extremely important to carefully design optogenetic experiments to minimize photon exposure and absorption, for instance by using short illumination duty cycles<sup>237</sup> and opsins with long open-state lifetimes and red-shifted absorption peaks<sup>30,77,242</sup>. Simulations<sup>107,237,243,244</sup> can be used to guide experimental design, but, as the effects of heating vary between cell types and brain regions, opsin-negative controls should always be performed.

**Multiphoton optogenetics.** Generating sufficient rates of multiphoton excitation requires the use of pulsed lasers with high peak energies, but as typical optogenetic stimulation protocols irradiate cells on millisecond timescales, the temperature rises induced by single-cell

multiphoton photostimulation are in the order of  $10^{-1}$  K (REF.<sup>244</sup>). Much larger temperature rises are induced during multi-target excitation due to the diffusion of heat from each target into the surrounding tissue. The resultant temperature increase occurs over hundreds of milliseconds and can approach or even exceed the 2 K threshold for thermal damage<sup>244</sup>. This effect can be mitigated by ensuring that the separation between adjacent targets is larger than the thermal diffusion length.

The risk of non-linear photodamage increases with peak fluence and could be a dominant source of photodamage in the case of spiral scanning, which typically requires higher photon density than parallel illumination. Non-linear photodamage can be reduced by increasing the repetition rate of the pulsed laser source, although this will increase photo-induced temperature rises<sup>244</sup>. In all-optical experiments that combine two-photon optogenetics with two-photon imaging, the possibility of thermal or non-linear damage induced by the imaging laser should also be considered<sup>243</sup>.

##### Interpreting optogenetic experiments

Light delivery schemes based on single-photon excitation are not generally capable of recapitulating physiological activity patterns. In most optogenetic gain and loss-of-function experiments, a set of cells is activated or silenced, and the effects of this manipulation are subsequently characterized by functional or behavioural read-outs to probe causal dependencies. Light delivery via an optic fibre can be precisely controlled in terms of output power and temporal pattern to influence neuronal functions such as the spike rate and spike pattern, and may be restricted to specific short behavioural epochs. However, such optogenetic manipulations typically lead to highly synchronous activity patterns, and might drive the circuits to states that are outside their physiological activity range, potentially confounding any causal inference regarding the natural functions of the circuit<sup>245</sup>. One major current effort aimed at overcoming these constraints is the development of tools for evoking naturalistic network activity patterns. Such manipulations would enable causal inference of the effects of an activity pattern on a given behaviour.

Non-physiological activity patterns can occur at the single-cell level as well as at the broader circuit scale<sup>226,227</sup>. On the single-cell level, ion pump-mediated hyperpolarization, for instance, can lead to rebound excitation upon inhibition release<sup>246</sup> or to supraphysiological ion concentrations<sup>45,94</sup>. High-frequency light pulse trains or constant illumination of an excitatory pyramidal neuron expressing a CCR can, for instance, lead to depolarization block, effectively reducing rather than increasing its firing rate<sup>247</sup>. Whether such rebound excitation or depolarization block occurs, and to what extent, is hard to predict, as it depends on many experiment-specific parameters which can greatly vary between laboratories. Although axonal stimulation can be used to effectively isolate the activity of an anatomically defined projection pathway, optogenetic stimulation of axons can cause antidromic activation of both neuronal cell bodies as well as collaterals to other brain regions, leading to reduced specificity which should be taken into account.

**Antidromic activation**  
Retrograde propagation of an action potential from the axon to the neuronal soma.

At the circuit level, particularly when a large portion of cells express ion translocation-based optogenetic tools such as ion channels or ion pumps, the simultaneous activation of these tools can lead to transient but significant changes in the ion composition of the local extracellular space, thereby indirectly affecting nearby non-opsin-expressing neurons<sup>248</sup>. Electrophysiological characterization of the optogenetic manipulation can be performed to quantify the extent of such unintended effects, allowing the optimization of light power and illumination paradigms. Optogenetic tools that modulate biochemical activity within the cells or ones that act on slower timescales, or only induce sub-threshold depolarization, are less prone to the caveats imposed by highly synchronous neuronal activation<sup>249</sup>. Finally, optogenetic firing rate modulation experiments are mostly designed to acutely alter the firing rates of targeted cells, which can have different effects from chronic manipulations. Brain circuits regulate their overall activity to achieve a homeostatic equilibrium, such that when the firing rate of a circuit is transiently increased or decreased it can acutely affect the independent functions of downstream circuits and lead to markedly different results compared with chronic manipulations<sup>249</sup>. Acute effects are normally more severe, and could lead to overestimation of the roles of targeted regions in a given behaviour. Although chronic manipulations such as lesions do not suffer from this limitation, plastic changes during lesion recovery can also lead to an underestimation of the necessity of a given input to a local circuit. In summary, a sound experimental strategy should balance the use of acute and powerful optogenetic approaches with chronic experiments, pharmacological manipulations or lesions, and use caution in claims of causality based purely on manipulations that might suffer from any of the above-mentioned artefacts.

## Outlook

### *Refinement of the optogenetic toolbox*

We anticipate a further optimization of existing tools in terms of kinetics, ion or substrate selectivity, and widening of the spectral range from UV to the near-infrared to enhance the use of optogenetics. Additional light-activated enzymes allowing for optogenetic control beyond cell excitability are still to be discovered. Efforts are currently directed at optogenetic control of translation, transcription, nucleotide modification and epigenetics, as well as protein degradation. We are also expecting better tools for the control of cellular mechanics, development and differentiation.

### *Enhancement of basic research*

Optogenetics will further advance the investigation of neural circuits. This will not only establish links of causality between neural activity and behaviour but, eventually, generate sufficient knowledge for a theory of the brain to emerge. Empirically observed neural activity in optogenetic experiments taking into account the activity of individual neurons may eventually allow deriving the neural code, which, when integrated into a solid theoretical framework, will bring the neurosciences on a par with other fields of natural sciences.

Optogenetics may also drive basic knowledge in other fields of life science, from cardiac physiology to plant physiology. For plant optogenetics, which is still in its infancy, there is great potential through the recently introduced in planta retinal synthesis, which now allows access for many rhodopsin-based manipulations. Implementing optogenetic approaches in any system of excitable cells will allow for the investigation of so far intangible questions. This may apply, for example, to the control of muscle contraction in the heart as well as the insulin secretion in the pancreas.

### *Open routes of translation*

Beyond advancing basic science, optogenetics also has translational potential, either by inspiring novel protocols of existing therapies or as a therapy in humans. Several possible optogenetically inspired medical interventions and therapies are already outlined in this Primer. Optogenetics can be used in vitro to analyse cellular processes in single cells, cultured tissue or brain slices. Optogenetics can also simulate clinically relevant scenarios in animal models of brain diseases, including optogenetics-informed electrical stimulation protocols or closed-feedback control schemes. Possible indications are epilepsy, Parkinson disease or addiction. Some of these interventions may eventually be emulated in humans, for example with refined deep brain stimulation protocols or pharmacology (see Supplementary Fig. 12).

With the recent proof of principle of optogenetic vision restoration in humans with retinitis pigmentosa, longer-term gene therapy options remain open for optogenetics, although several challenges need to be addressed. Optimization of gene delivery vectors that are safe and produce long-lasting expression and optimization of light delivery to the desired organ are essential. Novel methods for light delivery deep into the tissue, overcoming the limited optical penetration depth and thereby minimizing the use of optical fibres, are also needed. One non-conventional solution is to introduce in situ sources of biological light, such as luminopsins. Triggered by a chemical process such as simple substrate delivery, these luminopsins do not require device implantation and can be tuned to control inhibitory or excitatory actuators. Further remote trigger methods involve energy-conversion schemes via mechano-luminescent nanoparticles. The energy could be provided by intermittent focused ultrasound, thus recharging light-emitting materials that can deliver short opsin-engaging pulses. The mechanosensitive TRAAK K<sup>+</sup> channel, for example, could be specifically activated by ultrasound with submillisecond kinetics<sup>250</sup>, providing a new, orthogonal dimension for external non-invasive manipulation of neural circuits.

Clinical applications of optogenetics to the heart face many challenges compared with the more accessible, immune-privileged applications to the eye that have seen translational advances. Considering the potential impact for control of arrhythmias, efforts should continue to improve the genetic targeting by more specific promoters, safer viral vectors, longer-wavelength opsins for better tissue penetration and miniaturized

distributed light sources. Basic science experiments with optogenetic tools provide invaluable insights for improvement of current cardiac devices and may yield new strategies for arrhythmia control<sup>[11,19]</sup>. In the meantime, optogenetics-empowered high-throughput systems can more immediately improve cardiotoxicity testing and drug development. Similarly, in vitro assays for drug development and personalized medicine may use humanized optogenetic tools, patient-derived cells and engineered tissues coupled with highly parallel all-optical electrophysiology techniques to yield

a low-cost, faster and more efficient drug development pipeline.

Likewise, scalable optogenetic control of living plants, as discussed here, or microorganisms can be leveraged to address problems related to energy, food, biotechnology and climate challenges. As these do not involve deployment in the human body, they can be implemented on a shorter timescale, with less technical and regulatory obstacles.

Published online: 21 July 2022

- Famintzin, A. Die Wirkung der Liches auf die Bewegung der Chlamidomonas pulvisculus Ehr., Euglena viridis Ehr. und Oscillatoria insignis Tw. in *Melanges Biologiques tires du Bulletin de l'Academie Imperiale des Sciences De St. Petersburg* 73–93 (1866).
- Kühne, W. F. *Zur Photochemie der Netzhaut* [German] (Carl Winter's Universitätsbuchhandlung, 1877).
- Darwin, C. *The Power of Movements in Plants* (Appleton, 1881).
- Zemelman, B. V., Lee, G. A., Ng, M. & Miesenböck, G. Selective photostimulation of genetically chARGed neurons. *Neuron* **33**, 15–22 (2002).
- Boydén, E. S., Zhang, F., Bamberg, E., Nagel, G. & Deisseroth, K. Millisecond-timescale, genetically targeted optical control of neural activity. *Nat. Neurosci.* **8**, 1263–1268 (2005).
- Ishizuka, T., Kakuda, M., Araki, R. & Yawo, H. Kinetic evaluation of photosensitivity in genetically engineered neurons expressing green algae light-gated channels. *Neurosci. Res.* **54**, 85–94 (2006).
- Li, X. et al. Fast noninvasive activation and inhibition of neural and network activity by vertebrate rhodopsin and green algae channelrhodopsin. *Proc. Natl Acad. Sci. USA* **102**, 17816–17821 (2005).
- Nagel, G. et al. Light activation of channelrhodopsin-2 in excitable cells of *Caenorhabditis elegans* triggers rapid behavioral responses. *Curr. Biol.* **15**, 2279–2284 (2005).
- Schroll, C. et al. Light-induced activation of distinct modulatory neurons triggers appetitive or aversive learning in *Drosophila* larvae. *Curr. Biol.* **16**, 1741–1747 (2006).
- Adamantidis, A. R., Zhang, F., Aravanis, A. M., Deisseroth, K. & De Lecea, L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. *Nature* **450**, 420–424 (2007).
- Douglass, A. D., Kraves, S., Deisseroth, K., Schier, A. F. & Engert, F. Escape behavior elicited by single, channelrhodopsin-2-evoked spikes in zebrafish somatosensory neurons. *Curr. Biol.* **18**, 1133–1137 (2008).
- Han, X. et al. Millisecond-timescale optical control of neural dynamics in the nonhuman primate brain. *Neuron* **62**, 191–198 (2009).
- Bi, A. D. et al. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. *Neuron* **50**, 23–33 (2006).
- Ronzitti, E. et al. Recent advances in patterned photostimulation for optogenetics. *J. Opt.* **19**, 113001 (2017).
- Hull, K., Morstein, J. & Trauner, D. In vivo photopharmacology: beyond proof of principle. *J. Am. Chem. Soc.* **136**, 2178–2191 (2014).
- Kolar, K., Knobloch, C., Stork, H., Žnidarič, M. & Weber, W. OptoBase: a web platform for molecular optogenetics. *ACS Synth. Biol.* **7**, 1825–1828 (2018).
- Manoilov, K. Y., Verkhusha, V. V. & Shcherbakova, D. M. A guide to the optogenetic regulation of endogenous molecules. *Nat. Methods* **18**, 1027–1037 (2021).
- Nagel, G. et al. Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. *Proc. Natl Acad. Sci. USA* **100**, 13940–13945 (2003).
- Rozenberg, A. et al. Lateral gene transfer of anion-conducting channelrhodopsins between green algae and giant viruses. *Curr. Biol.* **30**, 4910–4920.e5 (2020).
- Vierock, J., Grimm, C., Nitzan, N. & Hegemann, P. Molecular determinants of proton selectivity and gating in the red-light activated channelrhodopsin Chrimson. *Sci. Rep.* **7**, 9928 (2017).
- Govorunova, E. G. et al. Kalium channelrhodopsins are natural light-gated potassium channels that mediate optogenetic inhibition. *Nat. Neurosci.* <https://doi.org/10.1038/s41593-022-01094-6> (2022).
- Govorunova, E. G. et al. The expanding family of natural anion channelrhodopsins reveals large variations in kinetics, conductance, and spectral sensitivity. *Sci. Rep.* **7**, 43358 (2017).
- Mahn, M. et al. High-efficiency optogenetic silencing with soma-targeted anion-conducting channelrhodopsins. *Nat. Commun.* **9**, 4125 (2018).
- Ben-Ari, Y. Excitatory actions of GABA during development: the nature of the nurture. *Pat. Rev. Neurosci.* **3**, 728–739 (2002).
- Schneider, F., Grimm, C. & Hegemann, P. Biophysics of channelrhodopsin. *Annu. Rev. Biophys.* **44**, 167–186 (2015).
- Kühne, J. et al. Unifying photocycle model for light adaptation and temporal evolution of cation conductance in channelrhodopsin-2. *Proc. Natl Acad. Sci. USA* **116**, 9380–9389 (2019).
- Sineshchikov, O. A., Govorunova, E. G., Li, H. & Spudich, J. L. Bacteriorhodopsin-like channelrhodopsins: alternative mechanism for control of cation conductance. *Proc. Natl Acad. Sci. USA* **114**, E9512–E9519 (2017).
- Kishi, K. E. et al. Structural basis for channel conduction in the pump-like channelrhodopsin ChRmine. *Cell* **185**, 672–689.e23 (2022).
- Klapoetke, N. C. et al. Independent optical excitation of distinct neural populations. *Nat. Methods* **11**, 338–346 (2014).
- Oda, K. et al. Crystal structure of the red light-activated channelrhodopsin Chrimson. *Nat. Commun.* **9**, 3949 (2018).
- Govorunova, E. G. et al. RubyACRs, non-algal anion channelrhodopsins with highly red-shifted absorption. *Proc. Natl Acad. Sci. USA* **117**, 22833–22840 (2020).
- Gradinaru, V. et al. Molecular and cellular approaches for diversifying and extending optogenetics. *Cell* **141**, 154–165 (2010).
- Vierock, J. et al. BiPOLES is an optogenetic tool developed for bidirectional dual-color control of neurons. *Nat. Commun.* **12**, 4527 (2021).
- Grusch, M. et al. Spatio-temporally precise activation of engineered receptor tyrosine kinases by light. *EMBO J.* **33**, 1713–1726 (2014).
- Kainrath, S., Stadler, M., Reichhart, E., Distel, M. & Janovjak, H. Green-light-induced inactivation of receptor signaling using cobalamin-binding domains. *Angew. Chem., Int. Ed.* **56**, 4608–4611 (2017).
- Chang, K.-Y. et al. Light-inducible receptor tyrosine kinases that regulate neurotrophin signalling. *Nat. Commun.* **5**, 4057 (2014).
- Stierl, M. et al. Light modulation of cellular cAMP by a small bacterial photoactivated adenylyl cyclase, bPAC, of the soil bacterium *Beggiatoa*. *J. Biol. Chem.* **286**, 1181–1188 (2011).
- Zhang, F. et al. Multimodal fast optical interrogation of neural circuitry. *Nature* **446**, 633–U634 (2007).
- Parker, D. Neuronal network analyses: premises, promises and uncertainties. *Philos. Trans. R. Soc. B Biol. Sci.* **365**, 2315–2328 (2010).
- Chuong, A. S. et al. Noninvasive optical inhibition with a red-shifted microbial rhodopsin. *Nat. Neurosci.* **17**, 1123–1129 (2014).
- Wiegert, J. S., Mahn, M., Prigge, M., Printz, Y. & Yizhar, O. Silencing neurons: tools, applications, and experimental constraints. *Neuron* **95**, 504–529 (2017).
- Rost, B. R. et al. Optogenetic acidification of synaptic vesicles and lysosomes. *Nat. Neurosci.* **18**, 1845–1852 (2015).
- Junge, W. Protons, the thylakoid membrane, and the chloroplast ATP synthase. *Ann. N. Y. Acad. Sci.* **574**, 268–286 (1989).
- Raimondo, J. V., Kay, L., Ellender, T. J. & Akerman, C. J. Optogenetic silencing strategies differ in their effects on inhibitory synaptic transmission. *Nat. Neurosci.* **15**, 1102–1104 (2012).
- Khorana, H. G., Knox, B. E., Nasi, E., Swanson, R. & Thompson, D. A. Expression of a bovine rhodopsin gene in *Xenopus* oocytes — demonstration of light-dependent ionic currents. *Proc. Natl Acad. Sci. USA* **85**, 7917–7921 (1988).
- Karunaratne, W. A., Giri, L., Patel, A. K., Venkatesh, K. V. & Gautam, N. Optical control demonstrates switch-like PIP3 dynamics underlying the initiation of immune cell migration. *Proc. Natl Acad. Sci. USA* **110**, E1575–E1583 (2013).
- Karunaratne, W. A., Giri, L., Kalyanaraman, V. & Gautam, N. Optically triggering spatiotemporally confined GPCR activity in a cell and programming neurite initiation and extension. *Proc. Natl Acad. Sci. USA* **110**, E1565–E1574 (2013).
- Masasek, O. A. et al. Vertebrate cone opsins enable sustained and highly sensitive rapid control of G<sub>i/o</sub> signaling in anxiety circuitry. *Neuron* **81**, 1263–1273 (2014).
- Bailes, H. J., Zhuang, L.-Y. & Lucas, R. J. Reproducible and sustained regulation of G signaling using a metazoan opsin as an optogenetic tool. *PLoS ONE* **7**, e30774 (2012).
- Spoida, K. et al. Melanopsin variants as intrinsic optogenetic on and off switches for transient versus sustained activation of G protein pathways. *Curr. Biol.* **26**, 1206–1212 (2016).
- Lin, B., Koizumi, A., Tanaka, N., Panda, S. & Masland, R. H. Restoration of visual function in retinal degeneration mice by ectopic expression of melanopsin. *Proc. Natl Acad. Sci. USA* **105**, 16009–16014 (2008).
- Tsunematsu, T., Tanaka, K. F., Yamanaka, A. & Koizumi, A. Ectopic expression of melanopsin in orexin/hypocretin neurons enables control of wakefulness of mice in vivo by blue light. *Neurosci. Res.* **75**, 23–28 (2013).
- Koyanagi, M. et al. In *Optogenetics* 141–151 (Springer, 2021).
- Eickelbeck, D. et al. Lamprey parainopsin ("UVLampP"): a bistable UV-sensitive optogenetic switch for ultrafast control of GPCR pathways. *ChemBioChem* **21**, 612 (2020).
- Copits, B. A. et al. A photoswitchable GPCR-based opsin for presynaptic inhibition. *Neuron* **109**, 1791–1809. e1711 (2021).
- Mahn, M. et al. Efficient optogenetic silencing of neurotransmitter release with a mosquito rhodopsin. *Neuron* **109**, 1621–1635 (2021).
- Kim, J.-M. et al. Light-driven activation of  $\beta_2$ -adrenergic receptor signaling by a chimeric rhodopsin containing the  $\beta_2$ -adrenergic receptor cytoplasmic loops. *Biochemistry* **44**, 2284–2292 (2005).
- Airan, R. D., Thompson, K. R., Fenno, L. E., Bernstein, H. & Deisseroth, K. Temporally precise in vivo control of intracellular signalling. *Nature* **458**, 1025–1029 (2009).
- Osorno, T. et al. Light control of G protein signaling pathways by a novel photopigment. *PLoS ONE* **13**, e0205015 (2018).
- Bradley, S. J. & Challiss, R. J. G protein-coupled receptor signalling in astrocytes in health and disease: a focus on metabotropic glutamate



- receptors. *Biochem. Pharmacol.* **84**, 249–259 (2012).
62. Bernal Sierra, Y. A. et al. Potassium channel-based optogenetic silencing. *Nat. Commun.* **9**, 4611 (2018).
63. De Marco, R. J., Groneberg, A. H., Yeh, C. M., Castillo Ramirez, L. A. & Ryu, S. Optogenetic elevation of endogenous glucocorticoid level in larval zebrafish. *Front. Neural Circuits* **7**, 82 (2013).
64. Jansen, V. et al. Controlling fertilization and cAMP signaling in sperm flagella by optogenetics. *eLife* **4**, e05161 (2015).
65. Zhang, S. X. et al. Hypothalamic dopamine neurons motivate mating through persistent cAMP signalling. *Nature* **597**, 245–249 (2021).
66. Scheib, U. et al. The rhodopsin–guanylyl cyclase of the aquatic fungus *Blastocladiella emersonii* enables fast optical control of cGMP signaling. *Sci. Signal.* **8**, rs8 (2015).
67. Scheib, U. et al. Rhodopsin-cyclases for photocontrol of cGMP/cAMP and 2.3 Å structure of the adenylyl cyclase domain. *Nat. Commun.* **9**, 2046 (2018).
68. Gao, S. et al. Optogenetic manipulation of cGMP in cells and animals by the tightly light-regulated guanylyl-cyclase opsin CycOp. *Nat. Commun.* **6**, 8046 (2015).
69. Broser, M. et al. NeoR, a near-infrared absorbing rhodopsin. *Nat. Commun.* **11**, 5682 (2020).
70. Rost, B. R., Schneider-Warme, F., Schmitz, D. & Hegemann, P. Optogenetic tools for subcellular applications in neuroscience. *Neuron* **96**, 572–603 (2017).
71. Polesskaya, O. et al. Optogenetic regulation of transcription. *BMC Neurosci.* **19**, 3–13 (2018).
72. Polstein, L. R. & Gersbach, C. A. Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors. *J. Am. Chem. Soc.* **134**, 16480–16483 (2012).
73. Konermann, S. et al. Optical control of mammalian endogenous transcription and epigenetic states. *Nature* **500**, 472 (2013).
74. Nihongaki, Y., Kawano, F., Nakajima, T. & Sato, M. Photoactivatable CRISPR–Cas9 for optogenetic genome editing. *Nat. Biotechnol.* **33**, 755–760 (2015).
75. Nihongaki, Y. et al. CRISPR–Cas9-based photoactivatable transcription systems to induce neuronal differentiation. *Nat. Methods* **14**, 963–966 (2017).
76. Raper, A. T., Stephenson, A. A. & Suo, Z. Functional insights revealed by the kinetic mechanism of CRISPR/Cas9. *J. Am. Chem. Soc.* **140**, 2971–2984 (2018).
77. Mardinly, A. R. et al. Precise multimodal optical control of neural ensemble activity. *Nat. Neurosci.* **21**, 881–893 (2018).
78. Arenkiel, B. R. et al. In vivo light-induced activation of neural circuitry in transgenic mice expressing channelrhodopsin-2. *Neuron* **54**, 205–218 (2007).
79. Madisen, L. et al. A toolbox of Cre-dependent optogenetic transgenic mice for light-induced activation and silencing. *Nat. Neurosci.* **15**, 793–802 (2012).
80. Madisen, L. et al. Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance. *Neuron* **85**, 942–958 (2015).
81. Lammel, S. et al. Diversity of transgenic mouse models for selective targeting of midbrain dopamine neurons. *Neuron* **85**, 429–438 (2015).
82. Song, A. J. & Palmiter, R. D. Detecting and avoiding problems when using the Cre–lox system. *Trends Genet.* **34**, 333–340 (2018).
83. Graybuck, L. T. et al. Enhancer viruses and a transgenic platform for combinatorial cell subclass-specific labeling. Preprint at *bioRxiv* <https://doi.org/10.1101/525014> (2020).
84. Nair, R. R., Blankvoort, S., Lagartos, M. J. & Kentros, C. Enhancer-driven gene expression (EDGE) enables the generation of viral vectors specific to neuronal subtypes. *iScience* **23**, 100888 (2020).
85. Jüttner, J. et al. Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans. *Nat. Neurosci.* **22**, 1345–1356 (2019).
86. Tervo, D. G. R. et al. A designer AAV variant permits efficient retrograde access to projection neurons. *Neuron* **92**, 372–382 (2016).
87. Zhang, S. et al. Long-range and local circuits for top-down modulation of visual cortex processing. *Science* **345**, 660–665 (2014).
88. Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. *Nat. Neurosci.* **20**, 1172–1179 (2017).
89. Challis, R. C. et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. *Nat. Protoc.* **14**, 379–414 (2019).
90. Mathiesen, S. N., Lock, J. L., Schoderboeck, L., Abraham, W. C. & Hughes, S. M. CNS transduction benefits of AAV-PHP:eB over AAV9 are dependent on administration route and mouse strain. *Mol. Ther. Methods Clin. Dev.* **19**, 447–458 (2020).
91. LoTurco, J., Manent, J.-B. & Sidiqi, F. New and improved tools for in utero electroporation studies of developing cerebral cortex. *Cereb. Cortex* **19**, i120–i125 (2009).
92. Dal Maschio, M. et al. High-performance and site-directed in utero electroporation by a triple-electrode probe. *Nat. Commun.* **3**, 960 (2012).
93. Rosin, J. M. & Kurrasch, D. M. In utero electroporation induces cell death and alters embryonic microglia morphology and expression signatures in the developing hypothalamus. *J. Neuroinflamm.* **15**, 181 (2018).
94. Mahn, M., Prigge, M., Ron, S., Levy, R. & Yizhar, O. Biophysical constraints of optogenetic inhibition at presynaptic terminals. *Nat. Neurosci.* **19**, 554–556 (2016).
95. Ullrich, S., Gueta, R. & Nagel, G. Degradation of channelrhodopsin-2 in the absence of retinal and degradation resistance in certain mutants. *Biol. Chem.* **394**, 271–280 (2013).
96. Hoffner, A., Fakler, B. & Klöcker, N. Selective Golgi export of Kir2.1 controls the stoichiometry of functional Kir2.x channel heteromers. *J. Cell Sci.* **118**, 1935–1943 (2005).
97. Mattis, J. et al. An analysis of new and existing opsins for scientific application. *Eur. Biophys. J. Biophys. Lett.* **40**, 68–69 (2011).
98. Zhou, Y. et al. Optogenetic control of plant growth by a microbial rhodopsin. *Nat. Plants* **7**, 144–151 (2021).
99. Adam, Y. et al. Voltage imaging and optogenetics reveal behaviour-dependent changes in hippocampal dynamics. *Nature* **569**, 413–417 (2019).
100. Wu, C., Ivanova, E., Zhang, Y. & Pan, Z.-H. rAAV-mediated subcellular targeting of optogenetic tools in retinal ganglion cells in vivo. *PLoS ONE* **8**, e66332 (2013).
101. Baker, C. A., Elyada, Y. M., Parra, A. & Bolton, M. M. Cellular resolution circuit mapping with temporal-focused excitation of soma-targeted channelrhodopsin. *eLife* **5**, e14193 (2016).
102. Shemesh, O. A. et al. Temporally precise single-cell-resolution optogenetics. *Nat. Neurosci.* **20**, 1796–1806 (2017).
103. Forli, A. et al. Two-photon bidirectional control and imaging of neuronal excitability with high spatial resolution in vivo. *Cell Rep.* **22**, 3087–3098 (2018).
104. Forli, A., Pisoni, M., Printz, Y., Yizhar, O. & Fellin, T. Optogenetic strategies for high-efficiency all-optical interrogation using blue-light-sensitive opsins. *eLife* **10**, e63559 (2021).
105. Spaulding, E. L. & Burgess, R. W. Accumulating evidence for axonal translation in neuronal homeostasis. *Front. Neurosci.* **11**, 312 (2017).
106. Johnson, H. E. & Toettcher, J. E. Illuminating developmental biology with cellular optogenetics. *Curr. Opin. Biotechnol.* **52**, 42–48 (2018).
107. Stujenske, J. M., Spellman, T. & Gordon, J. A. Modeling the spatiotemporal dynamics of light and heat propagation for in vivo optogenetics. *Cell Rep.* **12**, 525–534 (2015).
108. Rungta, R. L., Osmanski, B.-F., Boido, D., Tanter, M. & Chrapak, S. Light controls cerebral blood flow in naive animals. *Nat. Commun.* **8**, 14191 (2017).
109. Pisanello, M. et al. Tailoring light delivery for optogenetics by modal demultiplexing in tapered optical fibers. *Sci. Rep.* **8**, 4467 (2018).
110. Arrenberg, A. B., Stainier, D. Y., Baier, H. & Huiskens, J. Optogenetic control of cardiac function. *Science* **330**, 971–974 (2010).
111. Burton, R. A. et al. Optical control of excitation waves in cardiac tissue. *Nat. Photonics* **9**, 813–816 (2015).
112. Majumder, R. et al. Optogenetics enables real-time spatiotemporal control over spiral wave dynamics in an excitable cardiac system. *eLife* **7**, e41076 (2018).
113. Scardigli, M. et al. Real-time optical manipulation of cardiac conduction in intact hearts. *J. Physiol.* **596**, 3841–3858 (2018).
114. Chen, I.-W., Papagiakoumou, E. & Emiliani, V. Towards circuit optogenetics. *Curr. Opin. Neurobiol.* **50**, 179–189 (2018).
115. Mager, T. et al. High frequency neural spiking and auditory signaling by ultrafast red-shifted optogenetics. *Nat. Commun.* **9**, 1750 (2018).
116. Ronzitti, E. et al. Submillisecond optogenetic control of neuronal firing with two-photon holographic photoactivation of chronos. *J. Neurosci.* **37**, 10679–10689 (2017).
117. Pégard, N. C. et al. Three-dimensional scanless holographic optogenetics with temporal focusing (3D-SHOT). *Nat. Commun.* **8**, 1228 (2017).
118. Marshel, J. H. et al. Cortical layer-specific critical dynamics triggering perception. *Science* **365**, eaaw5202 (2019).
119. Lin, J., Knutsen, P., Muller, A., Kleinfeld, D. & Tsien, R. ReaChR: a red-shifted variant of channelrhodopsin enables neuronal activation through the intact skull. *Nat. Neurosci.* **16**, 1499–1508 (2013).
120. Yizhar, O. et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. *Nature* **477**, 171–178 (2011).
121. Chen, I.-W. et al. In vivo submillisecond two-photon optogenetics with temporally focused patterned light. *J. Neurosci.* **39**, 3484–3497 (2019).
122. Feldbauer, K. et al. Channelrhodopsin-2 is a leaky proton pump. *Proc. Natl Acad. Sci. USA* **106**, 12317–12322 (2009).
123. Papagiakoumou, E. et al. Scanless two-photon excitation of channelrhodopsin-2. *Nat. Methods* **7**, 848–854 (2010).
124. Andrasfalvy, B. K., Zemelman, B. V., Tang, J. & Vaziri, A. Two-photon single-cell optogenetic control of neuronal activity by sculpted light. *Proc. Natl Acad. Sci. USA* **107**, 11981–11986 (2010).
125. Packer, A. M., Russell, L. E., Dalgleish, H. W. & Häusser, M. Simultaneous all-optical manipulation and recording of neural circuit activity with cellular resolution in vivo. *Nat. Methods* **12**, 140–146 (2015).
126. Hernandez, O. et al. Three-dimensional spatiotemporal focusing of holographic patterns. *Nat. Commun.* **7**, 11928 (2016).
127. Accanto, N. et al. Multiplexed temporally focused light shaping for high-resolution multi-cell targeting. *Optica* **5**, 1478–1491 (2018).
128. Chaigneau, E. et al. Two-photon holographic stimulation of ReaChR. *Front. Cell. Neurosci.* **10**, 234 (2016).
129. Robinson, N. T. et al. Targeted activation of hippocampal place cells drives memory-guided spatial behavior. *Cell* **183**, 1586–1599.e10 (2020).
130. Dalgleish, H. W. et al. How many neurons are sufficient for perception of cortical activity? *eLife* **9**, e58889 (2020).
131. Gill, J. V. et al. Precise holographic manipulation of olfactory circuits reveals coding features determining perceptual detection. *Neuron* **108**, 382–393.e5 (2020).
132. Dal Maschio, M., Donovan, J. C., Helmbrecht, T. O. & Baier, H. Linking neurons to network function and behavior by two-photon holographic optogenetics and volumetric imaging. *Neuron* **94**, 774–789.e5 (2017).
133. Jennings, J. H. et al. Interacting neural ensembles in orbitofrontal cortex for social and feeding behaviour. *Nature* **565**, 645–649 (2019).
134. Accanto, N. et al. Multiplexed temporally focused light shaping through a gradient index lens for precise in-depth optogenetic photostimulation. *Sci. Rep.* **9**, 7603 (2019).
135. Rowlands, C. J. et al. Wide-field three-photon excitation in biological samples. *Light Sci. Appl.* **6**, e16255 (2017).
136. Jackman, S. L., Beneduce, B. M., Drew, I. R. & Regehr, W. G. Achieving high-frequency optical control of synaptic transmission. *J. Neurosci.* **34**, 7704–7714 (2014).
137. Cardin, J. A. et al. Targeted optogenetic stimulation and recording of neurons in vivo using cell-type-specific expression of channelrhodopsin-2. *Nat. Protoc.* **5**, 247 (2010).
138. Wu, J. et al. Improved orange and red Ca<sup>2+</sup> indicators and photophysical considerations for optogenetic applications. *ACS Chem. Neurosci.* **4**, 963–972 (2013).
139. Platasa, J. & Pierbone, V. A. Genetically encoded fluorescent voltage indicators: are we there yet? *Curr. Opin. Neurobiol.* **50**, 146–153 (2018).
140. Urakubo, H., Yagishita, S., Kasai, H., Kubota, Y. & Ishii, S. The critical balance between dopamine D2 receptor and RGS for the sensitive detection of a transient decay in dopamine signal. *PLoS Comput. Biol.* **17**, e1009364 (2021).
141. Wang, H., Jing, M. & Li, Y. Lighting up the brain: genetically encoded fluorescent sensors for imaging neurotransmitters and neuromodulators. *Curr. Opin. Neurobiol.* **50**, 171–178 (2018).
142. Leopold, A. V., Shcherbakova, D. M. & Verkhusha, V. V. Fluorescent biosensors for neurotransmission and



- neuromodulation: engineering and applications. *Front. Cell. Neurosci.* **13**, 474 (2019).
143. Gradinaru, V., Mogri, M., Thompson, K. R., Henderson, J. M. & Deisseroth, K. Optical deconstruction of parkinsonian neural circuitry. *Science* **324**, 354–359 (2009).
144. Wu, Y. E., Pan, L., Zuo, Y., Li, X. & Hong, W. Detecting activated cell populations using single-cell RNA-seq. *Neuron* **96**, 313–329 (2017).
145. Franceschini, A., Costantini, I., Pavone, F. S. & Silvestri, L. Dissecting neuronal activation on a brain-wide scale with immediate early genes. *Front. Neurosci.* **14**, 1111 (2020).
146. Guenther, C. J., Miyamichi, K., Yang, H. H., Heller, H. C. & Luo, L. Permanent genetic access to transiently active neurons via TRAP: targeted recombination in active populations. *Neuron* **78**, 773–784 (2013).
147. Grinvald, A., Lieke, E., Frostig, R. D., Gilbert, C. D. & Wiesel, T. N. Functional architecture of cortex revealed by optical imaging of intrinsic signals. *Nature* **324**, 361–364 (1986).
148. Juavinett, A. L., Nauha, I., Garrett, M. E., Zhuang, J. & Callaway, E. M. Automated identification of mouse visual areas with intrinsic signal imaging. *Nat. Protoc.* **12**, 32 (2017).
149. Lee, J. H. et al. Global and local fMRI signals driven by neurons defined optogenetically by type and wiring. *Nature* **465**, 788–792 (2010).
150. Uludag, K. & Blinder, P. Linking brain vascular physiology to hemodynamic response in ultra-high field MRI. *Neuroimage* **168**, 279–295 (2018).
151. Albers, F., Wachsmuth, L., Schache, D., Lambers, H. & Faber, C. Functional MRI readouts from bold and diffusion measurements differentially respond to optogenetic activation and tissue heating. *Front. Neurosci.* **13**, 1104 (2019).
152. Edelman, B. J. & Macé, E. Functional ultrasound brain imaging: bridging networks, neurons and behavior. *Curr. Opin. Biomed. Eng.* **18**, 100286 (2021).
153. Brecht, M. et al. Organization of rat vibrissa motor cortex and adjacent areas according to cytoarchitectonics, microstimulation, and intracellular stimulation of identified cells. *J. Comp. Neurol.* **479**, 360–373 (2004).
154. Heindorf, M., Arber, S. & Keller, G. B. Mouse motor cortex coordinates the behavioral response to unpredicted sensory feedback. *Neuron* **99**, 1040–1054.e5 (2018).
155. Dana, H. et al. High-performance calcium sensors for imaging activity in neuronal populations and microcompartments. *Nat. Methods* **16**, 649–657 (2019).
156. Guo, Z. V. et al. Flow of cortical activity underlying a tactile decision in mice. *Neuron* **81**, 179–194 (2014).
157. Jun, J. J. et al. Fully integrated silicon probes for high-density recording of neural activity. *Nature* **551**, 232–236 (2017).
158. Steinmetz, N. A. et al. Neuropixels 2.0: a miniaturized high-density probe for stable, long-term brain recordings. *Science* **372**, eabf4588 (2021).
159. Kvitsiani, D. et al. Distinct behavioural and network correlates of two interneuron types in prefrontal cortex. *Nature* **498**, 363–366 (2013).
160. Ferreira-Pinto, M. J. et al. Functional diversity for body actions in the mesencephalic locomotor region. *Cell* **184**, 4564–4578.e18 (2021).
161. Pascoli, V. et al. Contrasting forms of cocaine-evoked plasticity control components of relapse. *Nature* **509**, 459–464 (2014).
162. Burguière, E., Monteiro, P., Feng, G. & Graybiel, A. M. Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors. *Science* **340**, 1243–1246 (2013).
163. Hartong, D. T., Berson, E. L. & Dryja, T. P. Retinitis pigmentosa. *Lancet* **368**, 1795–1809 (2006).
164. de Jong, E. K., Geerlings, M. J. & den Hollander, A. I. Age-related macular degeneration. *Genet. Genomics Eye Dis.* <https://doi.org/10.1016/B978-0-12-816222-4.00010-1> (2020).
165. Sahel, J.-A. et al. Partial recovery of visual function in a blind patient after optogenetic therapy. *Nat. Med.* **27**, 1223–1229 (2021).
166. Tomita, H. et al. Restoration of the majority of the visual spectrum by using modified Volvox channelrhodopsin-1. *Mol. Ther.* **22**, 1434–1440 (2014).
167. Sengupta, A. et al. Red-shifted channelrhodopsin stimulation restores light responses in blind mice, macaque retina, and human retina. *EMBO Mol. Med.* **8**, 1248–1264 (2016).
168. Gauvain, G. et al. Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates. *Commun. Biol.* **4**, 125 (2021).
169. Mattis, J. et al. Principles for applying optogenetic tools derived from direct comparative analysis of microbial opsins. *Nat. Methods* **9**, 159–172 (2012).
170. Ganjawala, T. H., Lu, Q., Fenner, M. D., Abrams, G. W. & Pan, Z.-H. Improved CoChR variants restore visual acuity and contrast sensitivity in a mouse model of blindness under ambient light conditions. *Mol. Ther.* **27**, 1195–1205 (2019).
171. Cehajic-Kapetanovic, J. et al. Restoration of vision with ectopic expression of human rod opsin. *Curr. Biol.* **25**, 2111–2122 (2015).
172. Gaub, B. M., Berry, M. H., Holt, A. E., Isacoff, E. Y. & Flannery, J. G. Optogenetic vision restoration using rhodopsin for enhanced sensitivity. *Mol. Ther.* **23**, 1562–1571 (2015).
173. Berry, M. H. et al. Restoration of high-sensitivity and adapting vision with a cone opsin. *Nat. Commun.* **10**, 1221 (2019).
174. van Wyk, M., Pielecola-Fortuna, J., Löwel, S. & Kleinlogel, S. Restoring the ON switch in blind retinas: opto-mGluR6, a next-generation, cell-tailored optogenetic tool. *PLoS Biol.* **13**, e1002143 (2015).
175. Surace, E. M. & Auricchio, A. Versatility of AAV vectors for retinal gene transfer. *Vis. Res.* **48**, 353–359 (2008).
176. Ivanova, E., Hwang, G.-S., Pan, Z.-H. & Troilo, D. Evaluation of AAV-mediated expression of Chp2-GFP in the marmoset retina. *Investig. Ophthalmol. Vis. Sci.* **51**, S288–S296 (2010).
177. Yin, L. et al. Intravitreal injection of AAV2 transduces macaque inner retina. *Investig. Ophthalmol. Vis. Sci.* **52**, 2775–2783 (2011).
178. Lagali, P. S. et al. Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. *Nat. Neurosci.* **11**, 667–675 (2008).
179. Cronin, T. et al. Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. *EMBO Mol. Med.* **6**, 1175–1190 (2014).
180. Macé, E. et al. Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV restores ON and OFF visual responses in blind mice. *Mol. Ther.* **23**, 7–16 (2015).
181. Lu, Q., Ganjawala, T. H., Krstevski, A., Abrams, G. W. & Pan, Z.-H. Comparison of AAV-mediated optogenetic vision restoration between retinal ganglion cell expression and ON bipolar cell targeting. *Mol. Ther. Methods Clin. Dev.* **18**, 15–23 (2020).
182. Busskamp, V. et al. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. *Science* **329**, 413–417 (2010).
183. Marc, R. E., Jones, B. W., Watt, C. B. & Strettoi, E. Neural remodeling in retinal degeneration. *Prog. Retin. Eye Res.* **22**, 607–655 (2003).
184. Bruegmann, T., Beier, T., Vogt, C. C., Schrickel, J. W. & Sasse, P. Optogenetic termination of atrial fibrillation in mice. *Cardiovas. Res.* **114**, 713–723 (2018).
185. Bruegmann, T. et al. Optogenetic control of heart muscle in vitro and in vivo. *Nat. Methods* **7**, 897–900 (2010).
186. Nussinovitch, U. & Gepstein, L. Optogenetics for in vivo cardiac pacing and resynchronization therapies. *Nat. Biotechnol.* **33**, 750–754 (2015).
187. Bruegmann, T. et al. Optogenetic defibrillation terminates ventricular arrhythmia in mouse hearts and human simulations. *J. Clin. Invest.* **126**, 3894–3904 (2016).
188. Boyle, P. M., Williams, J. C., Ambrosi, C. M., Entcheva, E. & Trayanova, N. A. A comprehensive multiscale framework for simulating optogenetics in the heart. *Nat. Commun.* **4**, 2370 (2013).
189. Quiñonez Uribe, R. A., Luther, S., Diaz-Maue, L. & Richter, C. Energy-reduced arrhythmia termination using global photostimulation in optogenetic murine hearts. *Front. Physiol.* **9**, 1651 (2018).
190. Nyns, E. C. et al. An automated hybrid bioelectronic system for autogenous restoration of sinus rhythm in atrial fibrillation. *Sci. Transl. Med.* **11**, eaau6447 (2019).
191. Entcheva, E. & Kay, M. W. Cardiac optogenetics: a decade of enlightenment. *Nat. Rev. Cardiol.* **18**, 349–367 (2021).
192. Zaglia, T. et al. Optogenetic determination of the myocardial requirements for extrasystoles by cell type-specific targeting of channelrhodopsin-2. *Proc. Natl Acad. Sci. USA* **112**, E4495–E4504 (2015).
193. Ambrosi, C. M. & Entcheva, E. Optogenetics' promise: pacing and cardioversion by light? *Future Cardiol.* **10**, 1–4 (2014).
194. Williams, J. C. et al. Computational optogenetics: empirically-derived voltage-and light-sensitive channelrhodopsin-2 model. *PLoS Comput. Biol.* **9**, e1003220 (2013).
195. Karathanos, T. V., Boyle, P. M. & Trayanova, N. A. Optogenetics-enabled dynamic modulation of action potential duration in atrial tissue: feasibility of a novel therapeutic approach. *Europace* **16**, iv69–iv76 (2014).
196. Rajendran, P. S. et al. Identification of peripheral neural circuits that regulate heart rate using optogenetic and viral vector strategies. *Nat. Commun.* **10**, 1944 (2019).
197. Ambrosi, C. M., Sadananda, G., Han, J. L. & Entcheva, E. Adeno-associated virus mediated gene delivery: implications for scalable in vitro and in vivo cardiac optogenetic models. *Front. Physiol.* **10**, 168 (2019).
198. Wengrowski, A. M. et al. Optogenetic release of norepinephrine from cardiac sympathetic neurons alters mechanical and electrical function. *Cardiovas. Res.* **105**, 143–150 (2015).
199. Moreno, A. et al. Sudden heart rate reduction upon optogenetic release of acetylcholine from cardiac parasympathetic neurons in perfused hearts. *Front. Physiol.* **10**, 16 (2019).
200. Greenberg, B. et al. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. *Gene Ther.* **23**, 313–319 (2016).
201. Crocini, C. et al. Optogenetics design of mechanically-based stimulation patterns for cardiac defibrillation. *Sci. Rep.* **6**, 35628 (2016).
202. Hussaini, S. et al. Drift and termination of spiral waves in optogenetically modified cardiac tissue at sub-threshold illumination. *eLife* **10**, e59954 (2021).
203. Hochbaum, D. R. et al. All-optical electrophysiology in mammalian neurons using engineered microbial rhodopsins. *Nat. Methods* **11**, 825–833 (2014).
204. Klimas, A. et al. OptoDyCE as an automated system for high-throughput all-optical dynamic cardiac electrophysiology. *Nat. Commun.* **7**, 11542 (2016).
205. Klimas, A., Ortiz, G., Boggess, S. C., Miller, E. W. & Entcheva, E. Multimodal on-axis platform for all-optical electrophysiology with near-infrared probes in human stem-cell-derived cardiomyocytes. *Prog. Biophys. Mol. Biol.* **154**, 62–70 (2020).
206. Dempsey, G. T. et al. Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging. *J. Pharmacol. Toxicol. Meth.* **81**, 240–250 (2016).
207. Dwenger, M. et al. Chronic optical pacing conditioning of h-iPSC engineered cardiac tissues. *J. Tissue Eng.* **10**, 2041731419841748 (2019).
208. Quach, B., Krogh-Madsen, T., Entcheva, E. & Christini, D. J. Light-activated dynamic clamp using iPSC-derived cardiomyocytes. *Biophys. J.* **115**, 2206–2217 (2018).
209. Ochoa-Fernandez, R. et al. Optogenetic control of gene expression in plants in the presence of ambient white light. *Nat. Methods* **17**, 717–725 (2020).
210. Christie, J. M. & Zurbriggen, M. D. Optogenetics in plants. *New Phytol.* **229**, 3108–3115 (2021).
211. Omelina, E. S. et al. Optogenetic and chemical induction systems for regulation of transgene expression in plants: use in basic and applied research. *Int. J. Mol. Sci.* **23**, 1737 (2022).
212. Papanatsiou, M. et al. Optogenetic manipulation of stomatal kinetics improves carbon assimilation, water use, and growth. *Science* **363**, 1456–1459 (2019).
213. Reyer, A. et al. Channelrhodopsin-mediated optogenetics highlights a central role of depolarization-dependent plant proton pumps. *Proc. Natl Acad. Sci. USA* **117**, 20920–20925 (2020).
214. Zhou, Y. et al. Extending the anion channelrhodopsin-based toolbox for plant optogenetics. *Membranes* **11**, 287 (2021).
215. Huang, S. et al. Optogenetic control of the guard cell membrane potential and stomatal movement by the light-gated anion channel Gt ACR1. *Sci. Adv.* **7**, eabg4619 (2021).
216. Twill, D., Yamaguchi, J. & McCormick, S. Pollen-specific gene expression in transgenic plants: coordinate regulation of two different tomato gene promoters during microsporogenesis. *Development* **109**, 705–713 (1990).
217. Govorunova, E. G., Sineshchekov, O. A., Janz, R., Liu, X. & Spudis, J. L. NEUROSCIENCE. Natural light-gated anion channels: a family of microbial rhodopsins for advanced optogenetics. *Science* **349**, 647–650 (2015).
218. Gutermuth, T. et al. Pollen tube growth regulation by free anions depends on the interaction between the anion channel SLAH3 and calcium-dependent protein

- kinases CPK2 and CPK20. *Plant Cell* **25**, 4525–4543 (2013).
219. Gutermuth, T. et al. Tip-localized  $\text{Ca}^{2+}$ -permeable channels control pollen tube growth via kinase-dependent R- and S-type anion channel regulation. *New Phytol.* **218**, 1089–1105 (2018).
220. Gilroy, S. et al. ROS, calcium, and electric signals: key mediators of rapid systemic signaling in plants. *Plant Physiol.* **171**, 1606–1615 (2016).
221. Choi, W.-G. et al. Orchestrating rapid long-distance signaling in plants with  $\text{Ca}^{2+}$ , ROS and electrical signals. *Plant. J.* **90**, 698–707 (2017).
222. Fromm, J. & Lautner, S. Electrical signals and their physiological significance in plants. *Plant Cell Environ.* **30**, 249–257 (2007).
223. Vodenev, V., Katicheva, L. & Sukhov, V. Electrical signals in higher plants: mechanisms of generation and propagation. *Biophysics* **61**, 505–512 (2016).
224. Szechynska-Hebda, M., Lewa dowska, M. & Karpi ski, S. Electrical signaling, photosynthesis and systemic acquired acclimation. *Front. Physiol.* **8**, 684 (2017).
225. Hedrich, R. & Neher, E. Venus flytrap: how an excitable, carnivorous plant works. *Trends Plant. Sci.* **23**, 220–234 (2018).
226. Kravitz, A. & Bonci, A. Optogenetics, physiology, and emotions. *Front. Behav. Neurosci.* **7**, 169 (2013).
227. Häusser, M. Optogenetics: the age of light. *Nat. Methods* **11**, 1012–1014 (2014).
228. Dawydow, A. et al. Channelrhodopsin-2-XXL, a powerful optogenetic tool for low-light applications. *Proc. Natl Acad. Sci. USA* **111**, 13972–13977 (2014).
229. Inoue, S.-i & Kinoshita, T. Blue light regulation of stomatal opening and the plasma membrane  $\text{H}^{+}$ -ATPase. *Plant Physiol.* **174**, 531–538 (2017).
230. Pilot, G. et al. Guard cell inward  $\text{K}^{+}$  channel activity in *Arabidopsis* involves expression of the twin channel subunits KAT1 and KAT2. *J. Biol. Chem.* **276**, 3215–3221 (2001).
231. Catterall, W. A., Wisedchaisri, G. & Zheng, N. The chemical basis for electrical signaling. *Nat. Chem. Biol.* **13**, 455–463 (2017).
232. Duan, X., Nagel, G. & Gao, S. Mutated channelrhodopsins with increased sodium and calcium permeability. *Appl. Sci.* **9**, 664 (2019).
233. Miyashita, T., Shao, Y. R., Chung, J., Pourzia, O. & Feldman, D. Long-term channelrhodopsin-2 (ChR2) expression can induce abnormal axonal morphology and targeting in cerebral cortex. *Front. Neural Circuits* **7**, 8 (2013).
234. Rapti, K. et al. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. *Mol. Ther.* **20**, 73–83 (2012).
235. Al-Juboori, S. I. et al. Light scattering properties vary across different regions of the adult mouse brain. *PLoS ONE* **8**, e67626 (2013).
236. Shin, Y. et al. Characterization of fiber-optic light delivery and light-induced temperature changes in a rodent brain for precise optogenetic neuromodulation. *Biomed. Opt. Express* **7**, 4450–4471 (2016).
237. Arias-Gil, G., Ohl, F. W., Takagaki, K. & Lippert, M. T. Measurement, modeling, and prediction of temperature rise due to optogenetic brain stimulation. *Neurophotonics* **3**, 045007 (2016).
238. Owen, S. F., Liu, M. H. & Kreitzer, A. C. Thermal constraints on in vivo optogenetic manipulations. *Nat. Neurosci.* **22**, 1061–1065 (2019).
239. Yang, F. & Zheng, J. High temperature sensitivity is intrinsic to voltage-gated potassium channels. *eLife* **3**, e03255 (2014).
240. Sabatini, B. L. & Regehr, W. G. Timing of neurotransmission at fast synapses in the mammalian brain. *Nature* **384**, 170–172 (1996).
241. Moser, E. I. & Andersen, P. Conserved spatial learning in cooled rats in spite of slowing of dentate field potentials. *J. Neurosci.* **14**, 4458–4466 (1994).
242. Chen, R. et al. Deep brain optogenetics without intracranial surgery. *Nat. Biotechnol.* **39**, 161–164 (2021).
243. Podgorski, K. & Ranganathan, G. Brain heating induced by near-infrared lasers during multiphoton microscopy. *J. Neurophysiol.* **116**, 1012–1023 (2016).
244. Picot, A. et al. Temperature rise under two-photon optogenetic brain stimulation. *Cell Rep.* **24**, 1245–1253.e5 (2018).
245. Pan, Z.-H., Lu, Q., Bi, A., Dizhoor, A. M. & Abrams, G. W. Optogenetic approaches to restoring vision. *Annu. Rev. Vis. Sci.* **1**, 185–210 (2015).
246. Chuong, A., Miri, M. & Acker, L. Non-invasive optogenetic neural silencing. *Nat. Neurosci.* **17**, 1123–1129 (2014).
247. Herman, A. M., Huang, L., Murphey, D. K., Garcia, I. & Arenkiel, B. R. Cell type-specific and time-dependent light exposure contribute to silencing in neurons expressing channelrhodopsin-2. *eLife* **3**, e01481 (2014).
248. Ferenczi, E. A. et al. Optogenetic approaches addressing extracellular modulation of neural excitability. *Sci. Rep.* **6**, 23947 (2016).
249. Otchy, T. M. et al. Acute off-target effects of neural circuit manipulations. *Nature* **528**, 358–363 (2015).
250. Sorum, B., Rietmeijer, R. A., Gopakumar, K., Adesnik, H. & Brohawn, S. G. Ultrasound activates mechanosensitive TRAAK  $\text{K}^{+}$  channels through the lipid membrane. *Proc. Natl Acad. Sci. USA* **118**, e2006980118 (2021).
251. Strickland, D. et al. TULIPS: tunable, light-controlled interacting protein tags for cell biology. *Nat. Methods* **9**, 379–384 (2012).
252. Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. *Nat. Methods* **7**, 973–975 (2010).
253. Levskaya, A., Weiner, O. D., Lim, W. A. & Voigt, C. A. Spatiotemporal control of cell signalling using a light-switchable protein interaction. *Nature* **461**, 997–1001 (2009).
254. Farhi, S. L. et al. Wide-area all-optical neurophysiology in acute brain slices. *J. Neurosci.* **39**, 4889–4908 (2019).
255. Berndt, A. et al. High-efficiency channelrhodopsins for fast neuronal stimulation at low light levels. *Proc. Natl Acad. Sci. USA* **108**, 7595–7600 (2011).
256. Gong, X. et al. An ultra-sensitive step-function opsin for minimally invasive optogenetic stimulation in mice and macaques. *Neuron* **107**, 38–51.e8 (2020).
257. Rajasethupathy, P. et al. Projections from neocortex mediate top-down control of memory retrieval. *Nature* **526**, 653–659 (2015).
258. Shevchenko, V. et al. Inward  $\text{H}^{+}$  pump xenorhodopsin: mechanism and alternative optogenetic approach. *Sci. Adv.* **3**, e1603187 (2017).
259. Grimm, C., Silapetere, A., Vogt, A., Sierra, Y. A. B. & Hegemann, P. Electrical properties, substrate specificity and optogenetic potential of the engineered light-driven sodium pump eKR2. *Sci. Rep.* **8**, 9316 (2018).
260. Gradinaru, V., Thompson, K. R. & Deisseroth, K. eNpHR: a *Natronomonas* halorhodopsin enhanced for optogenetic applications. *Brain Cell Biol.* **36**, 129–139 (2008).
261. Subach, O. M. et al. FRCaMP, a red fluorescent genetically encoded calcium indicator based on calmodulin from *Schizosaccharomyces pombe* fungus. *Int. J. Mol. Sci.* **22**, 111 (2021).
262. Dalangin, R. et al. Far-red fluorescent genetically encoded calcium ion indicators. Preprint at *bioRxiv* <https://doi.org/10.1101/2020.11.12.380089> (2020).
263. Villette, V. et al. Ultrafast two-photon imaging of a high-gain voltage indicator in awake behaving mice. *Cell* **179**, 1590–1608.e23 (2019).
264. Abdelfattah, A. S. et al. Bright and photostable chemigenetic indicators for extended in vivo voltage imaging. *Science* **365**, 699–704 (2019).
265. Kannan, M. et al. Fast, in vivo voltage imaging using a red fluorescent indicator. *Nat. Methods* **15**, 1108–1116 (2018).
266. Piatkevich, K. D. et al. A robotic multidimensional directed evolution approach applied to fluorescent voltage reporters. *Nat. Chem. Biol.* **14**, 352–360 (2018).
267. Miesenböck, G., De Angelis, D. A. & Rothman, J. E. Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins. *Nature* **394**, 192–195 (1998).
268. Anikeeva, P. et al. Optetrode: a multichannel readout for optogenetic control in freely moving mice. *Nat. Neurosci.* **15**, 163–170 (2012).
269. Creed, M., Pascoli, V. J. & Lüscher, C. Refining deep brain stimulation to emulate optogenetic treatment of synaptic pathology. *Science* **347**, 659–664 (2015).
270. Kuhn, J., Gruendler, T. O., Klosterkötter, J. & Bartsch, C. Stimulating the addictive brain. *Front. Hum. Neurosci.* **6**, 220 (2012).

# Acknowledgements

This work was supported by the following funding sources: V.E. is supported by the IHU FOReSIGHT grant (Grant P-ALLOP3-IHU-000), the Axa Research Fund, the European Research Council (ERC) (ERC-2019-AdG; no. 885090) and the Agence National pour la Recherche (ANR-17-CE16-0021). E.E. is supported, in part, by the grants National Institutes of Health (NIH) R01 HL144157, NIH R21EB026152, National Science Foundation (NSF) 1705645 and NSF 1830941. J.V. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy (EXC-2049 – 390688087). R.H. is supported by the German Research Foundation (DFG) (Koselleck award HE1640/42-1). P.H. is supported by the DFG (SFB1078, SPP1926, UniSysCat and NeuroCure) and the ERC (Stardust 767092). P.H. is Hertie Professor for Neuroscience and supported by the Hertie Foundation. C.L. is supported by the ERC (ERC-2020-AdG, F-addict) and the Swiss National Science Foundations (no. 310030\_189188 and CRSII5\_186266). M.M. has received funding from the European Union's Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement no. 844492. Z.-H.P. is supported by the Ligon Research Center of Vision at Kresge Eye Institute, Dryer Foundation, Herrick Foundation and Research to Prevent Blindness to Department of Ophthalmology, Visual and Anatomical Sciences at Wayne State University School of Medicine. O.Y. is supported by the Joseph and Wolf Lebovic Charitable Foundation Chair for Research in Neuroscience, the ERC (grant no. 819496), the EU Horizon 2020 programme (H2020-ICT-2018-20 DEEPER 101016787) and the Israel Science Foundation [grant no. 3131/20].

# Author contributions

Introduction (C.L., E.E., J.V., M.M., O.Y., P.H., R.H., V.E. and Z.-H.P.); Experimentation (J.V., M.M., O.Y., P.H. and V.E.); Results (C.L., E.E., J.V., K.R.K., M.M., O.Y., P.H., R.H., R.R.S., V.E. and Z.-H.P.); Applications (C.L., E.E., K.R.K., O.Y., P.H., R.H., R.R.S., V.E. and Z.-H.P.); Reproducibility and data deposition (C.L., E.E., J.V., K.R.K., M.M., O.Y., P.H., R.H., R.R.S., V.E. and Z.-H.P.); Limitations and optimizations (C.L., E.E., J.V., M.M., O.Y., P.H., R.H., V.E. and Z.-H.P.); Outlook (C.L., E.E., O.Y., P.H., R.H., V.E. and Z.-H.P.); Overview of the Primer (O.Y. and P.H.). Authors are listed in alphabetical order.

# Competing interests

Z.-H.P. is a co-inventor on patents related to optogenetic vision restoration and is also a co-founder and scientific advisor of Ray Therapeutics. The other authors declare no competing interests.

# Peer review information

*Nature Reviews Methods Primers* thanks John Flannery and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

# Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

# Supplementary information

The online version contains supplementary material available at <https://doi.org/10.1038/s43586-022-00136-4>.

© Springer Nature Limited 2022

---


**Supplementary information**

---

**Optogenetics for light control of biological systems**

---


In the format provided by the  
authors and unedited



## Supplementary Figure 1. Mutational tuning of channelrhodopsin properties based on the ChR2 structure.

Cartoon of the CrChR2 (C2) structure with highlighted amino acids that have been mutated in C2 or related ChRs to successfully tune expression, selectivity, conductance, kinetics and degree of inactivation (selection). The blue regions depict high-probability locations of water molecules based on molecular dynamics calculations. N-terminal modification for improved expression: bReaChES<sup>1</sup>, CsChrimson<sup>2</sup>, iC<sup>++3</sup>; S63 and N258: Ca<sup>2+</sup>-conductance<sup>4</sup>; E83 (E2'): H<sup>+</sup>-conductance<sup>5,6</sup>; E90 (E3'): Cation conductance & selectivity: Chloc<sup>7</sup>, iC1C2<sup>5</sup>, ChromeQ<sup>8</sup>; E101: H<sup>+</sup>-conductance: ChrimsonS<sup>9</sup>, iChloc<sup>6</sup>, iC<sup>++3</sup> and faster kinetics: ChRoME2f<sup>10</sup>; E123 (counter ion Ci1): Fast kinetics: CheTA<sup>11</sup>, bReaChES<sup>1</sup>, Chronos<sup>12</sup>; T127: Red Shift in ChrimsonSA<sup>13</sup>; C128: Slow kinetics in SFOs<sup>14,15</sup>; L132: Large conductance and reduced inactivation in CatCh<sup>16,17</sup> and CoChR-3M<sup>18</sup>; H134: Selectivity, desensitization, kinetics: CrChR2-H134R<sup>19</sup>, ChrimsonR<sup>12</sup>; D156: Slow Kinetics in SFOs<sup>20</sup>, SSFOs<sup>21</sup>, CrChR2-XXL<sup>22</sup>; T159: Retinal binding and color: CrChR2-TC<sup>23</sup>; F219: Fast Kinetics: fChrimson<sup>24</sup>; S256: Red shift in ReaChR<sup>25,26</sup>, Chrimson<sup>13</sup> and larger photocurrents: ChRoME2s<sup>10</sup>.





## Supplementary Figure 2: Combining optical techniques: dual-opsin manipulations and all-optical approaches.

**Left:** Optical crosstalk: red shifted CCRs can also be activated by blue light but not vice versa. *Top)* Sample photocurrent traces for the red shifted CCR Chrimson showing significant depolarization in response to illumination with blue light. *Middle)* Action spectra of commonly used CCRs. *Inset:* Jablonski diagram. Y-axis represents the energy of the opsin bound retinal with possible energy states indicated by black bars. Absorption of a photon will result in an electron to be elevated from the ground state ( $S_0$ ) to an excited state (singlet state:  $S_1$ ). In the case of red-light sensitive opsins, the energy needed for a transition to the first excitation state is reduced compared to blue shifted opsins. However, the higher energy of blue light can lead to the transition to a higher excitation state ( $S_x$ ), making red-light sensitive opsins also sensitive to shorter wavelengths. *Bottom)* Current clamp recording of two neurons expressing the blue shifted opsin ChR2 (left) and the red shifted opsin Chrimson (right) respectively (adapted from <sup>27</sup>). In case of the red shifted opsin, both red and blue illumination leads to action potential firing.


**Right:** Despite this crosstalk optical techniques can still be combined using one of the following strategies:

**Adapt light intensity:** In carefully controlled experiments a blue wavelength light power range that allows for sufficient activation of a blue light sensitive tool without activation of the red sensitive tool can be determined. We refer to this as the operational range (blue shading). An example is the combination of an indicator excited by blue light (e.g. GCaMP) with a red shifted ion-pump (e.g. NpHR), that will not significantly hyperpolarize the cell at the light power necessary for sensor imaging. However, especially when sub action potential threshold effects are taken into consideration, the definition of “acceptable activator activation” becomes non-trivial.

**Compensate blue light activity:** This can be achieved by matching two opsin actuators so that the activation of the red shifted tool by blue light is compensated by the blue light sensitive tool with opposite but stronger effect. A recent example is BiPOLES, where the blue light activated anion channel GtACR2 suppresses blue light activity of the fused red shifted Chrimson channel<sup>27</sup>. Blue light inhibition and changes of input resistance during blue light illumination of BiPOLES expressing cells might however require careful evaluation when using BiPOLES for optical multiplexing.


**Choose red shifted sensors:** The blue light excitation of red shifted sensors is usually acceptable as fluorescence decay is much faster than the fluctuations of the measured parameter such as intracellular calcium levels. The sensor can often not be measured during blue light illumination, but the measurement can be directly continued thereafter. *Inset:* Example measurements from a stCoChR and jRCaMP1a expressing neuron. Scanning at 1100 nm does not lead to apparent firing rate changes, while holographic single cell stimulation using 920 nm light results in robust AP firing and jRCaMP1a fluorescence increase. *Top*) jRCaMP1a fluorescence read out by 1100 nm two-photon raster scanning. *Bottom*) Cell attached recording of the same neuron. Adapted from Forli et al., eLife 2021 (NEED TO ADD THIS REF: <https://elifesciences.org/articles/63359>)

**Choose fast opsins:** When using two-photon scan imaging, the use of opsins with a fast-closing kinetics combined with fast scanning of a large field of view enables to reduce the imaging cross talk by reducing the accumulation of current between two successive laser passes. Considering that photostimulation with spiral scanning works better with slow opsins, this strategy is particularly indicated in combination with parallel photostimulation in which case the evoked photocurrent is independent of the opsin kinetics.



### Supplementary Figure 3: Operational light sensitivity


The operational light sensitivity (OLS) can be defined as the photocurrent induced in a rhodopsin expressing cell for a given photon irradiance or photon exposure in case of a short light flash. OLS depends on the probability of an opsins to enter the photocycle upon photon absorption and, in addition, on the number of opsin proteins residing in the plasma membrane (A), the single-channel conductance (B), and the kinetic properties (C) of the opsin. The consequences of kinetic changes may be very different for channels (blue) and pumps (red).



**Supplementary Figure 4 Sequence motifs used for directing subcellular targeting of optogenetic tools.**

Left: Schematic of a neuron including subcellular compartments. Right: Commonly used amino-acid sequences to target transmembrane domain proteins. (1-3) Sequences employed to reduce intracellular accumulation by improved plasma-membrane targeting in plant (1) and mammalian cells (2-3). (4-9) Sequences utilized to target opsins to subcellular compartments.






### Supplementary Figure 5: Wavefront engineering: now


(A) In optogenetics, wavefront engineering is most commonly implemented using phase modulation since this approach maximizes light throughput. Phase modulation relies on the fact that light propagates at different velocities through media with different refractive indices (denoted  $n_0$  and  $n_1$  respectively). Propagation through a medium with a spatially varying refractive index introduces relative delays (known as phase shifts) between different parts of the wavefront. Liquid crystal on silicon spatial light modulators (LCOS-SLMs) are most widely used for implementing phase modulation. This relatively mature technology permits the dynamic generation of arbitrary wavefronts. Commercially available devices exhibit high pixel counts, minimal dead space between pixels and reasonably fast (tens of milliseconds) switching times. (B) The phase shift imparted by each pixel of an LCOS-SLM is determined by the voltage across the cell which corresponds to a particular orientation of the birefringent liquid crystal molecules and a consequent effective refractive index. (C) Simple wavefront shaping using Fourier holography and the most-intuitive “Gratings and Lenses” approach. In this configuration, the SLM is positioned at a focal length,  $f$ , prior to a lens. The output pattern is the Fourier transform of the modulated wavefront following the SLM and is generated in the focal plane (a distance  $f$  after the lens). For clarity, transmissive SLMs are shown in the schematic diagrams but, in practice, reflective SLMs are used for most optogenetics applications. (i) Consider the ideal case of a plane wave incident on an SLM. When a constant voltage is applied to all SLM pixels, the profile of

the wavefront is not distorted following propagation through the SLM, and hence is focused by the lens to a diffraction-limited spot in the focal plane. (ii) The diffraction limited spot can be displaced laterally throughout the focal plane by applying appropriate voltages to the SLM pixels such that the SLM imparts a linear phase ramp (grating) to the wavefront. (iii) Similarly, axial displacements can be obtained by imprinting the phase of a suitable lens profile on the wavefront using the SLM. (iv) Three-dimensional displacements can be obtained by a combination of phase ramps and lenses. (v) The simplest way to generate multiple spots with arbitrary three-dimensional positions is to apply voltages corresponding to a linear sum of the individual phase shifts to the SLM pixels. However, this approach generally results in an inhomogeneous, pattern-dependent, distribution of intensity between different spots since the amplitude of the complex field (LC-SLMs are usually only used to modulate phase) is neglected. This can be remedied by using a weighted iterative algorithm (typically a variant of the Gerchberg-Saxton approach) to optimize the hologram. (D)(i) Computer generated holography (CGH) can also be used to generate extended patterns. For optogenetics applications, CGH has been used to generate circular spots with diameter matched to the neuronal soma. (D)(ii) Schematic representation of the optical path used for generalized phase contrast (GPC), which is a different, interferometric, method used for wavefront shaping. In GPC, is a different, interferometric, method used for wavefront shaping for optogenetic applications. Schematic representation of the optical path used for generalized phase contrast. The beam is modulated using an SLM, which is used to impart a phase shift to the portion of the beam corresponding to the desired pattern. In case of binary GPC, the SLM usually imparts a  $\pi$  phase shift to the pixels within the pattern and 0 to those outside. A phase contrast filter (PCF) located in the Fourier plane (FP) after the first lens (L1) typically imparts a  $\pi$  phase shift to the “synthetic reference beam” (unmodulated field) with respect to the field that does not pass through the PCF. The different portions of the beam are recombined by L2 in the Image Plane (IP), where the modulated and synthetic reference fields interfere to form the desired, speckle-free, pattern.



**Supplementary Figure 6 Temporal focusing.**

In conventional 2P microscopy, a high numerical aperture objective is used to spatially focus light from an ultrafast (pulsed) laser source to a diffraction limited spot. In this configuration, 2PE is usually limited to a femtolitre volume in the vicinity of the focal point. However, for most optogenetic applications, this volume does not contain a sufficiently large number of actuators to adequately modulate the cellular parameter under investigation. Hence it is generally necessary to rapidly scan the excitation beam or to increase the lateral beam extent in order to excite actuators throughout the cell membrane. In general, increasing the lateral extent of the beam waist also increases its axial extent (due to diffraction) which results in a deterioration of axial resolution. Temporal focusing (TF) is widely used in 2P optogenetics to ameliorate the axial resolution of extended illumination patterns. TF is based on the use of a dispersive element (such as a diffraction grating) which introduces delays between different portions of the excitation beam, and increases the effective pulse duration at all planes outside of the temporal focus; the plane where the different frequency components are recombined (**b**). For temporally focused 2PE, the axial resolution is independent of the lateral beam extent and can approach that of a diffraction limited spot<sup>287</sup>. Panel **a** depicts a schematic diagram to illustrate the simplest implementation of temporal focusing. An optical element (a diffraction grating) is used to spatially separate the spectral frequencies (“colors”) of laser pulses. The different spatial frequencies are recombined at the focal plane of the microscope objective. (**b**) Spatial and temporal focusing maximize photon density, and, consequently, rates of two photon excitation at the focal plane. Spatial focusing (left) using a lens creates an axial gradient in photon density which decays quadratically with axial distance from the focal plane (inset),  $z_R$  and  $\phi$  refer to the Rayleigh range and half-angle divergence respectively. In temporal focusing (right), the duration of laser pulses increases with distance from the focal plane.




**Supplementary Figure 7. Comparison of current methods for 3-dimensional light shaping**

Generation of multiple extended temporally focused shapes is achieved in three-steps : (i) the beam amplitude shaping to control the shape and size of the illumination spot(ii) temporal focusing to axially confine the light absorption (iii) 3D spatial multiplexing to replicate the temporally focused shape in



the excitation volume. This can be done in multiple ways depending on the characteristic of the generated pattern.


- a)** The generation of multiple shapes, temporally focused, in 3D requires 2 LC-SLMs, SLM1 and SLM2, addressed in vertical tiles (parallel to the orientation of the grating lines and orthogonal to the linear dispersion), each tile addresses a different pattern (defined in SLM1) at a defined axial plane (defined in SLM2). Precisely, on SLM1 each tile generates a 2D holographic shape (here illustrated by a star and a square), on the TF grating. SLM2 performs an independent axial displacement for each shape by modulating the corresponding beams with the corresponding lens effect<sup>28</sup>.
- b)** The generation of multi temporally focused Gaussian beam (3DSHOT), requires 1 SLM which multiplexes in 3D the temporally focused gaussian spot generated at the TF grating. SLM2 is in this case illuminated with a temporally focused line or with an extended spot using an optical diffuser<sup>29</sup>.
- c)** The generation of multiplexed temporally focused holographic spots of adjustable size and shape is achieved using a first LC-SLM (SLM1) which generates an holographic shape at the TF grating, and a second one, SLM2, uniformly illuminated<sup>30</sup>, which multiplexes in 3D the temporally focused holographic shape.
- d)** For fast sequential light patterning, a collimated beam is reflected by a galvanometric mirror (GM) onto the diffraction grating and collimated onto the multiplexing SLM in the form of a horizontal (orthogonal to the orientation of the grating lines) line. A deflection of the beam by the GM results in a translation of the illuminating line on the SLM, addressed with  $n$  independent, tiled holograms. This leads to fast switching of different groups of (2D or 3D) light patterns.




**Supplementary Figure 8. Spectral ranges for two photon excitation of channelrhodopsins and genetically-encoded calcium sensors.**

A summary of the two-photon excitation spectra and closing kinetics of some of the most commonly used opsins. For each opsin, the horizontal bars span the wavelengths over which the peak normalized photocurrent is greater than 60% of the maximum value (indicated by an asterisk) and are coloured according to whether the channelrhodopsin predominantly conducts cations (blue) or anions (red). The vertical grey lines indicate activation wavelengths previously used in pubmed-indexed articles. The number of articles for a given wavelength is indicated by the shade of grey (see legend). Notably, and unlike the single photon case, the wavelengths used for two photon excitation of channelrhodopsins rarely coincides with the spectral peak but instead are clustered at 920 nm and between 1030 – 1070 nm. These clusters correspond to commercially available fixed wavelength laser sources with sufficiently high peak pulse energies to permit the photoactivation of multiple cells. Whilst tunable sources such as Ti:Sapphire lasers, optical parametric oscillators (OPO's) and optical parametric amplifiers (OPA's) provide greater flexibility in terms of excitation wavelength, commercially available versions do not currently offer comparable average powers to the fixed wavelength ytterbium fiber sources. For reference, the excitation wavelength ranges of the most commonly used calcium activity indicators is also shown (top).

## A. Rhythm control



## B. HT Cardiotoxicity testing



## Supplementary Figure 9: Cardiac applications of optogenetics.

A. Rhythm control can include optical pacemaking using atrial or ventricular sites (A. top left, with permission from <sup>31</sup>) or heart rate control (A. top right, with permission from <sup>32</sup>) by activating the sympathetic nervous system (increase) or the parasympathetic nervous system (decrease). Furthermore, restoration of normal rhythm can be achieved via cardioversion of ventricular tachycardia (VT) using patterned light in strategic shapes (A. bottom, with permission from <sup>33</sup>). B. High-throughput drug screening and cardiotoxicity testing is enabled by all-optical cardiac electrophysiology that allows high-content recordings and manipulation of the action potential by light. Voltage and calcium can be recorded optically under spontaneous conditions or under ChR2-mediated pacing in human iPSC-CMs (with permission from <sup>34</sup> and cardiotoxicity risk can be quantified for any drug).

## Cardiac Opportunities:

### A. Rhythm control:

Applications of optogenetics to the heart started about a decade ago <sup>31,35</sup> and are still lagging in scope and impact compared to neuroscience research <sup>32</sup>. The key benefits for clinical translation are sought in more versatile optogenetic pacing or suppression of wave propagation during arrhythmias, compared to currently used cardiac devices (pacemakers and cardioverter/defibrillators). Strategies for rhythm control, enabled by optogenetic actuators, aim to lower the energy needed to power the devices, thus extending battery life, and to eliminate discomfort and pain during classic cardioversion/defibrillation while being more effective in control of life-threatening arrhythmias and better quality of life. Optogenetics addresses these challenges through the ability to deliver longer lower-energy light pulses (electrical pulse duration is limited due to electrochemical toxicity via Faraday effects) and through cell-specific genetic targeting to engage the fast conduction system, e.g. His bundle or Purkinje fibers for pacing <sup>36, 37</sup>, or to target specifically the myocytes and avoid unintended contractions of thoracic skeletal muscle, diaphragm and vocal cords as pain-inducing electrical defibrillation does <sup>38</sup>. Computational modelling of the action of optogenetic tools in the heart has been developed to help explore strategies for control of arrhythmias, both with excitatory/depolarizing opsins and with inhibitory/hyperpolarizing opsins <sup>36,39-42</sup>.

For optogenetic cardiac pacing to become a viable clinical alternative to the very successful and safe electronic pacemakers, it needs to offer much lower energy to essentially eliminate battery replacement. Optogenetic control of arrhythmias may be a more viable clinical application. Atrial arrhythmias, such as atrial flutter and atrial fibrillation, have increased over 3-fold in the last 50 years, affecting a large proportion of the ageing population. They are potential targets for optogenetic cardioversion due to smaller tissue thickness and better accessibility <sup>43,44</sup>. Ventricular arrhythmias are typically more complex, can be lethal and will require a spatially distributed strategy of light application to terminate <sup>40 33 45</sup>. Autonomic control of cardiac function, via the sympathetic and the parasympathetic system, can be an attractive target for the cell-specific optogenetic tools (Suppl. Figure XX A). Increasing parasympathetic tone or suppression of sympathetic activity have been recognized as anti-arrhythmic tools in various cardiac pathologies. Several recent studies have demonstrated the use of excitatory opsins (ChR2) targeting the parasympathetic system in transgenic mice <sup>46,47</sup> or viral delivery of inhibitory opsins (ArchT) targeting the sympathetic system in dogs after



acute ischemia <sup>48</sup>. Such neuro-cardiac applications may find quicker path to the clinic as the light delivery may be implemented through easier to implant subcutaneous small LED-based devices, similar to the electrical vagal stimulators.

#### B. High-throughput all-optical cardiac electrophysiology:

All-optical cardiac electrophysiology, combining optogenetic actuators and optical/optogenetic sensors <sup>34,49,50</sup>, just like in neuroscience, offers immediate adoption and translation. Cardiotoxicity testing is particularly crucial in development of any new pharmaceutical and it is required as part of the drug development pipeline. High-throughput optogenetic methods with patient-derived cells enable new pursuits in personalized medicine <sup>51-53</sup>, Suppl. Figure XX B.

Bidirectional voltage control, using for example ChR2 and ArchT, in conjunction with an optical voltage readout (Quasar1) can be used to explore drug effects on ion channels, similar to the classic voltage clamp <sup>54</sup>. Dynamic clamp, that reacts in real time to control the voltage applied to a cell, can be realized using optogenetic tools (ArchT) and computer-controlled LEDs to “inject” modifying current that yields a more mature phenotype in human induced pluripotent stem cell derived cardiomyocytes, iPSC-CMs <sup>55</sup>.

High-content, high-throughput cell-based assays using optogenetic sensors and actuators and human iPSC-CMs represent the near-term translation of this technology to the cardiac area. They are more scalable and can provide more comprehensive information (about voltage, calcium and mechanical responses) compared to the automated planar-patch systems, due to the non-contact nature of interrogation by light. These assays can be deployed at the preclinical testing for all drugs to uncover electrophysiological and mechanical abnormalities beyond the currently used compound testing in heterologous systems on potassium voltage-gated channel subfamily H member 2 (also known as hERG) channel blocking, which a prime target for drugs. Regulatory agencies around the world are considering a shift to such more comprehensive cardiotoxicity assays with human iPSC-CMs <sup>52</sup>. Some high-throughput all-optical platforms have been already translated in the industrial setting for drug discover in cardiac and other applications <sup>56-58</sup>.

To advance personalized medicine, optogenetic tools have been used for disease modelling with patient-derived iPSC-CMs, for chronic stimulation to improve maturity of these cells and

obtain more adult-like phenotype <sup>59</sup>. Such approaches may help efforts towards regenerative medicine. Autologous sources of somatic cells, transduced with optogenetic tools, can be potentially used for in vivo cell delivery as alternative to classic gene therapy for tissue regeneration or rhythm control.

#### Specific Requirements and Challenges:


Longer-term in vivo clinical applications face the challenges of genetic modification of the hard-to-access cardiac muscle, potential immune responses, realizing embedded miniaturized light control devices that are reliable and safe <sup>32</sup>.

The main working cell type in the heart are ventricular myocytes. AAV9 is the most efficient serotype for targeting these cells in vivo when using an ubiquitous or specific promoter, such as Myh6, <sup>60</sup>. The other cells of interest in the heart that have been targeted optogenetically include atrial myocytes using NPPA promoter and a “gene painting” technique with ReaChR-AAV9 <sup>44</sup>, and targeting cardiac fibroblasts (WT1), cardiac macrophages (CX3CR1)<sup>61</sup>, fast conduction system cells (Cx40) <sup>37</sup>, sympathetic neurons (tyrosine hydrolase, TH)<sup>62</sup>, and parasympathetic neurons (choline acetyltransferase, ChAT) <sup>46,47</sup> in Cre-Lox transgenic mouse models. Most studies thus far have been performed in rodents – transgenic mice and in mice and rats with AAV9 as a delivery vector topically or systemically using tail-vein injection. To translate the approaches to larger animals, more work is needed in finding minimally-invasive ways of delivery to the heart, and in characterizing immune responses. Previous clinical trials on gene therapy for cardiac disorders found that large portion of the patients had antibodies against the viral vectors used, thus reducing the efficacy of the therapy.

Most of the published studies have used ChR2 (the H134R variant) as excitatory opsin, with occasional ReaChR use. Inhibitory pump opsins, ArchT and Halo, have been successfully used to hyperpolarize the membrane in myocytes and to terminate activity, although they are less successful in termination of complex arrhythmias compared to the depolarizing (ChR2) opsins, likely due to anode-break re-excitation of the tissue. Cl<sup>-</sup> based opsins, GtACR1<sup>63</sup>, are not trivially used in cardiac cells and tissues due to different Cl<sup>-</sup> gradient compared to neurons. In general, more efficient and fast inhibitory opsins are desirable for arrhythmia control applications. Also, there may be a niche for step-function-like depolarizing options that have fast recovery from inactivation as “clamping” tools in arrhythmia management. Bidirectional closed-loop control can make **optical clamp** [G] a reality at the whole organ level yet it will

require spectral compatibility to accommodate excitatory, inhibitory opsins as well as means for optical readout of voltage.


Light delivery to the dense thick ventricular wall is non-trivial and presents even bigger challenges compared to neuroscience applications due to the vigorous contractions and difficulties to stabilize the devices. Light penetration in the haemoglobin-rich heart muscle would require operation in the near-infrared and the deployment of opsins excitable in that range. The atria are thinner (human atria are  $< 5\text{mm}$ ) and along with autonomic nerves present easier targets.



**Supplementary Figure 10. Feeding or *in planta* production of retinal enables rhodopsin-based plant optogenetics**

(a) Scheme of an Arabidopsis plant upon external feeding of retinal for (b) simultaneous optical stimulation and membrane voltage recordings of leaf mesophyll cells with intracellular electrodes as indicated. Scheme in (b) from Reyer et al., 2020<sup>64</sup> with some minor modifications. (c) A representative membrane potential trace of a ChR2-XXL expressing (black) and wild type (red) *Arabidopsis thaliana* control leaf when extracellular retinal was added and a 5 s lasting blue-light pulse was applied. The ChR2-XXL-mediated depolarization is counteracted by the depolarization-activated  $H^+$ -pump activity at the plasma membrane when the blue-light pulse is terminated. Pictures and the example traces (from a to c) provided by courtesy of Dirk Becker and Antonella Reyer. (d) Stable introduction of the GtACR1 gene and that of retinal producing bacterial dioxxygenase into the tobacco plant allows the functional expression of GtACR1. This allows to steer (e) pollen tube growth direction caused by (f) large directed membrane potential depolarizations (upper trace) induced by GtACR1-driven photocurrents (lower trace) of up to several nA amplitude in the presence of green light (532 nm, 0.18 mW mm<sup>-2</sup>).







**Supplementary Figure 11. Ion gradients determine optogenetic response in plant and animal cell systems**

A scheme comparing the ion concentration gradients and direction of ion flow across the plasma membrane of *Chlamydomonas* as well as plant and animal soma cells when activating either ChR2 or GtACR1. In (a) *Chlamydomonas* and (b) plant cells the extracellular space facing the plasma membrane is low in ion concentration and pond water-like while (c) the extracellular space in most animal cells is rich in NaCl and sea water-like. The Ca<sup>2+</sup> inward gradient is comparable in most biological systems, but unlike animal cells, photosynthetically active cells have a steeper (2 pH units) inward H<sup>+</sup> gradient generating a steeper electric potential gradient (ΔV<sub>m</sub>). Therefore, ChR2 activation leads to depolarization, which in *Chlamydomonas* and plant cells is mostly based on an influx of Ca<sup>2+</sup> and H<sup>+</sup> but in animal soma cells on Ca<sup>2+</sup> and Na<sup>+</sup>. Due to the reversed anion gradients in plant and animal cells, GtACR1 activation leads to depolarization in plant cells but hyperpolarisation in the soma of neurons; however, cell specific conditions related to Cl<sup>-</sup> reversal potential with respect to the resting membrane potential determine GtACR1's action in other cell types.

### A. Start with successful optogenetic protocol



### B. Emulate with electrical stimulation in slice



### C. Implement optogenetically inspired DBS



## Supplementary Figure 12. Optogenetically inspired DBS.

a. The process starts with a successful optogenetic reversal protocol, inducing LTD at mPFC to NAc synapses (see also Fig 6). b. Using electrical stimulation in the NAc (left), a protocol is established that emulates the optogenetic stimulation (middle). Here D1R needed to be blocked (antagonist) to allow the induction of LTD in D1R-MSNs (right). c. In vivo implementation combines DBS with systemic injection of the antagonist (left) to reverse locomotor sensitization (right).

**Supplementary Table 1: Studies of optogenetic vision restoration in animal models**

Targeted major retinal cell types	Optogenetic tools	Vectors and delivery route	Promoters	Animal models	Electrophysiological assessments	Threshold light sensitivity (photons/cm <sup>2</sup> s <sup>1</sup> )*	Behavioral tests	Major results	References
RGCs	ChR2	AAV2; Intravitreal	CAG	<i>rdl</i> mice, wild-type mice and rats	WCR, MEA, VEP	At low 10 <sup>15</sup>		Restoration of ChR2-mediated VEP and light response in the retina of <i>rdl</i> mice	65
	ChR2	AAV2; Intravitreal	CAG	RCS rats	VEP			Restoration of VEP in RCS rats	66
	Melanopsin	AAV2; Intravitreal	CMV	<i>rdl</i> mice	WCR	~10 <sup>13</sup> (~100 lux)	PLR, open-field avoidance, water maze	Restoration of light response in the retina, PLR, light avoidance, and light/dark discrimination in <i>rdl</i> mice	67
	ChR2	Transgenic mice	Thy-1	Rats, light-induced retinal degeneration	WCR, VEP	Low 10 <sup>15</sup>	OMR	Restoration of OMR in ChR2 transgenic rats	68
	ChR2, eNpHR	AAV2; Intravitreal	CMV, CAG	<i>rdl</i> mice	WCR, MEA	ChR2: at low 10 <sup>15</sup> ; eNpHR: at low 10 <sup>16</sup>		Restoration of both ON and OFF light responses in the retina of <i>rdl</i> mice	69
	ChR2	AAV2; Intravitreal	CAG	C57BL/6J mice				Long-term safe expression of ChR2 in the retina	70
	ChR2	AAV2; Intravitreal	CAG	Marmoset	MEA			Functional expression of ChR2 in the non-human primate retina.	71
	ChR2	Transgenic mice	Thy 1	<i>rdl</i> mice	ECR, OIR	~10 <sup>13</sup>	OMR, water maze	Restoration of light responses in the retina and cortex but failed to restore functional vision	72
	ChR2	AAV2; Intravitreal	CAG	RCS rats	VEP	At low 10 <sup>15</sup>	OMR	Restoration of OMR	73
	ChR2	AAV2; Intravitreal 0.5 – 5 x10 <sup>10</sup> GP	CAG	RCS rats				Absence of immunologically harmful reactions of ChR2	74
	ChR2, eNpHR	Electroporation	CaMK IIa	Rabbit	WCR, ECR			Creation of ON and OFF antagonistic center-surround receptive field with motif targeting in RGCs	75
	ChR2	Transgenic mice	Thy 1	<i>rdl</i> mice	MEA		OMR	Restoration of vision using neural code	76

	ChR2, eNpHR	AAV2; Intravitreal	CAG, EF1 $\alpha$	C57BL/6J mice	MEA			AAV-mediated creation of ON and OFF center-surround antagonistic receptive field with targeting motifs	77
	ChR2-C132C/T159S	AAV2; Intravitreal	CAG	<i>rd1</i> mice	MEA	At low 10 <sup>13</sup>		Creation of ChR2 mutants with improved light sensitivity	78
	mVChR1 (ChR1/vChR1 chimera)	AAV2; Intravitreal	CAG	RCS rats	VEP		OMR	Creation of a red-shifted ChR for vision restoration	79
	mVChR1	AAV2; Intravitreal	CAG	RCS rats				Absence of immunologically harmful reactions with mVChR1	80
	ReaChR	AAV2; Intravitreal	hSyn 1	<i>rd1</i> mice, macaque, human retina	WCR, MEA		Locomotion, light avoidance	Restoration of vision for the toleration of high light intensity	81
	ChR2	Transgenic mice	Thy-1	<i>rd1</i> mice	MEA	$\sim 10^{15}$		Improvement of restored vision by the blockade of spontaneous activity	82
	ChR2	Transgenic mice	Thy-1	<i>rd1</i> mice	MEA	$\sim 10^{14}$		Improvement of restored vision by dampening spontaneous activity	83
	Human melanopsin	AAV2/8(Y733F); Subretinal	CAG	<i>rd1</i>	MEA, OIR	$\sim 10^{13}$	PLR, light-dark box, object recognition	Restoration of image forming vision with melanopsin	84
	ChR2 + mVChR1	Transgenic rats; AAV2; Intravitreal	Thy-1, CAG	Rats; chemical induced retinal degeneration	WCR, VEP			Co-expression of ChR2 and mVChR1 improved wavelength and light sensitivity	85
	ChR2, Melanopsin	AAV2; Intravitreal	hSyn 1	Canine <i>rd</i> model	MEA			Long-term safe expression in the retina of <i>rd</i> dogs	86
	ChR2-L132C	AAV2; Intravitreal	SNCG	<i>rd1</i> mice	MEA, VEP	$\sim 10^{14}$		Improvement of light sensitivity with RGC specific promoter	87
	ChR2-L132C/T159C	AAV2; Intravitreal	CAG	Macaques				Characterization of expression of ChR2 in the macaque retina	88
	ChR2-mutants	AAV2; Intravitreal	CAG	Transgenic (Opn4 <sup>-/-</sup> Gnat1 <sup>-/-</sup> Cnga3 <sup>-/-</sup> ) mice			PLR, OMR	Restoration of vision using a triple knock-out blind mouse model and optomotor assay	89



	CoChR-H94E/L112C/K264T	AAV2 or AAV2.7m8 (Y444F); Intravitreal	CAG	Transgenic (Opn4 <sup>-/-</sup> Gnat1 <sup>-/-</sup> Cnga3 <sup>-/-</sup> ) mice	MEA	~10 <sup>12</sup>	OMR	Restoration of visual acuity and contrast sensitivity under ambient light condition	18
	Human melanopsin	AAV2/8; subretinal	CMV	<i>rdl</i> mice	ERG, VEP		Locomotion	Long-term safe expression of melanopsin, but only transient restoration of visual response	90
	Green cone opsin	AAV2/2-4YF; Intravitreal	hsyn-1	<i>rdl</i> mice	MEA	~10 <sup>11</sup>	Light avoidance, exploratory behavior	Restoration of vision with high light sensitivity, light adaptation, and pattern discrimination	91
	ReaChR; ChR2-L132C	AAV2; Intravitreal	hsyn-1	Macaques	MEA			Restoration of visual acuity of 20/72 estimated based on MEA recordings	92
	ChrimsonR	AAV2.7m8; Intravitreal	CAG	Macaques	MEA	At low 10 <sup>15</sup>		Restoration of visual acuity of 20/249 estimated based on MEA recordings	93
	ChrimsonR	AAV2; Intravitreal	CAG	Macaques	ROI			Response persistent over one year	94
	mVChR1/ChR2/CoChR chimera	AAV2; Intravitreal	CAG	RCS rats	VEP	~10 <sup>13</sup>	OMR	Development of a ChR chimera with improved light sensitivity	95
ON BCs	ChR2	Electroporation	mGluR6 200En	<i>rdl</i> mice	WCR, MEA, VEP	~10 <sup>14</sup>	OMR, locomotion	Restoration of visual responses and functional vision through ON BC targeting	96
	ChR2	Sc-AAV2/8; Subretinal	mGluR6 200En	<i>rdl</i> , <i>rd10</i> , <i>rd16</i> mice	MEA	Low 10 <sup>16</sup>	Water maze	AAV-mediated targeting ChR2 to ON BCs	97
	ChR2(L132C)	AAV2/8BP2; Subretinal	4x mGluR6 200En	<i>rdl</i> mice	MEA	At low 10 <sup>15</sup>		Improved transduction efficiency with AAV2/8BP2	98
	ChR2(H134R)	AAV2.7m8; Intravitreal	mGluR6 200En	<i>rdl</i> mice	MEA, VEP	~10 <sup>14</sup>	Light avoidance	Improved transduction efficiency with AAV2.7m8	99
	Melanopsin/mGluR6 chimera	AAV2, transgenic mice	mGluR6 200En	<i>rdl</i> , transgenic mice	WCR, MEA, OIR	~10 <sup>12</sup>	OMR, water maze	Creation of melanopsin/mGluR6 receptor chimera for vision restoration	100
	Rhodopsin	AAV2; Intravitreal	mGluR6 200En, CAG	<i>rdl</i> mice	MEA	~10 <sup>12</sup>	Locomotion, natural scenes stimulation	Restoration of vision with rhodopsin	101
	Rhodopsin	AAV2; Intravitreal	4x mGluR6 200En	<i>rdl</i> mice	MEA, VEP	~10 <sup>12</sup>	Light avoidance, water maze,	Restoration of vision with rhodopsin	102

							fear conditioning		
	ChR2 mutant + Chrimson	AAV2; Intravitreal	mGluR 6 200En	<i>rd10</i> mice			Water maze	Restoration of vision using dual wavelength ChRs	103
	CoChR-L112C	AAV2; Intravitreal	mGluR 6 promoter with introns and 200En; CAG	TKO (Opn4 <sup>-/-</sup> Gnat1 <sup>-/-</sup> Cnga3 <sup>-/-</sup> ) mice	MEA		PLR, OMR	RGC expression exhibited higher efficacy than ON BC targeting	104
	ChR2 mutant + Chrimson	AAV2; Intravitreal	mGluR 6 200En	<i>rd10</i> mice	WCR	~10 <sup>15</sup>	Water maze, OMR	Restoration of vision using dual wavelength ChRs	105
	Green cone opsin	AAV2.7m8 ; Intravitreal	hGRM 6 promoter with 770En	<i>rd1</i> mice			OMR	Restoration of OMR with an improved human GluR6 promoter	106
<b>Cones</b>	eNpHR	AAV2/8; Subretinal	hRho, hRo	<i>rd1</i> and Cnga3 <sup>-/-</sup> Rho <sup>-/-</sup> mice	WCR, MEA, VEP	At low 10 <sup>13</sup>	OMR, Light avoidance	Restoration of vision by targeting surviving cone photoreceptors	107

WCR: whole-cell recording; ECR: extracellular recording; OIR: optical imaging recording; MEA: multi-electrode array recording; OMR: optomotor response; VEP: visually evoked potential; PLR: pupillary light reflex; RGC: retinal ganglion cell; ON BC: ON bipolar cell.

\* The Threshold Light sensitivity is estimated based on retinal electrophysiological recordings.

**Supplementary Table 2: Clinical trials of optogenetic therapies for vision restoration**

Company	Optogenetic tool	Targeted retinal cells	Vector construct & delivery route	Link to clinical trial	Status	Results and notes
RetroSense Therapeutics	ChR2	RGCs	AAV2-CAG-ChR2; Intravitreal injection	<a href="https://clinicaltrials.gov/ct2/show/NCT02556736">https://clinicaltrials.gov/ct2/show/NCT02556736</a>	Phase 1/2a	RetroSense was acquired by Allergan in 2016. No result has been released.
GenSight Biologics	ChrimsonR	RGCs	AAV2.7m8-CAG-ChrimsonR-tdTomato; Intravitreal injection	<a href="https://clinicaltrials.gov/ct2/show/NCT03326336">https://clinicaltrials.gov/ct2/show/NCT03326336</a>	Phase 1/2a	Partial recovery of visual function in a blind patient using light-stimulating goggles (Ref. 45).
Bionic Sight	Chronos	RGCs	AAV-Chronos-FP; Intravitreal injection	<a href="https://clinicaltrials.gov/ct2/show/NCT04278131">https://clinicaltrials.gov/ct2/show/NCT04278131</a>	Phase 1/2	Restoration of light perception and motion detection (source: <a href="https://www.fightingblindness.org/research/bionic-sight-s-optogenetic-therapy-enables-blind-patients-to-detect-light-and-motion-in-early-trial-217">https://www.fightingblindness.org/research/bionic-sight-s-optogenetic-therapy-enables-blind-patients-to-detect-light-and-motion-in-early-trial-217</a> ).
Nanoscope Therapeutics	ChR2 mutant + Chrimson	ON BCs	AAV2-mGluR6-ChR2 mutant/Chrimson-FP; Intravitreal injection	<a href="https://clinicaltrials.gov/ct2/show/NCT04945772">https://clinicaltrials.gov/ct2/show/NCT04945772</a>	Phase 2	Improvement of vision and visual acuity in the ambient light environment (source: <a href="https://nanos therapeutics.com/2021/06/03/nanosopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision/">https://nanos therapeutics.com/2021/06/03/nanosopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision/</a> ).

## References for Supplementary Information

- 1 Rajasethupathy, P. *et al.* Projections from neocortex mediate top-down control of memory retrieval. *Nature* **526**, 653-659 (2015).
- 2 Urmann, D. *et al.* Photochemical Properties of the Red-shifted Channelrhodopsin Chrimson. *Photochem Photobiol* **93**, 782-795 (2017).
- 3 Berndt, A. *et al.* Structural foundations of optogenetics: Determinants of channelrhodopsin ion selectivity. *Proc Natl Acad Sci U S A* **113**, 822-829, (2016).
- 4 Plazzo, A. P. *et al.* Bioinformatic and Mutational Analysis of Channelrhodopsin-2 Protein Cation-conducting Pathway. *Journal of Biological Chemistry* **287**, 4818-4825 (2012).
- 5 Berndt, A., Lee, S. Y., Ramakrishnan, C. & Deisseroth, K. Structure-guided transformation of channelrhodopsin into a light-activated chloride channel. *Science* **344**, 420-424 (2014).
- 6 Wietek, J. *et al.* An improved chloride-conducting channelrhodopsin for light-induced inhibition of neuronal activity in vivo. *Scientific reports* **5**, 1-11 (2015).
- 7 Wietek, J. *et al.* Conversion of channelrhodopsin into a light-gated chloride channel. *Science* **344**, 409-412, (2014).
- 8 Cho, Y. K. *et al.* Multidimensional screening yields channelrhodopsin variants having improved photocurrent and order-of-magnitude reductions in calcium and proton currents. *Journal of Biological Chemistry* **294**, 3806-3821 (2019).
- 9 Vierock, J., Grimm, C., Nitzan, N. & Hegemann, P. Molecular determinants of proton selectivity and gating in the red-light activated channelrhodopsin Chrimson. *Sci Rep* **7**, 9928, (2017).
- 10 Sridharan, S. *et al.* High-performance microbial opsins for spatially and temporally precise perturbations of large neuronal networks. *Neuron* **110**, 1139-1155. e1136 (2022).
- 11 Gunaydin, L. A. *et al.* Ultrafast optogenetic control. *Nature Neuroscience* **13**, 387-U327 (2010).
- 12 Klapoetke, N. C. *et al.* Independent optical excitation of distinct neural populations. *Nat Methods* **11**, 338-346 (2014).
- 13 Oda, K. *et al.* Crystal structure of the red light-activated channelrhodopsin Chrimson. *Nat Commun* **9**, 3949 (2018).
- 14 Berndt, A., Yizhar, O., Gunaydin, L. A., Hegemann, P. & Deisseroth, K. Bi-stable neural state switches. *Nature Neuroscience* **12**, 229-234 (2009).
- 15 Schoenenberger, P., Gerosa, D. & Oertner, T. G. Temporal Control of Immediate Early Gene Induction by Light. *Plos One* **4** (2009).
- 16 Kleinlogel, S. *et al.* Ultra light-sensitive and fast neuronal activation with the Ca<sup>2+</sup>-permeable channelrhodopsin CatCh. *Nature Neuroscience* **14**, 513-U152 (2011).
- 17 Schneider, F., Gradmann, D. & Hegemann, P. Ion Selectivity and Competition in Channelrhodopsins. *Biophysical Journal* **105**, 91-100 (2013).
- 18 Ganjawala, T. H., Lu, Q., Fenner, M. D., Abrams, G. W. & Pan, Z.-H. Improved CoChR variants restore visual acuity and contrast sensitivity in a mouse model of blindness under ambient light conditions. *Molecular Therapy* **27**, 1195-1205 (2019).
- 19 Nagel, G. *et al.* Light activation of channelrhodopsin-2 in excitable cells of *Caenorhabditis elegans* triggers rapid Behavioral responses. *Current Biology* **15**, 2279-2284 (2005).
- 20 Bamann, C., Gueta, R., Kleinlogel, S., Nagel, G. & Bamberg, E. Structural Guidance of the Photocycle of Channelrhodopsin-2 by an Interhelical Hydrogen Bond. *Biochemistry* **49**, 267-278 (2010).

- 21 Yizhar, O. *et al.* Neocortical excitation/inhibition balance in information processing and social dysfunction. *Nature* **477**, 171-178 (2011).
- 22 Dawydow, A. *et al.* Channelrhodopsin-2–XXL, a powerful optogenetic tool for low-light applications. *Proceedings of the National Academy of Sciences* **111**, 13972-13977 (2014).
- 23 Berndt, A. *et al.* High-efficiency channelrhodopsins for fast neuronal stimulation at low light levels. *Proceedings of the National Academy of Sciences of the United States of America* **108**, 7595-7600 (2011).
- 24 Mager, T. *et al.* High frequency neural spiking and auditory signaling by ultrafast red-shifted optogenetics. *Nature communications* **9**, 1-14 (2018).
- 25 Lin, J. Y., Knutsen, P. M., Muller, A., Kleinfeld, D. & Tsien, R. Y. ReaChR: a red-shifted variant of channelrhodopsin enables deep transcranial optogenetic excitation. *Nature Neuroscience* **16**, 1499 (2013).
- 26 Krause, B. S. *et al.* Complex photochemistry within the green-absorbing channelrhodopsin ReaChR. *Biophysical journal* **112**, 1166-1175 (2017).
- 27 Vierock, J. *et al.* BiPOLES is an optogenetic tool developed for bidirectional dual-color control of neurons. *Nature Communications* **12**, 1-20 (2021).
- 28 Hernandez, O. *et al.* Three-dimensional spatiotemporal focusing of holographic patterns. *Nature communications* **7**, 1-11 (2016).
- 29 Pégard, N. C. *et al.* Three-dimensional scanless holographic optogenetics with temporal focusing (3D-SHOT). *Nature communications* **8**, 1-14 (2017).
- 30 Accanto, N. *et al.* Multiplexed temporally focused light shaping for high-resolution multi-cell targeting. *Optica* **5**, 1478-1491 (2018).
- 31 Bruegmann, T. *et al.* Optogenetic control of heart muscle in vitro and in vivo. *Nature methods* **7**, 897-900 (2010).
- 32 Entcheva, E. & Kay, M. W. Cardiac optogenetics: a decade of enlightenment. *Nature Reviews Cardiology* **18**, 349-367 (2021).
- 33 Crocini, C. *et al.* Optogenetics design of mechanistically-based stimulation patterns for cardiac defibrillation. *Scientific reports* **6**, 1-7 (2016).
- 34 Klimas, A., Ortiz, G., Boggess, S. C., Miller, E. W. & Entcheva, E. Multimodal on-axis platform for all-optical electrophysiology with near-infrared probes in human stem-cell-derived cardiomyocytes. *Progress in biophysics and molecular biology* **154**, 62-70 (2020).
- 35 Arrenberg, A. B., Stainier, D. Y., Baier, H. & Huisken, J. Optogenetic control of cardiac function. *Science* **330**, 971-974 (2010).
- 36 Boyle, P. M., Williams, J. C., Ambrosi, C. M., Entcheva, E. & Trayanova, N. A. A comprehensive multiscale framework for simulating optogenetics in the heart. *Nature communications* **4**, 1-9 (2013).
- 37 Zaglia, T. *et al.* Optogenetic determination of the myocardial requirements for extrasystoles by cell type-specific targeting of ChannelRhodopsin-2. *Proceedings of the National Academy of Sciences* **112**, E4495-E4504 (2015).
- 38 Ambrosi, C. M. & Entcheva, E. Optogenetics ‘promise: pacing and cardioversion by light? *Future cardiology* **10**, 1-4 (2014).
- 39 Williams, J. C. *et al.* Computational optogenetics: empirically-derived voltage-and light-sensitive channelrhodopsin-2 model. *PLoS computational biology* **9**, e1003220 (2013).
- 40 Bruegmann, T. *et al.* Optogenetic defibrillation terminates ventricular arrhythmia in mouse hearts and human simulations. *The Journal of clinical investigation* **126**, 3894-3904 (2016).



- 41 Karathanos, T. V., Boyle, P. M. & Trayanova, N. A. Optogenetics-enabled dynamic modulation of action potential duration in atrial tissue: feasibility of a novel therapeutic approach. *Europace* **16**, iv69-iv76 (2014).
- 42 Majumder, R. *et al.* Optogenetics enables real-time spatiotemporal control over spiral wave dynamics in an excitable cardiac system. *Elife* **7**, e41076 (2018).
- 43 Bruegmann, T., Beiert, T., Vogt, C. C., Schrickel, J. W. & Sasse, P. Optogenetic termination of atrial fibrillation in mice. *Cardiovascular research* **114**, 713-723 (2018).
- 44 Nyns, E. C. *et al.* An automated hybrid bioelectronic system for autogenous restoration of sinus rhythm in atrial fibrillation. *Science translational medicine* **11** (2019).
- 45 Quiñonez Uribe, R. A., Luther, S., Diaz-Maue, L. & Richter, C. Energy-reduced arrhythmia termination using global photostimulation in optogenetic murine hearts. *Frontiers in physiology* **9**, 1651 (2018).
- 46 Rajendran, P. S. *et al.* Identification of peripheral neural circuits that regulate heart rate using optogenetic and viral vector strategies. *Nature communications* **10**, 1-13 (2019).
- 47 Moreno, A. *et al.* Sudden heart rate reduction upon optogenetic release of acetylcholine from cardiac parasympathetic neurons in perfused hearts. *Frontiers in physiology* **10**, 16 (2019).
- 48 Yu, L. *et al.* Optogenetic modulation of cardiac sympathetic nerve activity to prevent ventricular arrhythmias. *Journal of the American College of Cardiology* **70**, 2778-2790 (2017).
- 49 Klimas, A. *et al.* OptoDyCE as an automated system for high-throughput all-optical dynamic cardiac electrophysiology. *Nature communications* **7**, 1-12 (2016).
- 50 Hochbaum, D. R. *et al.* All-optical electrophysiology in mammalian neurons using engineered microbial rhodopsins. *Nature Methods* **11**, 825-833, doi:Doi 10.1038/Nmeth.3000 (2014).
- 51 Shi, Y., Inoue, H., Wu, J. C. & Yamanaka, S. Induced pluripotent stem cell technology: a decade of progress. *Nature reviews Drug discovery* **16**, 115-130 (2017).
- 52 Gintant, G. *et al.* Use of human induced pluripotent stem cell-derived cardiomyocytes in preclinical cancer drug cardiotoxicity testing: a scientific statement from the American Heart Association. *Circulation research* **125**, e75-e92 (2019).
- 53 Shaheen, N. *et al.* Human induced pluripotent stem cell-derived cardiac cell sheets expressing genetically encoded voltage indicator for pharmacological and arrhythmia studies. *Stem cell reports* **10**, 1879-1894 (2018).
- 54 Streit, J. & Kleinlogel, S. Dynamic all-optical drug screening on cardiac voltage-gated ion channels. *Scientific reports* **8**, 1-13 (2018).
- 55 Quach, B., Krogh-Madsen, T., Entcheva, E. & Christini, D. J. Light-activated dynamic clamp using iPSC-derived cardiomyocytes. *Biophysical journal* **115**, 2206-2217 (2018).
- 56 Dempsey, G. T. *et al.* Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging. *Journal of pharmacological and toxicological methods* **81**, 240-250 (2016).
- 57 Werley, C. A., Chien, M.-P. & Cohen, A. E. Ultrawidefield microscope for high-speed fluorescence imaging and targeted optogenetic stimulation. *Biomedical optics express* **8**, 5794-5813 (2017).
- 58 Nguyen, C. *et al.* Simultaneous voltage and calcium imaging and optogenetic stimulation with high sensitivity and a wide field of view. *Biomedical optics express* **10**, 789-806 (2019).

- 59 Dwenger, M. *et al.* Chronic optical pacing conditioning of h-iPSC engineered cardiac tissues. *Journal of tissue engineering* **10**, 2041731419841748 (2019).
- 60 Ambrosi, C. M., Sadananda, G., Han, J. L. & Entcheva, E. Adeno-associated virus mediated gene delivery: implications for scalable in vitro and in vivo cardiac optogenetic models. *Frontiers in physiology* **10**, 168 (2019).
- 61 Hulsmans, M. *et al.* Macrophages facilitate electrical conduction in the heart. *Cell* **169**, 510-522. e520 (2017).
- 62 Wengrowski, A. M. *et al.* Optogenetic release of norepinephrine from cardiac sympathetic neurons alters mechanical and electrical function. *Cardiovascular research* **105**, 143-150 (2015).
- 63 Govorunova, E. G., Cunha, S. R., Sineshchekov, O. A. & Spudich, J. L. Anion channelrhodopsins for inhibitory cardiac optogenetics. *Sci Rep* **6**, 33530, doi:10.1038/srep33530 (2016).
- 64 Reyer, A. *et al.* Channelrhodopsin-mediated optogenetics highlights a central role of depolarization-dependent plant proton pumps. *Proceedings of the National Academy of Sciences* **117**, 20920-20925 (2020).
- 65 Bi, A. D. *et al.* Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. *Neuron* **50**, 23-33 (2006).
- 66 Tomita, H. *et al.* Restoration of visual response in aged dystrophic RCS rats using AAV-mediated channelrhodopsin-2 gene transfer. *Investigative ophthalmology & visual science* **48**, 3821-3826 (2007).
- 67 Lin, B., Koizumi, A., Tanaka, N., Panda, S. & Masland, R. H. Restoration of visual function in retinal degeneration mice by ectopic expression of melanopsin. *Proceedings of the National Academy of Sciences* **105**, 16009-16014 (2008).
- 68 Tomita, H. *et al.* Visual properties of transgenic rats harboring the channelrhodopsin-2 gene regulated by the thy-1.2 promoter. *PloS one* **4**, e7679 (2009).
- 69 Zhang, Y., Ivanova, E., Bi, A. & Pan, Z.-H. Ectopic expression of multiple microbial rhodopsins restores ON and OFF light responses in retinas with photoreceptor degeneration. *Journal of Neuroscience* **29**, 9186-9196 (2009).
- 70 Ivanova, E. & Pan, Z.-H. Evaluation of the adeno-associated virus mediated long-term expression of channelrhodopsin-2 in the mouse retina. *Molecular vision* **15**, 1680 (2009).
- 71 Ivanova, E., Hwang, G.-S., Pan, Z.-H. & Troilo, D. Evaluation of AAV-mediated expression of ChR2-GFP in the marmoset retina. *Investigative ophthalmology & visual science* **51**, 5288-5296 (2010).
- 72 Thyagarajan, S. *et al.* Visual function in mice with photoreceptor degeneration and transgenic expression of channelrhodopsin 2 in ganglion cells. *Journal of Neuroscience* **30**, 8745-8758 (2010).
- 73 Tomita, H. *et al.* Channelrhodopsin-2 gene transduced into retinal ganglion cells restores functional vision in genetically blind rats. *Experimental eye research* **90**, 429-436 (2010).
- 74 Sugano, E. *et al.* Immune responses to adeno-associated virus type 2 encoding channelrhodopsin-2 in a genetically blind rat model for gene therapy. *Gene therapy* **18**, 266-274 (2011).
- 75 Greenberg, K. P., Pham, A. & Werblin, F. S. Differential targeting of optical neuromodulators to ganglion cell soma and dendrites allows dynamic control of center-surround antagonism. *Neuron* **69**, 713-720 (2011).
- 76 Nirenberg, S. & Pandarinath, C. Retinal prosthetic strategy with the capacity to restore normal vision. *Proceedings of the National Academy of Sciences* **109**, 15012-15017 (2012).

- 77 Wu, C., Ivanova, E., Zhang, Y. & Pan, Z.-H. rAAV-mediated subcellular targeting of optogenetic tools in retinal ganglion cells in vivo. *PloS one* **8**, e66332 (2013).
- 78 Pan, Z.-H., Ganjawala, T. H., Lu, Q., Ivanova, E. & Zhang, Z. ChR2 mutants at L132 and T159 with improved operational light sensitivity for vision restoration. *PLoS One* **9**, e98924 (2014).
- 79 Tomita, H. *et al.* Restoration of the majority of the visual spectrum by using modified Volvox channelrhodopsin-1. *Molecular Therapy* **22**, 1434-1440 (2014).
- 80 Sugano, E. *et al.* Local and systemic responses following intravitreal injection of AAV2-encoded modified Volvox channelrhodopsin-1 in a genetically blind rat model. *Gene therapy* **23**, 158-166 (2016).
- 81 Sengupta, A. *et al.* Red-shifted channelrhodopsin stimulation restores light responses in blind mice, macaque retina, and human retina. *EMBO molecular medicine* **8**, 1248-1264 (2016).
- 82 Barrett, J. M., Degenaar, P. & Sernagor, E. Blockade of pathological retinal ganglion cell hyperactivity improves optogenetically evoked light responses in rd1 mice. *Frontiers in cellular neuroscience* **9**, 330 (2015).
- 83 Barrett, J. M., Hilgen, G. & Sernagor, E. Dampening spontaneous activity improves the light sensitivity and spatial acuity of optogenetic retinal prosthetic responses. *Scientific reports* **6**, 1-14 (2016).
- 84 De Silva, S. R. *et al.* Long-term restoration of visual function in end-stage retinal degeneration using subretinal human melanopsin gene therapy. *Proceedings of the National Academy of Sciences* **114**, 11211-11216 (2017).
- 85 Sato, M. *et al.* Visual responses of photoreceptor-degenerated rats expressing two different types of channelrhodopsin genes. *Scientific reports* **7**, 1-10 (2017).
- 86 Ameline, B. *et al.* Long-term expression of melanopsin and channelrhodopsin causes no gross alterations in the dystrophic dog retina. *Gene therapy* **24**, 735-741 (2017).
- 87 Chaffiol, A. *et al.* A new promoter allows optogenetic vision restoration with enhanced sensitivity in macaque retina. *Molecular Therapy* **25**, 2546-2560 (2017).
- 88 Wang, W., Nan, Y., Pan, Z.-H. & Pu, M. Morphological evaluation of retinal ganglion cells expressing the L132C/T159C ChR2 mutant transgene in young adult cynomolgus monkeys. *Science China Life Sciences* **60**, 1157-1167 (2017).
- 89 Lu, Q., Ganjawala, T. H., Hattar, S., Abrams, G. W. & Pan, Z.-H. A Robust optomotor assay for assessing the efficacy of optogenetic tools for vision restoration. *Investigative ophthalmology & visual science* **59**, 1288-1294 (2018).
- 90 Liu, M.-M. *et al.* Human melanopsin-AAV2/8 transfection to retina transiently restores visual function in rd1 mice. *International journal of ophthalmology* **9**, 655 (2016).
- 91 Berry, M. H. *et al.* Restoration of high-sensitivity and adapting vision with a cone opsin. *Nature communications* **10**, 1-12 (2019).
- 92 Ferrari, U. *et al.* Towards optogenetic vision restoration with high resolution. *PLoS computational biology* **16**, e1007857 (2020).
- 93 Gauthier, G. *et al.* Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates. *Communications biology* **4**, 1-15 (2021).
- 94 McGregor, J. E. *et al.* Optogenetic restoration of retinal ganglion cell activity in the living primate. *Nature communications* **11**, 1-9 (2020).
- 95 Watanabe, Y. *et al.* Development of an optogenetic gene sensitive to daylight and its implications in vision restoration. *NPJ Regenerative medicine* **6**, 1-11 (2021).
- 96 Lagali, P. S. *et al.* Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. *Nature neuroscience* **11**, 667-675 (2008).

- 97 Doroudchi, M. M. *et al.* Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. *Molecular Therapy* **19**, 1220-1229 (2011).
- 98 Cronin, T. *et al.* Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. *EMBO molecular medicine* **6**, 1175-1190 (2014).
- 99 Macé, E. *et al.* Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV restores ON and OFF visual responses in blind mice. *Molecular Therapy* **23**, 7-16 (2015).
- 100 van Wyk, M., Pielecka-Fortuna, J., Löwel, S. & Kleinlogel, S. Restoring the ON switch in blind retinas: opto-mGluR6, a next-generation, cell-tailored optogenetic tool. *PLoS Biol* **13**, e1002143 (2015).
- 101 Cehajic-Kapetanovic, J. *et al.* Restoration of vision with ectopic expression of human rod opsin. *Current Biology* **25**, 2111-2122 (2015).
- 102 Gaub, B. M., Berry, M. H., Holt, A. E., Isacoff, E. Y. & Flannery, J. G. Optogenetic vision restoration using rhodopsin for enhanced sensitivity. *Molecular Therapy* **23**, 1562-1571 (2015).
- 103 Wright, W. W. *et al.* Restoring vision in mice with retinal degeneration using multicharacteristic opsin. *Neurophotonics* **4**, 041505 (2017).
- 104 Lu, Q., Ganjawala, T. H., Krstevski, A., Abrams, G. W. & Pan, Z.-H. Comparison of AAV-Mediated optogenetic vision restoration between retinal ganglion cell expression and ON bipolar cell targeting. *Molecular Therapy-Methods & Clinical Development* **18**, 15-23 (2020).
- 105 Batabyal, S. *et al.* Sensitization of ON-bipolar cells with ambient light activatable multi-characteristic opsin rescues vision in mice. *Gene therapy* **28**, 162-176 (2021).
- 106 Hulliger, E. C., Hostettler, S. M. & Kleinlogel, S. Empowering retinal gene therapy with a specific promoter for human rod and cone ON-bipolar cells. *Molecular Therapy-Methods & Clinical Development* **17**, 505-519 (2020).
- 107 Busskamp, V. *et al.* Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. *science* **329**, 413-417 (2010).